# Clinical Pharmacology Tracker

**Generated:** 12/12/2025, 8:12:31 pm
**Source:** ClinicalAssist Disease Database

--- 

### 1. Acetaminophen (undefined)
- **Class:** Analgesic/Antipyretic
- **Dosing:** 650 mg Q4-6H SOS
- **Rationale:** Symptomatic relief for headache and myalgia.

### 2. Ipratropium Bromide (undefined)
- **Class:** Anticholinergic (Nasal)
- **Dosing:** 0.06% Spray 2 sprays/nostril TID
- **Rationale:** Specifically reduces serous nasal secretions.

### 3. Cetirizine (undefined)
- **Class:** Antihistamine (2nd Gen)
- **Dosing:** 10 mg OD (HS)
- **Rationale:** Reduces histamine-mediated symptoms with less sedation.

### 4. Oral Rehydration Salts (ORS) (undefined)
- **Class:** Electrolyte Replenisher
- **Dosing:** 200-400ml After every loose stool
- **Rationale:** Exploits Glucose-Na+ cotransport to absorb water.

### 5. Ondansetron (undefined)
- **Class:** 5-HT3 Antagonist
- **Dosing:** 4 mg Single dose (Stat)
- **Rationale:** Enables oral hydration by stopping vomiting centrally.

### 6. Zinc Sulfate (undefined)
- **Class:** Mineral Supplement
- **Dosing:** 20 mg OD x 14 days
- **Rationale:** Reduces duration and severity of diarrhea episodes.

### 7. Amoxicillin-Clavulanate (undefined)
- **Class:** Beta-Lactam
- **Dosing:** 625 mg TID x 5-7 days
- **Rationale:** Covers S. pneumoniae and H. influenzae.

### 8. Azithromycin (undefined)
- **Class:** Macrolide
- **Dosing:** 500 mg OD x 3 days
- **Rationale:** Covers Legionella/Mycoplasma.

### 9. Paracetamol (undefined)
- **Class:** Antipyretic
- **Dosing:** 650 mg SOS
- **Rationale:** Symptomatic relief.

### 10. Amlodipine (undefined)
- **Class:** CCB (DHP)
- **Dosing:** 5 mg OD
- **Rationale:** Smooth vasodilation without electrolyte disturbance.

### 11. Telmisartan (undefined)
- **Class:** ARB
- **Dosing:** 40 mg OD
- **Rationale:** Renal protection and long half-life (24h control).

### 12. Chlorthalidone (undefined)
- **Class:** Thiazide Diuretic
- **Dosing:** 12.5 mg OD (Morning)
- **Rationale:** Reduces volume status.

### 13. Sumatriptan (undefined)
- **Class:** Triptan (5-HT1B/1D)
- **Dosing:** 50 mg Stat at onset
- **Rationale:** Vasoconstriction of cranial vessels.

### 14. Naproxen (undefined)
- **Class:** NSAID
- **Dosing:** 500 mg Stat with Triptan
- **Rationale:** Synergistic effect preventing recurrence.

### 15. Propranolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** 40 mg BD
- **Rationale:** Reduces frequency of attacks.

### 16. Metformin (undefined)
- **Class:** Biguanide
- **Dosing:** 500 mg BD after meals
- **Rationale:** Reduces hepatic glucose output.

### 17. Glimepiride (undefined)
- **Class:** Sulfonylurea
- **Dosing:** 1 mg OD before breakfast
- **Rationale:** Stimulates insulin secretion (Watch for hypos).

### 18. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 10 mg HS (Night)
- **Rationale:** Cardiovascular risk reduction.

### 19. Salbutamol (undefined)
- **Class:** SABA
- **Dosing:** 2 puffs / 2.5mg Neb PRN / Q20min
- **Rationale:** Rapid bronchodilation.

### 20. Budesonide (undefined)
- **Class:** Inhaled Corticosteroid
- **Dosing:** 400 mcg BD
- **Rationale:** Treats underlying inflammation.

### 21. Prednisolone (undefined)
- **Class:** Oral Steroid
- **Dosing:** 40 mg OD x 5 days
- **Rationale:** Prevents relapse and reduces edema.

### 22. Pantoprazole (undefined)
- **Class:** PPI
- **Dosing:** 40 mg OD (Empty Stomach)
- **Rationale:** Irreversible H+/K+ ATPase inhibition.

### 23. Domperidone (undefined)
- **Class:** Prokinetic
- **Dosing:** 10 mg TID
- **Rationale:** Increases LES tone and gastric emptying.

### 24. Sucralfate (undefined)
- **Class:** Mucosal Protectant
- **Dosing:** 10 ml TID
- **Rationale:** Coats the esophagus.

### 25. Fludrocortisone (undefined)
- **Class:** Mineralocorticoid
- **Dosing:** 0.1 mg OD (Morning)
- **Rationale:** Increases sodium and water retention to boost blood volume.

### 26. Midodrine (undefined)
- **Class:** Alpha-1 Agonist
- **Dosing:** 2.5-5 mg TID (Daytime only)
- **Rationale:** Increases vascular tone. Avoid before bed to prevent supine hypertension.

### 27. Tiotropium (undefined)
- **Class:** LAMA (Long-Acting Muscarinic Antagonist)
- **Dosing:** 18 mcg OD (Inhaler)
- **Rationale:** Bronchodilation and reduction of exacerbations.

### 28. Formoterol + Budesonide (undefined)
- **Class:** LABA + ICS
- **Dosing:** 6/200 mcg BD
- **Rationale:** Reduces inflammation and improves FEV1.

### 29. Carbidopa-Levodopa (undefined)
- **Class:** Dopamine Precursor/Decarboxylase Inhibitor
- **Dosing:** 25/100 mg TID
- **Rationale:** Levodopa converts to dopamine; Carbidopa prevents peripheral breakdown.

### 30. Pramipexole (undefined)
- **Class:** Dopamine Agonist
- **Dosing:** 0.125 mg TID (Titrate)
- **Rationale:** Delays need for Levodopa; reduces risk of dyskinesias.

### 31. Insulin Glargine (undefined)
- **Class:** Long-acting Insulin (Basal)
- **Dosing:** 0.2-0.4 U/kg/day OD (Bedtime)
- **Rationale:** Suppresses hepatic glucose production between meals.

### 32. Insulin Lispro/Aspart (undefined)
- **Class:** Rapid-acting Insulin (Bolus)
- **Dosing:** Carb ratio based Before meals
- **Rationale:** Covers glucose rise from food intake.

### 33. Pantoprazole (undefined)
- **Class:** Proton Pump Inhibitor
- **Dosing:** 40 mg BD (if H.pylori) or OD
- **Rationale:** Maintains pH > 4 to allow mucosal healing.

### 34. Clarithromycin + Amoxicillin (undefined)
- **Class:** Antibiotics
- **Dosing:** 500mg + 1g BD x 14 days
- **Rationale:** Standard triple therapy backbone (with PPI).

### 35. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 40-80 mg IV Bolus
- **Rationale:** Manages volume status; does not 'jumpstart' kidneys but aids fluid balance.

### 36. Calcium Gluconate (undefined)
- **Class:** Electrolyte Supplement
- **Dosing:** 10 ml (10%) IV Stat
- **Rationale:** Stabilizes cardiac membrane to prevent arrhythmia (does not lower K+).

### 37. Sodium Bicarbonate (undefined)
- **Class:** Alkalinizing Agent
- **Dosing:** 1 mEq/kg IV Infusion
- **Rationale:** Corrects metabolic acidosis (pH < 7.1).

### 38. Ferrous Ascorbate (undefined)
- **Class:** Iron Supplement
- **Dosing:** 100 mg (Elemental) BD
- **Rationale:** Ascorbate salt has better GI tolerability and absorption than sulfate.

### 39. Folic Acid (undefined)
- **Class:** Vitamin
- **Dosing:** 5 mg OD
- **Rationale:** Supportive for erythropoiesis.

### 40. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 2 g IV OD x 7-14 days
- **Rationale:** Highly effective against MDR strains.

### 41. Azithromycin (undefined)
- **Class:** Macrolide
- **Dosing:** 500-1000 mg PO OD x 7 days
- **Rationale:** Intracellular penetration makes it effective for Salmonella.

### 42. Paracetamol (undefined)
- **Class:** Antipyretic
- **Dosing:** 650 mg SOS
- **Rationale:** Symptomatic control.

### 43. Hydroxychloroquine (undefined)
- **Class:** Antimalarial
- **Dosing:** 200-400 mg OD
- **Rationale:** Prevents flares and reduces organ damage. Requires annual eye exam.

### 44. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.5-1 mg/kg OD (Taper)
- **Rationale:** Rapid anti-inflammatory action.

### 45. Mycophenolate Mofetil (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 1 g BD
- **Rationale:** Sparing agent for steroid reduction.

### 46. Tamoxifen (undefined)
- **Class:** SERM
- **Dosing:** 20 mg OD
- **Rationale:** Blocks estrogen receptors in breast tissue. Increases risk of endometrial cancer/DVT.

### 47. Letrozole (undefined)
- **Class:** Aromatase Inhibitor
- **Dosing:** 2.5 mg OD
- **Rationale:** Inhibits peripheral conversion of androgens to estrogen. More effective than Tamoxifen but causes osteoporosis.

### 48. Trastuzumab (undefined)
- **Class:** HER2 Monoclonal Ab
- **Dosing:** Protocol based IV q3 weeks
- **Rationale:** Targets HER2 receptor tyrosine kinase. Cardiotoxicity is a key side effect.

### 49. Succimer (DMSA) (undefined)
- **Class:** Chelating Agent
- **Dosing:** 10 mg/kg TID x 5 days
- **Rationale:** Oral chelator; binds lead and excretes it in urine.

### 50. Calcium Carbonate (undefined)
- **Class:** Mineral Supplement
- **Dosing:** 500 mg BD
- **Rationale:** Competes with lead for absorption in the gut.

### 51. Ethinylestradiol + Cyproterone (undefined)
- **Class:** OCP (Anti-androgenic)
- **Dosing:** Standard pill OD x 21 days
- **Rationale:** Increases SHBG to bind free testosterone; regulates shedding.

### 52. Metformin (undefined)
- **Class:** Biguanide
- **Dosing:** 500-1000 mg BD
- **Rationale:** Improves insulin sensitivity and spontaneous ovulation.

### 53. Letrozole (undefined)
- **Class:** Aromatase Inhibitor
- **Dosing:** 2.5 mg CD 3-7
- **Rationale:** First-line ovulation induction agent.

### 54. Alendronate (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 70 mg Once Weekly
- **Rationale:** Inhibits osteoclast-mediated bone resorption. Take on empty stomach, stay upright 30 mins.

### 55. Calcium Carbonate (undefined)
- **Class:** Supplement
- **Dosing:** 500 mg BD
- **Rationale:** Essential substrate for bone mineralization.

### 56. Cholecalciferol (undefined)
- **Class:** Vitamin D3
- **Dosing:** 60,000 IU Weekly x 8 weeks
- **Rationale:** Increases gut calcium absorption.

### 57. White Soft Paraffin / Coconut Oil (undefined)
- **Class:** Emollient
- **Dosing:** Apply liberally Q4H (Continuous)
- **Rationale:** Restores skin barrier function. Foundation of therapy.

### 58. Mometasone Furoate (undefined)
- **Class:** Topical Corticosteroid
- **Dosing:** 0.1% Cream OD (Acute flares)
- **Rationale:** Anti-inflammatory. Use potent steroids for short duration.

### 59. Tacrolimus (undefined)
- **Class:** Calcineurin Inhibitor
- **Dosing:** 0.03% or 0.1% BD
- **Rationale:** Non-steroidal option suitable for thin skin areas.

### 60. Epinephrine (Adrenaline) (undefined)
- **Class:** Sympathomimetic
- **Dosing:** 0.5 mg (1:1000) IM Stat (Repeat q5min)
- **Rationale:** Alpha-1 vasoconstriction (BP) + Beta-2 bronchodilation (Airway) + Mast cell stabilization.

### 61. Hydrocortisone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 200 mg IV Stat
- **Rationale:** Reduces late-phase inflammation (slow onset).

### 62. Pheniramine (undefined)
- **Class:** Antihistamine
- **Dosing:** 45 mg IV Stat
- **Rationale:** Relieves itching and hives only.

### 63. Atorvastatin (undefined)
- **Class:** HMG-CoA Reductase Inhibitor
- **Dosing:** 40-80 mg OD (Night)
- **Rationale:** Pleiotropic effects stabilize plaque and lower LDL.

### 64. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75-150 mg OD
- **Rationale:** Prevents thrombotic events over ruptured plaque.

### 65. Ezetimibe (undefined)
- **Class:** Cholesterol Absorption Inhibitor
- **Dosing:** 10 mg OD
- **Rationale:** Inhibits intestinal absorption of cholesterol.

### 66. Rifampin (undefined)
- **Class:** Antitubercular (R)
- **Dosing:** 10 mg/kg (Max 600) OD
- **Rationale:** Bactericidal; inhibits RNA polymerase. Red/Orange urine warning.

### 67. Isoniazid (undefined)
- **Class:** Antitubercular (H)
- **Dosing:** 5 mg/kg (Max 300) OD
- **Rationale:** Inhibits mycolic acid synthesis. Hepatotoxic.

### 68. Pyrazinamide (undefined)
- **Class:** Antitubercular (Z)
- **Dosing:** 25 mg/kg OD
- **Rationale:** Active in acidic pH (macrophages). Increases Uric Acid.

### 69. Ethambutol (undefined)
- **Class:** Antitubercular (E)
- **Dosing:** 15 mg/kg OD
- **Rationale:** Inhibits arabinosyl transferase. Monitor visual acuity.

### 70. Risperidone (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 2-6 mg OD/BD
- **Rationale:** Serotonin-Dopamine Antagonist (SDA); treats positive & negative symptoms.

### 71. Olanzapine (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 5-20 mg HS
- **Rationale:** High affinity for D2/5HT2A; sedative effect useful for sleep. High metabolic risk.

### 72. Trihexyphenidyl (undefined)
- **Class:** Anticholinergic
- **Dosing:** 2 mg BD
- **Rationale:** Manages drug-induced parkinsonism (EPS).

### 73. Methimazole (undefined)
- **Class:** Thionamide
- **Dosing:** 10-20 mg OD
- **Rationale:** Blocks thyroid peroxidase (TPO) and coupling of iodotyrosines.

### 74. Propranolol (undefined)
- **Class:** Beta Blocker (Non-selective)
- **Dosing:** 10-40 mg TID/QID
- **Rationale:** Controls tachycardia/tremors and inhibits peripheral T4 to T3 conversion.

### 75. Budesonide (undefined)
- **Class:** Corticosteroid
- **Dosing:** 9 mg OD
- **Rationale:** High first-pass metabolism reduces systemic side effects compared to systemic steroids.

### 76. Azathioprine (undefined)
- **Class:** Immunomodulator
- **Dosing:** 2-2.5 mg/kg OD
- **Rationale:** Inhibits purine synthesis; steroid-sparing agent. Monitor bone marrow.

### 77. Mesalamine (undefined)
- **Class:** 5-ASA
- **Dosing:** 2-4 g Divided
- **Rationale:** Local anti-inflammatory effect (limited efficacy in Crohn's vs UC).

### 78. Telmisartan (undefined)
- **Class:** ARB
- **Dosing:** 40-80 mg OD
- **Rationale:** Reduces intraglomerular pressure; renoprotective even if BP is normal.

### 79. Calcium Acetate (undefined)
- **Class:** Phosphate Binder
- **Dosing:** 667 mg TID with meals
- **Rationale:** Binds dietary phosphorus in the gut to prevent absorption.

### 80. Erythropoietin (EPO) (undefined)
- **Class:** ESA
- **Dosing:** 4000 IU Twice Weekly (SC)
- **Rationale:** Stimulates erythropoiesis usually deficient due to renal mass loss.

### 81. Cyanocobalamin (undefined)
- **Class:** Vitamin B12
- **Dosing:** 1000 mcg IM OD x 7d, then Weekly
- **Rationale:** Parenteral route bypasses intrinsic factor defects (Pernicious Anemia).

### 82. Folic Acid (undefined)
- **Class:** Vitamin B9
- **Dosing:** 5 mg OD
- **Rationale:** Replenishes stores; crucial for DNA synthesis.

### 83. Benzathine Penicillin G (undefined)
- **Class:** Antibiotic (Beta-lactam)
- **Dosing:** 2.4 Million Units IM Stat (Single dose)
- **Rationale:** Maintains treponemicidal levels for >2 weeks. Gold Standard.

### 84. Doxycycline (undefined)
- **Class:** Tetracycline
- **Dosing:** 100 mg BD x 14 days
- **Rationale:** Bacteriostatic alternative; less effective than Penicillin.

### 85. Methotrexate (undefined)
- **Class:** DMARD (Antimetabolite)
- **Dosing:** 10-25 mg Once Weekly
- **Rationale:** Inhibits AICAR transformylase and increases adenosine (anti-inflammatory).

### 86. Folic Acid (undefined)
- **Class:** Vitamin
- **Dosing:** 5 mg Weekly (Day after MTX)
- **Rationale:** Prevents mucositis and hepatotoxicity from Methotrexate.

### 87. Hydroxychloroquine (undefined)
- **Class:** DMARD
- **Dosing:** 200-400 mg OD
- **Rationale:** Modulates TLR signaling; lipid-lowering benefits.

### 88. Cisplatin (undefined)
- **Class:** Platinum Agent
- **Dosing:** 75 mg/m2 IV q3 weeks
- **Rationale:** Cross-links DNA inhibiting replication.

### 89. Pemetrexed (undefined)
- **Class:** Antifolate
- **Dosing:** 500 mg/m2 IV q3 weeks
- **Rationale:** Inhibits thymidylate synthase. Requires B12/Folate supplementation.

### 90. Osimertinib (undefined)
- **Class:** Tyrosine Kinase Inhibitor
- **Dosing:** 80 mg OD
- **Rationale:** Targeted therapy for specific mutation; oral route.

### 91. Atropine (undefined)
- **Class:** Anticholinergic
- **Dosing:** 2-5 mg (Doubling dose) IV q5-10min
- **Rationale:** Competitively blocks ACh at muscarinic receptors to dry secretions. No limit on max dose.

### 92. Pralidoxime (PAM) (undefined)
- **Class:** Oxime
- **Dosing:** 1-2 g IV Infusion
- **Rationale:** Reactivates AChE enzyme if given early (before 'aging' of bond).

### 93. Diazepam (undefined)
- **Class:** Benzodiazepine
- **Dosing:** 10 mg IV Stat
- **Rationale:** Prevents CNS toxicity and seizures.

### 94. Dienogest (undefined)
- **Class:** Progestin
- **Dosing:** 2 mg OD
- **Rationale:** Specific activity against endometriotic tissue; induces atrophy.

### 95. Mefenamic Acid (undefined)
- **Class:** NSAID
- **Dosing:** 500 mg TID
- **Rationale:** Inhibits prostaglandins which drive uterine cramping.

### 96. Combined Oral Contraceptive (undefined)
- **Class:** Hormone
- **Dosing:** Standard OD (Continuous)
- **Rationale:** Suppresses ovulation and thins the endometrium.

### 97. Paracetamol (undefined)
- **Class:** Analgesic
- **Dosing:** 650-1000 mg TID
- **Rationale:** First-line for pain relief with safety profile better than NSAIDs.

### 98. Diclofenac Gel (undefined)
- **Class:** Topical NSAID
- **Dosing:** 1% Gel QID
- **Rationale:** Effective concentration in joint with minimal systemic absorption.

### 99. Duloxetine (undefined)
- **Class:** SNRI
- **Dosing:** 30-60 mg OD
- **Rationale:** Modulates central pain pathways; useful when NSAIDs contraindicated.

### 100. Adapalene (undefined)
- **Class:** Topical Retinoid
- **Dosing:** 0.1% Gel OD (Night)
- **Rationale:** Normalizes follicular keratinization and reduces microcomedones.

### 101. Benzoyl Peroxide (undefined)
- **Class:** Antimicrobial
- **Dosing:** 2.5% Gel OD (Day/Night)
- **Rationale:** Releases free radicals to kill C. acnes; prevents antibiotic resistance.

### 102. Doxycycline (undefined)
- **Class:** Antibiotic (Tetracycline)
- **Dosing:** 100 mg BD
- **Rationale:** Anti-inflammatory and antibacterial action.

### 103. Norepinephrine (undefined)
- **Class:** Vasopressor
- **Dosing:** Start 0.05 mcg/kg/min Continuous Infusion
- **Rationale:** Alpha-1 agonist; increases SVR to maintain MAP > 65 mmHg.

### 104. Piperacillin-Tazobactam (undefined)
- **Class:** Antibiotic
- **Dosing:** 4.5 g IV Q6H
- **Rationale:** Broad spectrum covering Pseudomonas and Gram-negatives.

### 105. Normal Saline / Ringer Lactate (undefined)
- **Class:** Crystalloid
- **Dosing:** 30 ml/kg Stat Bolus
- **Rationale:** Restores intravascular volume.

### 106. Nitroglycerin (undefined)
- **Class:** Nitrate
- **Dosing:** 0.5 mg SL Stat (Max 3 doses)
- **Rationale:** Venodilation reduces preload; coronary dilation improves supply.

### 107. Metoprolol (undefined)
- **Class:** Beta Blocker (Cardioselective)
- **Dosing:** 25-50 mg BD
- **Rationale:** Reduces heart rate and contractility, lowering oxygen demand.

### 108. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75 mg OD
- **Rationale:** Prevents platelet aggregation on atherosclerotic plaques.

### 109. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** Titrate to SpO2 >94% Continuous
- **Rationale:** Increases FiO2 to improve alveolar-arterial gradient.

### 110. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 6 mg OD
- **Rationale:** Reduces alveolar inflammation and improves gas exchange.

### 111. Salbutamol (undefined)
- **Class:** Bronchodilator
- **Dosing:** 2.5 mg Nebulization Q4H
- **Rationale:** Relieves airflow obstruction improving ventilation/perfusion match.

### 112. Escitalopram (undefined)
- **Class:** SSRI
- **Dosing:** 10-20 mg OD (Morning)
- **Rationale:** Selectively inhibits serotonin reuptake with minimal drug interactions.

### 113. Sertraline (undefined)
- **Class:** SSRI
- **Dosing:** 50-100 mg OD
- **Rationale:** Safe in cardiac patients; broad efficacy.

### 114. Clonazepam (undefined)
- **Class:** Benzodiazepine
- **Dosing:** 0.25-0.5 mg HS (Short term)
- **Rationale:** Bridging therapy for sleep until SSRI takes effect.

### 115. Levothyroxine (undefined)
- **Class:** Synthetic T4
- **Dosing:** 1.6 mcg/kg OD (Early Morning)
- **Rationale:** Restores euthyroid state; long half-life (7 days) allows stable levels.

### 116. Mesalamine (undefined)
- **Class:** 5-ASA
- **Dosing:** 2-4 g Divided
- **Rationale:** Topical anti-inflammatory effect on colonic mucosa.

### 117. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 40 mg OD (Taper)
- **Rationale:** Rapidly induces remission but not for maintenance due to side effects.

### 118. Azathioprine (undefined)
- **Class:** Immunomodulator
- **Dosing:** 2.5 mg/kg OD
- **Rationale:** Steroid-sparing agent for frequent relapsers.

### 119. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Suppresses T-cell cytokine production that damages podocytes.

### 120. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 40 mg BD
- **Rationale:** Promotes natriuresis to manage fluid overload.

### 121. Ramipril (undefined)
- **Class:** ACE Inhibitor
- **Dosing:** 2.5-5 mg OD
- **Rationale:** Reduces intraglomerular pressure, lowering protein loss.

### 122. Hydroxyurea (undefined)
- **Class:** Antimetabolite
- **Dosing:** 15-35 mg/kg OD
- **Rationale:** Increases HbF (Fetal Hemoglobin) which inhibits polymerization of HbS.

### 123. Folic Acid (undefined)
- **Class:** Vitamin
- **Dosing:** 5 mg OD
- **Rationale:** High RBC turnover increases folate demand; prevents megaloblastic crisis.

### 124. Tramadol (undefined)
- **Class:** Opioid Analgesic
- **Dosing:** 50 mg TID (during crisis)
- **Rationale:** Management of severe vaso-occlusive pain.

### 125. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 500 mg / 1 g IM Stat
- **Rationale:** Highly effective single-dose regimen due to increasing resistance to oral agents.

### 126. Azithromycin (undefined)
- **Class:** Macrolide
- **Dosing:** 1 g PO Stat
- **Rationale:** Covers Chlamydia and may delay cephalosporin resistance.

### 127. Clobetasol Propionate (undefined)
- **Class:** Topical Corticosteroid
- **Dosing:** 0.05% Ointment BD
- **Rationale:** Potent anti-inflammatory and anti-proliferative.

### 128. Calcipotriol (undefined)
- **Class:** Vitamin D Analog
- **Dosing:** 0.005% Cream BD
- **Rationale:** Inhibits keratinocyte proliferation; steroid-sparing.

### 129. Methotrexate (undefined)
- **Class:** Immunomodulator
- **Dosing:** 10-15 mg Weekly
- **Rationale:** Systemic suppression of T-cell function.

### 130. Leuprolide (undefined)
- **Class:** GnRH Agonist
- **Dosing:** 7.5 mg Depot Monthly IM
- **Rationale:** Desensitizes pituitary GnRH receptors, stopping LH/FSH and Testosterone production.

### 131. Bicalutamide (undefined)
- **Class:** Anti-androgen
- **Dosing:** 50 mg OD
- **Rationale:** Blocks androgen receptors to prevent initial testosterone flare from GnRH agonists.

### 132. Docetaxel (undefined)
- **Class:** Chemotherapy
- **Dosing:** 75 mg/m2 IV q3 weeks
- **Rationale:** Microtubule stabilizer inhibiting cell division.

### 133. Oxygen (Normobaric) (undefined)
- **Class:** Medical Gas
- **Dosing:** 100% via Non-rebreather mask Continuous
- **Rationale:** Competitively displaces CO from Hemoglobin.

### 134. Hyperbaric Oxygen (undefined)
- **Class:** Therapy
- **Dosing:** 2.5-3 ATM Session
- **Rationale:** Dissolves O2 in plasma independent of Hb; prevents delayed neurological sequelae.

### 135. Sildenafil (undefined)
- **Class:** PDE5 Inhibitor
- **Dosing:** 50 mg PRN (1h before activity)
- **Rationale:** Inhibits breakdown of cGMP, sustaining vasodilation and inflow.

### 136. Tadalafil (undefined)
- **Class:** PDE5 Inhibitor
- **Dosing:** 10-20 mg PRN or 5mg OD
- **Rationale:** Long half-life (36h); 'The Weekend Pill'.

### 137. Indomethacin (undefined)
- **Class:** NSAID
- **Dosing:** 50 mg TID
- **Rationale:** Potent COX inhibition reduces prostaglandins and pain.

### 138. Colchicine (undefined)
- **Class:** Anti-mitotic
- **Dosing:** 0.5 mg BD/TID
- **Rationale:** Inhibits microtubule polymerization and neutrophil migration.

### 139. Allopurinol (undefined)
- **Class:** Xanthine Oxidase Inhibitor
- **Dosing:** 100-300 mg OD
- **Rationale:** Inhibits uric acid production. Titrate to UA < 6 mg/dL.

### 140. Cephalexin (undefined)
- **Class:** Cephalosporin (1st Gen)
- **Dosing:** 500 mg QID
- **Rationale:** Good skin penetration and coverage of Gram-positives.

### 141. Clindamycin (undefined)
- **Class:** Lincosamide
- **Dosing:** 300-450 mg QID
- **Rationale:** Inhibits protein synthesis; covers MRSA.

### 142. Amoxicillin-Clavulanate (undefined)
- **Class:** Beta-lactam
- **Dosing:** 625 mg TID
- **Rationale:** Used if anaerobes or bite wound suspected.

### 143. Ringer Lactate (undefined)
- **Class:** Crystalloid
- **Dosing:** 1-2 L Bolus Stat
- **Rationale:** Isotonic volume expander; preferred over Saline in trauma to avoid acidosis.

### 144. Norepinephrine (undefined)
- **Class:** Vasopressor
- **Dosing:** Titrated IV Infusion
- **Rationale:** Use ONLY after fluid resuscitation to maintain MAP > 65.

### 145. Tranexamic Acid (undefined)
- **Class:** Antifibrinolytic
- **Dosing:** 1 g IV Stat
- **Rationale:** Prevents clot breakdown; effective if given within 3 hours.

### 146. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 300-325 mg (Chewable) Stat
- **Rationale:** Rapidly inhibits COX-1 and Thromboxane A2 to stop clot growth.

### 147. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 80 mg OD
- **Rationale:** High intensity statin reduces inflammation and stabilizes plaque acutely.

### 148. Clopidogrel (undefined)
- **Class:** P2Y12 Inhibitor
- **Dosing:** 300-600 mg Loading Stat
- **Rationale:** Synergistic platelet inhibition required post-stent or fibrinolysis.

### 149. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** 100% Continuous
- **Rationale:** Immediate reversal of hypoxemia via Ambu bag or Intubation.

### 150. Epinephrine (undefined)
- **Class:** Sympathomimetic
- **Dosing:** 1 mg (1:10,000) IV q3-5min
- **Rationale:** Vasoconstriction improves coronary and cerebral perfusion pressure.

### 151. Sodium Bicarbonate (undefined)
- **Class:** Alkalinizer
- **Dosing:** 1 mEq/kg IV
- **Rationale:** Corrects metabolic acidosis in prolonged arrest (Controversial).

### 152. Lithium Carbonate (undefined)
- **Class:** Mood Stabilizer
- **Dosing:** 300-900 mg BD/TID
- **Rationale:** Gold standard for suicide prevention. Modulates second messenger systems.

### 153. Sodium Valproate (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 500-1000 mg BD
- **Rationale:** Increases GABA levels; preferred for rapid cycling.

### 154. Quetiapine (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 300-600 mg HS
- **Rationale:** Dopamine/Serotonin antagonism; effective for both poles.

### 155. Ketoconazole (undefined)
- **Class:** Steroidogenesis Inhibitor
- **Dosing:** 200-400 mg BD
- **Rationale:** Inhibits adrenal enzymes (17-alpha-hydroxylase) to lower cortisol rapidly.

### 156. Spironolactone (undefined)
- **Class:** MRA
- **Dosing:** 50-100 mg BD
- **Rationale:** Blocks mineralocorticoid and androgen effects of excess precursors.

### 157. Pasireotide (undefined)
- **Class:** Somatostatin Analog
- **Dosing:** 600 mcg SC BD
- **Rationale:** Inhibits ACTH secretion.

### 158. Supportive Care (undefined)
- **Class:** N/A
- **Dosing:** N/A N/A
- **Rationale:** No specific antiviral exists. Disease is self-limiting.

### 159. Ondansetron (undefined)
- **Class:** Antiemetic
- **Dosing:** 4 mg TID
- **Rationale:** Allows oral intake to prevent dehydration.

### 160. Vitamin K (undefined)
- **Class:** Vitamin
- **Dosing:** 10 mg PO/SC
- **Rationale:** Supports clotting factor synthesis if cholestasis is present.

### 161. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 40 mg BD
- **Rationale:** Manages edema and helps control blood pressure by reducing volume.

### 162. Nifedipine (undefined)
- **Class:** CCB
- **Dosing:** 10-20 mg BD
- **Rationale:** Vasodilation to control BP (ACEi usually avoided initially if AKI is severe).

### 163. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Suppresses glomerular inflammation.

### 164. Deferasirox (undefined)
- **Class:** Iron Chelator
- **Dosing:** 20-30 mg/kg OD (Dispersible)
- **Rationale:** Oral chelator; binds excess iron and excretes it via bile/feces.

### 165. Folic Acid (undefined)
- **Class:** Vitamin
- **Dosing:** 5 mg OD
- **Rationale:** Prevents megaloblastic changes due to high bone marrow turnover.

### 166. Hydroxyurea (undefined)
- **Class:** HbF Inducer
- **Dosing:** 15 mg/kg OD
- **Rationale:** Increases Gamma-globin (HbF) to bind excess Alpha chains.

### 167. Rifampicin (undefined)
- **Class:** Antimycobacterial
- **Dosing:** 600 mg Monthly (Supervised)
- **Rationale:** Highly bactericidal; key component of WHO Multi-Drug Therapy.

### 168. Dapsone (undefined)
- **Class:** Sulfone
- **Dosing:** 100 mg Daily
- **Rationale:** Bacteriostatic. Monitor for G6PD deficiency hemolysis.

### 169. Clofazimine (undefined)
- **Class:** Dye/Antimycobacterial
- **Dosing:** 50 mg Daily + 300 mg Monthly Daily/Monthly
- **Rationale:** Anti-inflammatory and antibacterial. Causes skin discoloration.

### 170. Indomethacin (undefined)
- **Class:** NSAID
- **Dosing:** 25-50 mg TID
- **Rationale:** Highly effective for inflammatory back pain; often diagnostic response.

### 171. Sulfasalazine (undefined)
- **Class:** DMARD
- **Dosing:** 1 g BD
- **Rationale:** Effective for knee/hip involvement, less so for spine.

### 172. Adalimumab (undefined)
- **Class:** TNF Alpha Inhibitor
- **Dosing:** 40 mg SC every 2 weeks
- **Rationale:** Biologic that halts disease progression and fusion.

### 173. 5-Fluorouracil (5-FU) (undefined)
- **Class:** Antimetabolite
- **Dosing:** Protocol based IV Infusion
- **Rationale:** Inhibits thymidylate synthase, blocking DNA replication.

### 174. Oxaliplatin (undefined)
- **Class:** Platinum Agent
- **Dosing:** 85 mg/m2 IV q2 weeks
- **Rationale:** Forms DNA crosslinks; synergistic with 5-FU.

### 175. Leucovorin (undefined)
- **Class:** Folinic Acid
- **Dosing:** 400 mg/m2 IV
- **Rationale:** Potentiates 5-FU binding to thymidylate synthase.

### 176. Naloxone (undefined)
- **Class:** Opioid Antagonist
- **Dosing:** 0.4-2 mg IV/IM/Nasal Stat
- **Rationale:** Competitively displaces opioids from receptors. Repeat q2-3min until breathing improves.

### 177. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** High Flow Continuous
- **Rationale:** Supportive care while waiting for antagonist effect.

### 178. Tamsulosin (undefined)
- **Class:** Alpha-1 Blocker
- **Dosing:** 0.4 mg OD (Night)
- **Rationale:** Relaxes smooth muscle in bladder neck and prostate capsule. Rapid relief.

### 179. Finasteride (undefined)
- **Class:** 5-Alpha Reductase Inhibitor
- **Dosing:** 5 mg OD
- **Rationale:** Blocks conversion of Testosterone to DHT; shrinks prostate over 6 months.

### 180. Tadalafil (undefined)
- **Class:** PDE5 Inhibitor
- **Dosing:** 5 mg OD
- **Rationale:** Reduces LUTS and treats erectile dysfunction simultaneously.

### 181. Pregabalin (undefined)
- **Class:** Gabapentinoid
- **Dosing:** 75-150 mg BD
- **Rationale:** Binds Alpha-2-Delta calcium channels to reduce neurotransmitter release.

### 182. Duloxetine (undefined)
- **Class:** SNRI
- **Dosing:** 30-60 mg OD
- **Rationale:** Increases Serotonin/NE in descending inhibitory pain pathways.

### 183. Amitriptyline (undefined)
- **Class:** TCA
- **Dosing:** 10-25 mg HS
- **Rationale:** Low dose improves sleep architecture and pain threshold.

### 184. Terbinafine (undefined)
- **Class:** Allylamine
- **Dosing:** 250 mg OD x 2-4 weeks
- **Rationale:** Fungicidal; inhibits squalene epoxidase. Gold standard for oral therapy.

### 185. Clotrimazole / Luliconazole (undefined)
- **Class:** Azole Topical
- **Dosing:** 1% Cream BD x 2-4 weeks
- **Rationale:** Inhibits ergosterol synthesis. Continue 1 week after rash clears.

### 186. Itraconazole (undefined)
- **Class:** Azole Systemic
- **Dosing:** 100-200 mg BD
- **Rationale:** Alternative systemic agent; check liver enzymes.

### 187. Ringer Lactate (undefined)
- **Class:** Crystalloid
- **Dosing:** Parkland Formula IV Continuous
- **Rationale:** Isotonic fluid of choice; large volumes needed to counter capillary leak.

### 188. Silver Sulfadiazine (undefined)
- **Class:** Topical Antimicrobial
- **Dosing:** 1% Cream OD/BD dressing
- **Rationale:** Broad spectrum coverage against Pseudomonas and Staph.

### 189. Morphine (undefined)
- **Class:** Opioid
- **Dosing:** 0.1 mg/kg IV Small Boluses
- **Rationale:** IV route preferred as IM/SC absorption is erratic in shock.

### 190. Sacubitril-Valsartan (undefined)
- **Class:** ARNI
- **Dosing:** 50 mg BD BD
- **Rationale:** Superior to ACEi; inhibits neprilysin to increase natriuretic peptides.

### 191. Metoprolol Succinate (undefined)
- **Class:** Beta Blocker
- **Dosing:** 25-50 mg OD (XL)
- **Rationale:** Prevents remodeling and arrhythmia. Do NOT start in acute decompensated shock.

### 192. Dapagliflozin (undefined)
- **Class:** SGLT2 Inhibitor
- **Dosing:** 10 mg OD
- **Rationale:** Reduces hospitalization and mortality independent of diabetes status.

### 193. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** Titrate Continuous
- **Rationale:** Corrects hypoxemia regardless of cause.

### 194. Furosemide (undefined)
- **Class:** Diuretic
- **Dosing:** 40 mg IV Stat
- **Rationale:** Rapid relief for cardiac dyspnea (Pulmonary Edema).

### 195. Salbutamol (undefined)
- **Class:** Bronchodilator
- **Dosing:** 2.5 mg Neb Stat
- **Rationale:** Relieves airflow obstruction.

### 196. Levetiracetam (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 500-1000 mg BD
- **Rationale:** SV2A protein binding; safe profile, few drug interactions.

### 197. Sodium Valproate (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 500 mg BD
- **Rationale:** Broad spectrum; avoid in young women (Teratogenic/PCOS risk).

### 198. Carbamazepine (undefined)
- **Class:** Sodium Channel Blocker
- **Dosing:** 200-400 mg TID
- **Rationale:** First-line for focal onset; risk of hyponatremia/SJS.

### 199. Hydrocortisone (undefined)
- **Class:** Glucocorticoid
- **Dosing:** 15-25 mg Divided (2/3 AM, 1/3 PM)
- **Rationale:** Mimics circadian rhythm. Stress dosing (Double dose) needed during illness.

### 200. Fludrocortisone (undefined)
- **Class:** Mineralocorticoid
- **Dosing:** 0.05-0.1 mg OD
- **Rationale:** Maintains sodium balance and blood pressure.

### 201. Entecavir (undefined)
- **Class:** Nucleoside Analog
- **Dosing:** 0.5 mg OD (Empty Stomach)
- **Rationale:** Potent viral suppression with high barrier to resistance. First-line.

### 202. Tenofovir Disoproxil (TDF) (undefined)
- **Class:** Nucleotide Analog
- **Dosing:** 300 mg OD
- **Rationale:** First-line alternative; prefer TAF (Alafenamide) if renal/bone issues exist.

### 203. Peg-Interferon (undefined)
- **Class:** Cytokine
- **Dosing:** 180 mcg Weekly SC
- **Rationale:** Finite duration therapy (48 weeks) aiming for seroconversion.

### 204. Diclofenac (undefined)
- **Class:** NSAID
- **Dosing:** 75 mg IM/IV Stat
- **Rationale:** Reduces ureteric spasm and glomerular filtration rate, relieving capsular distension.

### 205. Tamsulosin (undefined)
- **Class:** Alpha-1 Blocker
- **Dosing:** 0.4 mg OD
- **Rationale:** Relaxes distal ureter smooth muscle to facilitate stone passage.

### 206. Potassium Citrate (undefined)
- **Class:** Urinary Alkalinizer
- **Dosing:** 1080 mg TID
- **Rationale:** Citrate inhibits crystal aggregation; essential for Uric acid/CaOx stone prevention.

### 207. Factor VIII / IX Concentrate (undefined)
- **Class:** Clotting Factor
- **Dosing:** 20-50 IU/kg Stat / Prophylaxis
- **Rationale:** Direct replacement. Dose depends on severity of bleed and desired % rise.

### 208. Tranexamic Acid (undefined)
- **Class:** Antifibrinolytic
- **Dosing:** 1 g TID
- **Rationale:** Stabilizes the clot; useful for dental bleeds or epistaxis.

### 209. Desmopressin (undefined)
- **Class:** Vasopressin Analog
- **Dosing:** 0.3 mcg/kg SC/IV
- **Rationale:** Releases stored Factor VIII from endothelial cells.

### 210. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 2 g IV BD
- **Rationale:** Excellent CSF penetration; covers Pneumococcus and Meningococcus.

### 211. Vancomycin (undefined)
- **Class:** Glycopeptide
- **Dosing:** 15-20 mg/kg IV BD/TID
- **Rationale:** Added for resistant Pneumococcus (DRSP).

### 212. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 10 mg IV Q6H x 4 days
- **Rationale:** Dampens inflammatory response to bacterial lysis.

### 213. Pyridostigmine (undefined)
- **Class:** AChE Inhibitor
- **Dosing:** 60 mg TID/QID
- **Rationale:** Prolongs ACh presence in synaptic cleft to improve transmission.

### 214. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** Start low, titrate up OD
- **Rationale:** Reduces antibody production. Start low to avoid initial transient worsening.

### 215. Azathioprine (undefined)
- **Class:** Immunomodulator
- **Dosing:** 2-3 mg/kg OD
- **Rationale:** Long term maintenance.

### 216. Cytarabine (Ara-C) (undefined)
- **Class:** Antimetabolite
- **Dosing:** 100-200 mg/m2 Continuous IV x 7d
- **Rationale:** Inhibits DNA polymerase.

### 217. Daunorubicin (undefined)
- **Class:** Anthracycline
- **Dosing:** 60-90 mg/m2 IV x 3d
- **Rationale:** Intercalates DNA. Cardiotoxic risk.

### 218. Vincristine (undefined)
- **Class:** Vinca Alkaloid
- **Dosing:** 1.4 mg/m2 Weekly
- **Rationale:** Microtubule inhibitor. Neuropathy risk.

### 219. N-Acetylcysteine (NAC) (undefined)
- **Class:** Antidote
- **Dosing:** 150 mg/kg Load -> 50 -> 100 IV Protocol (21h)
- **Rationale:** Replenishes Glutathione stores to detoxify NAPQI. Life-saving.

### 220. Activated Charcoal (undefined)
- **Class:** Adsorbent
- **Dosing:** 1 g/kg Stat
- **Rationale:** Binds drug in gut preventing absorption. Separate from oral NAC by 2h.

### 221. Doxycycline (undefined)
- **Class:** Tetracycline
- **Dosing:** 100 mg BD x 7 days
- **Rationale:** Superior efficacy for rectal/urogenital infection compared to Azithromycin.

### 222. Azithromycin (undefined)
- **Class:** Macrolide
- **Dosing:** 1 g Stat (Single dose)
- **Rationale:** Safe in pregnancy; convenient but slightly lower cure rates.

### 223. Naproxen (undefined)
- **Class:** NSAID
- **Dosing:** 500 mg BD
- **Rationale:** Reduces prostaglandin-mediated inflammation and pain.

### 224. Tizanidine (undefined)
- **Class:** Muscle Relaxant
- **Dosing:** 2 mg HS/BD
- **Rationale:** Central alpha-2 agonist reduces spasticity associated with spondylosis.

### 225. Pregabalin (undefined)
- **Class:** Gabapentinoid
- **Dosing:** 75 mg BD
- **Rationale:** Stabilizes nerve membranes to treat shooting/burning nerve pain.

### 226. Pembrolizumab (undefined)
- **Class:** Immune Checkpoint Inhibitor (PD-1)
- **Dosing:** 200 mg IV q3 weeks
- **Rationale:** Unleashes T-cells to attack cancer cells. Standard of care.

### 227. Dabrafenib + Trametinib (undefined)
- **Class:** Targeted Therapy (BRAF/MEK)
- **Dosing:** Oral regimen Daily
- **Rationale:** Blocks the MAPK pathway. Rapid response but resistance develops.

### 228. Calcium Gluconate (undefined)
- **Class:** Membrane Stabilizer
- **Dosing:** 10 ml (10%) IV Stat
- **Rationale:** Antagonizes membrane effect of K+ to prevent arrhythmia. Effect lasts 30-60 min.

### 229. Insulin + Dextrose (undefined)
- **Class:** Shifter
- **Dosing:** 10U Regular + 50ml D50 IV Stat
- **Rationale:** Insulin drives K+ into cells via Na-K ATPase. Dextrose prevents hypoglycemia.

### 230. Salbutamol (undefined)
- **Class:** Beta-2 Agonist
- **Dosing:** 10-20 mg Nebulization Stat
- **Rationale:** Stimulates Na-K pump. Dose is 4-8x higher than asthma dose.

### 231. Metoprolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** 25-50 mg BD
- **Rationale:** Slows AV node conduction to keep heart rate <110 bpm.

### 232. Apixaban (undefined)
- **Class:** DOAC (Factor Xa Inhibitor)
- **Dosing:** 5 mg BD
- **Rationale:** Prevents thromboembolism without need for INR monitoring (unlike Warfarin).

### 233. Amiodarone (undefined)
- **Class:** Antiarrhythmic (Class III)
- **Dosing:** 200 mg OD (after loading)
- **Rationale:** Maintains sinus rhythm in symptomatic patients or heart failure.

### 234. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** 100% Continuous
- **Rationale:** Washes out nitrogen by creating a steep diffusion gradient.

### 235. Hyperbaric Oxygen Therapy (HBOT) (undefined)
- **Class:** Recompression
- **Dosing:** US Navy Table 6 Session
- **Rationale:** Compresses bubbles (Boyles Law) and forces nitrogen back into solution.

### 236. IV Fluids (Crystalloids) (undefined)
- **Class:** Supportive
- **Dosing:** Bolus + Maintenance Continuous
- **Rationale:** Maintains perfusion; DCS causes hemoconcentration and capillary leak.

### 237. Escitalopram (undefined)
- **Class:** SSRI
- **Dosing:** 10-20 mg OD
- **Rationale:** Increases serotonin availability; better tolerability than TCAs.

### 238. Buspirone (undefined)
- **Class:** Anxiolytic (Non-benzo)
- **Dosing:** 5-10 mg TID
- **Rationale:** 5-HT1A partial agonist; no sedation or addiction risk.

### 239. Clonazepam (undefined)
- **Class:** Benzodiazepine
- **Dosing:** 0.25-0.5 mg SOS / HS
- **Rationale:** Rapid GABA-A modulation for immediate relief.

### 240. Octreotide LAR (undefined)
- **Class:** Somatostatin Analog
- **Dosing:** 20-30 mg IM Monthly
- **Rationale:** Inhibits GH secretion by binding to pituitary SSTR2 receptors.

### 241. Cabergoline (undefined)
- **Class:** Dopamine Agonist
- **Dosing:** 0.5 mg Twice Weekly
- **Rationale:** Inhibits GH (paradoxical effect in acromegaly, unlike normal physiology).

### 242. Pegvisomant (undefined)
- **Class:** GH Receptor Antagonist
- **Dosing:** 10-30 mg SC Daily
- **Rationale:** Blocks peripheral action of GH; normalizes IGF-1 but does not shrink tumor.

### 243. Sofosbuvir + Velpatasvir (undefined)
- **Class:** Direct Acting Antiviral (DAA)
- **Dosing:** 400/100 mg OD x 12 weeks
- **Rationale:** Inhibits NS5B polymerase and NS5A protein. High cure rate (>95%).

### 244. Glecaprevir + Pibrentasvir (undefined)
- **Class:** DAA
- **Dosing:** 300/120 mg 3 tabs OD x 8 weeks
- **Rationale:** Alternative regimen, useful in renal failure.

### 245. Nitrofurantoin (undefined)
- **Class:** Nitrofuran
- **Dosing:** 100 mg BD x 5 days
- **Rationale:** Concentrates in urine; low collateral damage to gut flora. Avoid if GFR < 30.

### 246. Fosfomycin (undefined)
- **Class:** Phosphonic Acid Derivative
- **Dosing:** 3 g Single Sachet
- **Rationale:** Single-dose convenience improves adherence.

### 247. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 1 g IV OD
- **Rationale:** Broad coverage for Gram-negatives including some resistant strains.

### 248. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Suppresses antibody production and reticuloendothelial phagocytosis of platelets.

### 249. IVIG (undefined)
- **Class:** Immunoglobulin
- **Dosing:** 1 g/kg IV x 2 days
- **Rationale:** Rapidly increases count by saturating Fc receptors on macrophages (blockade).

### 250. Eltrombopag (undefined)
- **Class:** TPO Receptor Agonist
- **Dosing:** 50 mg OD
- **Rationale:** Stimulates megakaryocytes to produce more platelets.

### 251. Tenofovir Disoproxil (TDF) (undefined)
- **Class:** NRTI
- **Dosing:** 300 mg OD
- **Rationale:** Nucleotide analog inhibiting reverse transcriptase.

### 252. Lamivudine (3TC) (undefined)
- **Class:** NRTI
- **Dosing:** 300 mg OD
- **Rationale:** Synergistic with Tenofovir; high barrier to resistance in combination.

### 253. Dolutegravir (undefined)
- **Class:** Integrase Inhibitor (INSTI)
- **Dosing:** 50 mg OD
- **Rationale:** Rapid viral suppression, high barrier to resistance. Part of 'TLD' regimen.

### 254. Artificial Tears (CMC) (undefined)
- **Class:** Lubricant
- **Dosing:** gtts q2-4h PRN
- **Rationale:** Symptomatic relief of corneal dryness.

### 255. Pilocarpine (undefined)
- **Class:** Cholinergic Agonist
- **Dosing:** 5 mg QID
- **Rationale:** Stimulates muscarinic receptors to increase residual gland secretion.

### 256. Hydroxychloroquine (undefined)
- **Class:** Immunomodulator
- **Dosing:** 200-400 mg OD
- **Rationale:** Treats fatigue and joint pain; prevents systemic progression.

### 257. Doxorubicin (Adriamycin) (undefined)
- **Class:** Anthracycline
- **Dosing:** 25 mg/m2 Days 1, 15
- **Rationale:** DNA intercalation. Risk of cardiomyopathy.

### 258. Bleomycin (undefined)
- **Class:** Antitumor Antibiotic
- **Dosing:** 10 U/m2 Days 1, 15
- **Rationale:** DNA strand scission. Risk of Pulmonary Fibrosis.

### 259. Vinblastine (undefined)
- **Class:** Vinca Alkaloid
- **Dosing:** 6 mg/m2 Days 1, 15
- **Rationale:** Microtubule inhibition. Risk of neuropathy.

### 260. Dimercaprol (BAL) (undefined)
- **Class:** Chelating Agent
- **Dosing:** 3-5 mg/kg IM q4h
- **Rationale:** Sulfhydryl donor that binds arsenic; crosses BBB. Use with caution (painful injection).

### 261. Succimer (DMSA) (undefined)
- **Class:** Chelator
- **Dosing:** 10 mg/kg PO TID
- **Rationale:** Oral analogue of BAL; safer side effect profile.

### 262. Penicillamine (undefined)
- **Class:** Chelator
- **Dosing:** 250-500 mg QID
- **Rationale:** Used if DMSA unavailable; high allergic potential.

### 263. Clomiphene Citrate (undefined)
- **Class:** SERM
- **Dosing:** 50-100 mg OD (Day 2-6)
- **Rationale:** Blocks estrogen feedback to hypothalamus, increasing FSH/LH surge.

### 264. Letrozole (undefined)
- **Class:** Aromatase Inhibitor
- **Dosing:** 2.5-5 mg OD (Day 3-7)
- **Rationale:** Often superior to Clomiphene for live birth rates in PCOS; mono-follicular growth.

### 265. Metformin (undefined)
- **Class:** Insulin Sensitizer
- **Dosing:** 500-1000 mg BD
- **Rationale:** Improves insulin resistance and spontaneous ovulation rates.

### 266. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Suppresses immune-mediated muscle destruction.

### 267. Methotrexate (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 15-25 mg Weekly
- **Rationale:** Long term maintenance for Polymyositis/Dermatomyositis.

### 268. Coenzyme Q10 (undefined)
- **Class:** Supplement
- **Dosing:** 100-200 mg OD
- **Rationale:** Repletes mitochondrial CoQ10 depleted by statins (Evidence mixed but commonly used).

### 269. Mupirocin (undefined)
- **Class:** Topical Antibiotic
- **Dosing:** 2% Ointment TID x 5-7 days
- **Rationale:** Inhibits bacterial protein synthesis. Highly effective for limited lesions.

### 270. Cephalexin (undefined)
- **Class:** Cephalosporin (1st Gen)
- **Dosing:** 500 mg QID
- **Rationale:** Systemic coverage for MSSA and Strep.

### 271. Amoxicillin-Clavulanate (undefined)
- **Class:** Beta-lactam
- **Dosing:** 625 mg TID
- **Rationale:** Covers beta-lactamase producing Staph.

### 272. IV Fluids (Normal Saline) (undefined)
- **Class:** Crystalloid
- **Dosing:** Bolus (Cooled) Stat
- **Rationale:** Restores perfusion. Use cooled fluids to assist temp reduction.

### 273. Benzodiazepines (Diazepam) (undefined)
- **Class:** Sedative
- **Dosing:** 5-10 mg IV Stat
- **Rationale:** Shivering generates heat, counteracting cooling measures. Must be suppressed.

### 274. Mannitol (undefined)
- **Class:** Osmotic Diuretic
- **Dosing:** 0.25 g/kg IV
- **Rationale:** Maintains renal flow and reduces intracranial pressure if present.

### 275. Norepinephrine (undefined)
- **Class:** Vasopressor
- **Dosing:** 0.05-0.1 mcg/kg/min IV Infusion
- **Rationale:** Increases SVR (Alpha-1) and contractility (Beta-1) with less arrhythmia risk than Dopamine.

### 276. Dobutamine (undefined)
- **Class:** Inotrope
- **Dosing:** 2-20 mcg/kg/min IV Infusion
- **Rationale:** Beta-1 agonist; increases contractility. Use only if BP permits.

### 277. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 40-80 mg IV Bolus
- **Rationale:** Reduces preload to relieve pulmonary edema.

### 278. Pancrelipase (undefined)
- **Class:** Enzyme Replacement
- **Dosing:** Titrated to fat intake With every meal/snack
- **Rationale:** Replaces lipase/protease/amylase to allow nutrient absorption.

### 279. Tobramycin (undefined)
- **Class:** Aminoglycoside
- **Dosing:** 300 mg Nebulized BD (28 days on/off)
- **Rationale:** Inhaled route delivers high lung concentrations with minimal systemic toxicity.

### 280. Ivacaftor / Lumacaftor (undefined)
- **Class:** CFTR Modulator
- **Dosing:** Genotype dependent BD
- **Rationale:** Corrects the folding or gating defect of the CFTR protein.

### 281. Donepezil (undefined)
- **Class:** Acetylcholinesterase Inhibitor
- **Dosing:** 5-10 mg OD (Night)
- **Rationale:** Increases synaptic acetylcholine. Side effect: Vivid dreams/Bradycardia.

### 282. Memantine (undefined)
- **Class:** NMDA Antagonist
- **Dosing:** 10-20 mg BD
- **Rationale:** Prevents glutamate excitotoxicity. Can be combined with Donepezil.

### 283. Quetiapine (undefined)
- **Class:** Antipsychotic
- **Dosing:** 12.5-25 mg SOS
- **Rationale:** Black Box Warning (mortality), but used for safety when non-pharm fails.

### 284. Somatropin (undefined)
- **Class:** Recombinant Human GH
- **Dosing:** 0.025-0.05 mg/kg/day SC Daily (Evening)
- **Rationale:** Mimics physiological nocturnal surge. Promotes linear growth via IGF-1.

### 285. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 40 mg OD x 28 days
- **Rationale:** Reduces inflammatory cytokine storm. Survival benefit in severe cases.

### 286. Pentoxifylline (undefined)
- **Class:** TNF Inhibitor (Non-specific)
- **Dosing:** 400 mg TID
- **Rationale:** Alternative for severe hepatitis (weak evidence but renal protective).

### 287. Thiamine (Vit B1) (undefined)
- **Class:** Vitamin
- **Dosing:** 100 mg IV/IM Daily
- **Rationale:** Prevents Wernicke's Encephalopathy (Triad: Confusion, Ataxia, Ophthalmoplegia).

### 288. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Suppresses glomerular inflammation and crescent formation.

### 289. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 40-80 mg BD
- **Rationale:** Essential for managing edema and hypertension in oliguric patients.

### 290. Ramipril (undefined)
- **Class:** ACE Inhibitor
- **Dosing:** 2.5-5 mg OD
- **Rationale:** Reduces intraglomerular pressure; use with caution if Creatinine is rising rapidly.

### 291. Hydroxyurea (undefined)
- **Class:** Cytoreductive
- **Dosing:** 500-1000 mg OD
- **Rationale:** Suppresses bone marrow production of all cell lines.

### 292. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75 mg OD
- **Rationale:** Reduces risk of cardiovascular events and controls erythromelalgia.

### 293. Ruxolitinib (undefined)
- **Class:** JAK1/2 Inhibitor
- **Dosing:** 10 mg BD
- **Rationale:** Targeted therapy reducing spleen size and symptom burden.

### 294. Oseltamivir (undefined)
- **Class:** Neuraminidase Inhibitor
- **Dosing:** 75 mg BD x 5 days
- **Rationale:** Prevents release of new viral particles. Reduces illness duration by ~1 day.

### 295. Paracetamol (undefined)
- **Class:** Antipyretic
- **Dosing:** 650 mg Q6H SOS
- **Rationale:** Symptomatic relief. Avoid Aspirin in children (Reye's Syndrome).

### 296. Baloxavir (undefined)
- **Class:** Endonuclease Inhibitor
- **Dosing:** 40-80 mg Single Dose
- **Rationale:** Newer single-dose alternative; blocks viral replication earlier.

### 297. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** High dose required to halt inflammation. Taper slowly over months.

### 298. Methotrexate (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 15-25 mg Weekly
- **Rationale:** First-line adjunct to reduce steroid load and toxicity.

### 299. IVIG (undefined)
- **Class:** Immunoglobulin
- **Dosing:** 2 g/kg Monthly
- **Rationale:** Modulates immune system; effective for resistant skin/muscle disease.

### 300. Gemcitabine (undefined)
- **Class:** Antimetabolite
- **Dosing:** 1000 mg/m2 Weekly
- **Rationale:** Standard backbone. Inhibits DNA synthesis.

### 301. Nab-Paclitaxel (undefined)
- **Class:** Taxane
- **Dosing:** 125 mg/m2 Weekly
- **Rationale:** Albumin-bound paclitaxel improves uptake in pancreatic stroma.

### 302. Pancrelipase (undefined)
- **Class:** Enzyme Replacement
- **Dosing:** 40k-50k Units With meals
- **Rationale:** Treats malabsorption and steatorrhea caused by duct blockage.

### 303. Flumazenil (undefined)
- **Class:** GABA Antagonist
- **Dosing:** 0.2 mg IV Stat (Repeat up to 3mg)
- **Rationale:** Competitively blocks BZD binding site. Contraindicated in chronic users due to seizure risk.

### 304. Activated Charcoal (undefined)
- **Class:** Adsorbent
- **Dosing:** 1 g/kg Stat
- **Rationale:** Reduces absorption; only if airway is protected.

### 305. Medroxyprogesterone (undefined)
- **Class:** Progestin
- **Dosing:** 10 mg OD x 10 days
- **Rationale:** Induces withdrawal bleed to diagnose anovulation and shed endometrium.

### 306. Ethinylestradiol + Desogestrel (undefined)
- **Class:** OCP
- **Dosing:** Standard OD
- **Rationale:** Provides estrogen replacement and regulates cycles in PCOS/Hypogonadism.

### 307. Cabergoline (undefined)
- **Class:** Dopamine Agonist
- **Dosing:** 0.25-0.5 mg Weekly
- **Rationale:** Shrinks pituitary prolactinomas and restores ovulation.

### 308. Tacrolimus (undefined)
- **Class:** Calcineurin Inhibitor
- **Dosing:** Titrated to trough (5-10 ng/mL) BD
- **Rationale:** Inhibits IL-2 production blocking T-cell activation. Potent but nephrotoxic.

### 309. Mycophenolate Mofetil (undefined)
- **Class:** Antimetabolite
- **Dosing:** 500-1000 mg BD
- **Rationale:** Inhibits purine synthesis specific to lymphocytes.

### 310. Methylprednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 500-1000 mg (Pulse) IV OD x 3d
- **Rationale:** Pulse therapy to rapidly halt cellular rejection.

### 311. Fluconazole (undefined)
- **Class:** Azole Antifungal
- **Dosing:** 150 mg Stat (Single dose) or Weekly
- **Rationale:** Systemic distribution; inhibits ergosterol synthesis.

### 312. Clotrimazole (undefined)
- **Class:** Topical Azole
- **Dosing:** 1% Cream/Pessary BD / HS
- **Rationale:** Direct topical action with minimal absorption.

### 313. Nystatin (undefined)
- **Class:** Polyene
- **Dosing:** 100,000 U/ml Susp QID (Swish & Swallow)
- **Rationale:** Non-absorbable; works locally in the gut/mouth.

### 314. Calcium Gluconate (undefined)
- **Class:** Electrolyte
- **Dosing:** 10-20 ml (10%) IV Slow Bolus
- **Rationale:** Rapidly raises ionized calcium. Less irritating to veins than Calcium Chloride.

### 315. Calcium Carbonate (undefined)
- **Class:** Supplement
- **Dosing:** 500-1000 mg BD/TID with meals
- **Rationale:** Requires stomach acid for absorption (take with food). 40% elemental calcium.

### 316. Calcitriol (undefined)
- **Class:** Active Vitamin D
- **Dosing:** 0.25-0.5 mcg OD
- **Rationale:** Bypasses renal activation step to increase gut absorption.

### 317. Enoxaparin (undefined)
- **Class:** LMWH
- **Dosing:** 1 mg/kg BD SC
- **Rationale:** Immediate action; safe in pregnancy and cancer. Bridge to oral agents.

### 318. Warfarin (undefined)
- **Class:** Vitamin K Antagonist
- **Dosing:** Titrated to INR 2-3 OD
- **Rationale:** Cost-effective standard; requires monitoring.

### 319. Apixaban (undefined)
- **Class:** DOAC
- **Dosing:** 10 mg BD x 7d -> 5 mg BD
- **Rationale:** No monitoring needed; lower bleed risk than Warfarin.

### 320. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** High FiO2 / PEEP Continuous
- **Rationale:** PEEP recruits collapsed alveoli to improve oxygenation.

### 321. Methylprednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Reduces inflammation and fibrosis (Benefit mainly in first 7-14 days).

### 322. Furosemide (undefined)
- **Class:** Diuretic
- **Dosing:** 20-40 mg IV
- **Rationale:** Conservative fluid strategy ('Keeping dry') improves lung function.

### 323. Donepezil (undefined)
- **Class:** AChE Inhibitor
- **Dosing:** 5-10 mg OD
- **Rationale:** Though approved for AD, shows modest benefit in Vascular Dementia.

### 324. Clopidogrel (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75 mg OD
- **Rationale:** Prevents recurrent strokes/TIAs.

### 325. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 20-40 mg OD
- **Rationale:** Stabilizes plaque and reduces lipid burden.

### 326. Cinacalcet (undefined)
- **Class:** Calcimimetic
- **Dosing:** 30 mg BD
- **Rationale:** Increases sensitivity of calcium-sensing receptor to extracellular calcium, lowering PTH.

### 327. Zoledronic Acid (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 4 mg IV Yearly
- **Rationale:** Inhibits osteoclast activity to protect bone density.

### 328. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 20-40 mg BD
- **Rationale:** Increases renal calcium excretion (Only after rehydration).

### 329. Ringer Lactate (undefined)
- **Class:** Crystalloid
- **Dosing:** Aggressive Bolus + Rate Continuous
- **Rationale:** Preferred over Saline; reduces SIRS response and maintains perfusion.

### 330. Fentanyl / Morphine (undefined)
- **Class:** Opioid
- **Dosing:** Titrated IV
- **Rationale:** Analgesia is a priority. (Morphine causing sphincter of Oddi spasm is largely theoretical/clinical myth).

### 331. Ondansetron (undefined)
- **Class:** Antiemetic
- **Dosing:** 4-8 mg IV TID
- **Rationale:** Prevents vomiting and allows bowel rest.

### 332. Sevelamer (undefined)
- **Class:** Phosphate Binder
- **Dosing:** 800 mg TID with meals
- **Rationale:** Non-calcium binder; prevents vascular calcification while lowering serum phosphate.

### 333. Erythropoietin (EPO) (undefined)
- **Class:** ESA
- **Dosing:** 4000-10000 IU Twice Weekly SC
- **Rationale:** Stimulates red cell production (kidneys no longer produce endogenous EPO).

### 334. Calcitriol (undefined)
- **Class:** Active Vitamin D
- **Dosing:** 0.25 mcg OD/Pulse
- **Rationale:** Suppresses PTH secretion to prevent renal bone disease.

### 335. Anti-Thymocyte Globulin (ATG) (undefined)
- **Class:** Immunosuppressant
- **Dosing:** Protocol based IV infusion (Inpatient)
- **Rationale:** Destroys cytotoxic T-cells attacking stem cells. Equine ATG is superior to Rabbit ATG.

### 336. Cyclosporine (undefined)
- **Class:** Calcineurin Inhibitor
- **Dosing:** 5 mg/kg BD (Trough monitoring)
- **Rationale:** Inhibits T-cell activation/IL-2 production to maintain response.

### 337. Eltrombopag (undefined)
- **Class:** TPO Receptor Agonist
- **Dosing:** 50-150 mg OD
- **Rationale:** Stimulates stem cell proliferation directly (Tri-lineage response).

### 338. Acyclovir (undefined)
- **Class:** Nucleoside Analog
- **Dosing:** 400 mg TID x 7-10d (Primary) or 5d (Recurrent)
- **Rationale:** Inhibits viral DNA polymerase. Needs phosphorylation by viral thymidine kinase.

### 339. Valacyclovir (undefined)
- **Class:** Prodrug
- **Dosing:** 1 g BD
- **Rationale:** Better bioavailability than Acyclovir; allows less frequent dosing.

### 340. Lidocaine Jelly (undefined)
- **Class:** Anesthetic
- **Dosing:** 2% Topical SOS
- **Rationale:** Symptomatic relief for painful genital/oral ulcers.

### 341. Levothyroxine (undefined)
- **Class:** Synthetic T4
- **Dosing:** 1.6 mcg/kg OD (Empty Stomach)
- **Rationale:** Replacement therapy. Dose titration based on TSH every 6-8 weeks.

### 342. Selenium (undefined)
- **Class:** Supplement
- **Dosing:** 200 mcg OD
- **Rationale:** May reduce anti-TPO titers and inflammation (Evidence mixed but commonly prescribed).

### 343. Rituximab (undefined)
- **Class:** Monoclonal Antibody
- **Dosing:** 375 mg/m2 Day 1
- **Rationale:** Targets CD20 antigen on B-cells causing lysis. Cornerstone of R-CHOP.

### 344. Cyclophosphamide (undefined)
- **Class:** Alkylating Agent
- **Dosing:** 750 mg/m2 Day 1
- **Rationale:** DNA cross-linking. Risk of hemorrhagic cystitis.

### 345. Doxorubicin (undefined)
- **Class:** Anthracycline
- **Dosing:** 50 mg/m2 Day 1
- **Rationale:** DNA intercalation. Dose-limiting cardiotoxicity.

### 346. Succimer (DMSA) (undefined)
- **Class:** Chelator
- **Dosing:** 10 mg/kg TID x 5 days
- **Rationale:** Oral, water-soluble analog of BAL with less toxicity. Increases urinary excretion of mercury.

### 347. Dimercaprol (BAL) (undefined)
- **Class:** Chelator
- **Dosing:** 3-5 mg/kg IM q4h
- **Rationale:** Traditional antidote containing sulfhydryl groups. Toxic and painful; reserve for severe renal compromise.

### 348. Penicillamine (undefined)
- **Class:** Chelator
- **Dosing:** 250 mg QID
- **Rationale:** Third-line agent used if DMSA is unavailable; high risk of hypersensitivity reactions.

### 349. Mefenamic Acid (undefined)
- **Class:** NSAID
- **Dosing:** 500 mg TID
- **Rationale:** Potent inhibitor of PG synthesis and blocks PG receptors. 'Ponstan' is a staple in India.

### 350. Drotaverine (undefined)
- **Class:** Antispasmodic
- **Dosing:** 40-80 mg TID
- **Rationale:** Phosphodiesterase inhibitor leading to smooth muscle relaxation. Often combined with NSAID.

### 351. Combined OCP (undefined)
- **Class:** Hormonal Contraceptive
- **Dosing:** Standard OD
- **Rationale:** Suppresses ovulation and thins endometrium, reducing PG production substrate.

### 352. Levocetirizine (undefined)
- **Class:** Antihistamine (2nd Gen H1)
- **Dosing:** 5 mg OD
- **Rationale:** Potent H1 blockade with minimal sedation compared to first-gen agents.

### 353. Pheniramine (Avil) (undefined)
- **Class:** Antihistamine (1st Gen H1)
- **Dosing:** 25-50 mg IM/IV/PO
- **Rationale:** Rapid onset but sedating. Common emergency use in India for immediate relief.

### 354. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.5-1 mg/kg OD x 3-5 days
- **Rationale:** Suppresses late-phase inflammatory cytokines; prevents recurrence.

### 355. Permethrin (undefined)
- **Class:** Pyrethroid
- **Dosing:** 5% Cream Overnight x 1 (Repeat in 7 days)
- **Rationale:** Neurotoxic to mites (Na+ channel blocker). Apply neck-down; wash off after 8-12 hours.

### 356. Ivermectin (undefined)
- **Class:** Anti-parasitic
- **Dosing:** 200 mcg/kg Stat (Repeat in 7-14 days)
- **Rationale:** Paralyzes mites (Glutamate-gated Cl- channels). Easier compliance than cream.

### 357. Levocetirizine (undefined)
- **Class:** Antihistamine
- **Dosing:** 5 mg HS
- **Rationale:** Symptomatic relief for itch to allow sleep.

### 358. Dextrose 5% (D5W) (undefined)
- **Class:** Free Water
- **Dosing:** Calculated Deficit Slow IV Infusion
- **Rationale:** Provides free water to dilute serum sodium. Metabolized to water.

### 359. 0.45% Saline (Half Normal) (undefined)
- **Class:** Hypotonic Saline
- **Dosing:** Maintenance IV
- **Rationale:** Replaces volume while providing some free water (safer than D5W in shock).

### 360. Desmopressin (undefined)
- **Class:** ADH Analog
- **Dosing:** 10-40 mcg Intranasal/Oral
- **Rationale:** Replaces missing ADH to concentrate urine and retain water.

### 361. Enoxaparin (undefined)
- **Class:** LMWH
- **Dosing:** 1 mg/kg SC BD
- **Rationale:** Immediate action. Preferred over Heparin unless renal failure exists.

### 362. Apixaban (undefined)
- **Class:** DOAC
- **Dosing:** 10 mg BD x 7d -> 5 mg BD BD
- **Rationale:** Oral monotherapy (no bridge needed). Non-inferior to Warfarin with less bleeding.

### 363. Alteplase (tPA) (undefined)
- **Class:** Thrombolytic
- **Dosing:** 100 mg IV Infusion (2h)
- **Rationale:** Dissolves clot rapidly. ONLY for hemodynamically unstable patients due to bleed risk.

### 364. Supportive Care (undefined)
- **Class:** N/A
- **Dosing:** N/A N/A
- **Rationale:** No specific cure exists. Focus on symptom relief and preventing complications.

### 365. Bronchodilators (undefined)
- **Class:** Beta-agonist/Anticholinergic
- **Dosing:** Standard PRN
- **Rationale:** Symptomatic relief if mixed obstructive pattern exists.

### 366. Isoniazid (undefined)
- **Class:** Antitubercular
- **Dosing:** 300 mg OD
- **Rationale:** Essential in patients with positive Mantoux due to high reactivation risk.

### 367. Alteplase (tPA) (undefined)
- **Class:** Thrombolytic
- **Dosing:** 0.9 mg/kg (Max 90mg) Stat (10% Bolus, 90% Infusion)
- **Rationale:** Converts plasminogen to plasmin to dissolve clot. Strict inclusion/exclusion criteria.

### 368. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 300 mg Stat (Rectal/Oral)
- **Rationale:** Prevents recurrent thrombosis. Give immediately if tPA excluded.

### 369. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 80 mg OD
- **Rationale:** Plaque stabilization and neuroprotection.

### 370. Calcium Carbonate (undefined)
- **Class:** Calcium Supplement
- **Dosing:** 1-2 g elemental Divided doses with meals
- **Rationale:** Binds dietary phosphate and provides calcium.

### 371. Calcitriol (undefined)
- **Class:** Active Vitamin D
- **Dosing:** 0.25-1 mcg OD/BD
- **Rationale:** PTH is needed to activate Vit D in kidney; Calcitriol bypasses this step.

### 372. Calcium Gluconate (undefined)
- **Class:** IV Calcium
- **Dosing:** 10-20 ml (10%) Slow IV
- **Rationale:** Rapid correction of ionized calcium to stabilize membranes.

### 373. Diclofenac (undefined)
- **Class:** NSAID
- **Dosing:** 75 mg IM Stat
- **Rationale:** Reduces prostaglandin-mediated gallbladder contraction and pain. Superior to opioids for colic.

### 374. Ursodeoxycholic Acid (UDCA) (undefined)
- **Class:** Bile Acid
- **Dosing:** 10-15 mg/kg HS
- **Rationale:** Reduces cholesterol saturation in bile. Works only for small, radiolucent stones; high recurrence.

### 375. Mebeverine (undefined)
- **Class:** Antispasmodic
- **Dosing:** 135 mg TID
- **Rationale:** Relieves smooth muscle spasm.

### 376. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 80-200 mg (High dose) IV Bolus
- **Rationale:** Maintains urine output to manage volume; does not speed up kidney recovery.

### 377. Calcium Gluconate (undefined)
- **Class:** Electrolyte
- **Dosing:** 10 ml (10%) IV Stat
- **Rationale:** Stabilizes cardiac membrane against arrhythmia.

### 378. Sodium Bicarbonate (undefined)
- **Class:** Alkalinizer
- **Dosing:** 1 mEq/kg IV
- **Rationale:** Shifts potassium intracellularly and corrects pH.

### 379. Fresh Frozen Plasma (FFP) (undefined)
- **Class:** Blood Product
- **Dosing:** 15 ml/kg Stat
- **Rationale:** Replaces all clotting factors.

### 380. Cryoprecipitate (undefined)
- **Class:** Blood Product
- **Dosing:** 10 units Stat
- **Rationale:** Concentrated source of Fibrinogen and Factor VIII.

### 381. Platelet Concentrate (undefined)
- **Class:** Blood Product
- **Dosing:** 1 Unit/10kg Stat
- **Rationale:** Replaces consumed platelets. Avoid in TTP, but indicated in DIC with bleeding.

### 382. Paracetamol (undefined)
- **Class:** Antipyretic
- **Dosing:** 500-650 mg Q6H SOS
- **Rationale:** Safe analgesic. NSAIDs (Aspirin/Ibuprofen) are CONTRAINDICATED due to bleeding risk.

### 383. Normal Saline / Ringer Lactate (undefined)
- **Class:** Crystalloid
- **Dosing:** Maintenance + Deficit IV
- **Rationale:** Maintains intravascular volume against capillary leak. Rate titration is key.

### 384. ORS (undefined)
- **Class:** Electrolyte Solution
- **Dosing:** Ad libitum Oral
- **Rationale:** Prevents dehydration in outpatient setting.

### 385. Methylprednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 g IV OD x 3-5 days
- **Rationale:** High dose speeds up recovery from attack but does not alter long-term outcome.

### 386. Interferon Beta-1a (undefined)
- **Class:** DMT (Disease Modifying Therapy)
- **Dosing:** Standard SC/IM
- **Rationale:** Reduces relapse rate and lesion accumulation.

### 387. Ocrelizumab (undefined)
- **Class:** Anti-CD20 Monoclonal Ab
- **Dosing:** 600 mg IV q6 months
- **Rationale:** Depletes B-cells; highly effective modern therapy.

### 388. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 4-16 mg Divided doses
- **Rationale:** Rapidly reduces vasogenic edema and ICP, improving neurological function.

### 389. Temozolomide (undefined)
- **Class:** Alkylating Agent
- **Dosing:** 75 mg/m2 Daily (with Radiation)
- **Rationale:** Oral chemo agent that crosses BBB. Works best if MGMT promoter is methylated.

### 390. Levetiracetam (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 500-1000 mg BD
- **Rationale:** Prevents seizures which increase ICP. Safe metabolic profile.

### 391. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 4-8 mg BD
- **Rationale:** Used mainly perioperatively or if significant mass effect exists.

### 392. Levetiracetam (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 500 mg BD
- **Rationale:** Used if tumor location is epileptogenic (Cortical surface).

### 393. Hydroxyurea (undefined)
- **Class:** Chemotherapy
- **Dosing:** Variable Daily
- **Rationale:** Limited efficacy; Surgery/Radiation is primary treatment.

### 394. Filgrastim (G-CSF) (undefined)
- **Class:** Colony Stimulating Factor
- **Dosing:** 5-10 mcg/kg SC Daily
- **Rationale:** Accelerates neutrophil recovery to prevent opportunistic sepsis.

### 395. Potassium Iodide (KI) (undefined)
- **Class:** Thyroid Shield
- **Dosing:** 130 mg Stat
- **Rationale:** Saturates thyroid gland with stable iodine, blocking uptake of radioactive I-131.

### 396. Ondansetron (undefined)
- **Class:** Antiemetic
- **Dosing:** 8 mg TID
- **Rationale:** Control of symptoms to prevent dehydration.

### 397. Ciprofloxacin (undefined)
- **Class:** Fluoroquinolone
- **Dosing:** 500 mg BD x 4-6 weeks
- **Rationale:** Excellent tissue penetration. Long duration required to eradicate deep-seated infection.

### 398. Tamsulosin (undefined)
- **Class:** Alpha-1 Blocker
- **Dosing:** 0.4 mg HS
- **Rationale:** Relaxes bladder neck/prostate smooth muscle to improve flow and reduce reflux.

### 399. Celecoxib (undefined)
- **Class:** NSAID
- **Dosing:** 200 mg BD
- **Rationale:** Anti-inflammatory effect helps with chronic pelvic pain symptoms.

### 400. Imiglucerase (undefined)
- **Class:** Enzyme Replacement Therapy (ERT)
- **Dosing:** 60 U/kg IV q2 weeks
- **Rationale:** Recombinant enzyme taken up by macrophages to break down substrate. Reverses organomegaly.

### 401. Eliglustat (undefined)
- **Class:** Substrate Reduction Therapy (SRT)
- **Dosing:** 84 mg BD
- **Rationale:** Inhibits glucosylceramide synthase, reducing substrate production to match defective clearance.

### 402. Alendronate (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 70 mg Weekly
- **Rationale:** Prevents bone loss and fractures secondary to marrow infiltration.

### 403. Salicylic Acid (undefined)
- **Class:** Keratolytic
- **Dosing:** 16-26% Paint Daily
- **Rationale:** Chemically destroys infected keratinocytes and stimulates local immunity.

### 404. Imiquimod (undefined)
- **Class:** Immune Response Modifier
- **Dosing:** 5% Cream 3x/week
- **Rationale:** Induces Interferon-alpha production to clear virus. High recurrence rate if stopped early.

### 405. Podophyllotoxin (undefined)
- **Class:** Antimitotic
- **Dosing:** 0.5% Solution BD x 3 days
- **Rationale:** Arrests cell division in metaphase causing necrosis of wart tissue.

### 406. Cholecalciferol (Vit D3) (undefined)
- **Class:** Vitamin Supplement
- **Dosing:** 60,000 IU Weekly x 8 weeks
- **Rationale:** Loading dose to rapidly saturate body stores. Follow with monthly maintenance.

### 407. Calcium Carbonate (undefined)
- **Class:** Mineral Supplement
- **Dosing:** 500 mg BD
- **Rationale:** Provides substrate for bone mineralization. Take with food for absorption.

### 408. Calcitriol (undefined)
- **Class:** Active Vitamin D
- **Dosing:** 0.25 mcg OD
- **Rationale:** Use ONLY if hydroxylation is impaired; otherwise native D3 is preferred.

### 409. Atorvastatin (undefined)
- **Class:** HMG-CoA Reductase Inhibitor
- **Dosing:** 40-80 mg OD (Any time)
- **Rationale:** Potent LDL reduction (>50%). Stabilizes atherosclerotic plaques.

### 410. Fenofibrate (undefined)
- **Class:** Fibrate
- **Dosing:** 145 mg OD
- **Rationale:** Activates PPAR-alpha to lower TG. Caution with statins (myopathy risk).

### 411. Ezetimibe (undefined)
- **Class:** Cholesterol Absorption Inhibitor
- **Dosing:** 10 mg OD
- **Rationale:** Inhibits NPC1L1 transporter in gut; useful if statin target not met.

### 412. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** Titrate to SpO2 > 90% Continuous (LTOT)
- **Rationale:** Prevents pulmonary hypertension and improves quality of life.

### 413. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** Trial dose OD
- **Rationale:** Limited evidence; generally ineffective for established fibrosis but tried if inflammation suspected.

### 414. Influenza Vaccine (undefined)
- **Class:** Vaccine
- **Dosing:** 0.5 ml Annually
- **Rationale:** Prevents acute respiratory decompensation.

### 415. Mannitol (undefined)
- **Class:** Osmotic Diuretic
- **Dosing:** 0.25-1 g/kg IV Bolus q4-6h
- **Rationale:** Draws water out of brain tissue to reduce edema and intracranial pressure.

### 416. Labetalol (undefined)
- **Class:** Alpha/Beta Blocker
- **Dosing:** 10-20 mg IV Push
- **Rationale:** Rapidly lowers BP without increasing ICP (unlike vasodilators like Nitroprusside).

### 417. Vitamin K / FFP (undefined)
- **Class:** Reversal Agent
- **Dosing:** 10 mg / 15 ml/kg IV Stat
- **Rationale:** Immediate reversal of anticoagulation is mandatory.

### 418. Metformin (undefined)
- **Class:** Biguanide
- **Dosing:** 500 mg BD
- **Rationale:** Improves insulin sensitivity and assists mild weight loss.

### 419. Telmisartan (undefined)
- **Class:** ARB
- **Dosing:** 40 mg OD
- **Rationale:** Has PPAR-gamma agonist properties; improves insulin sensitivity unlike Beta-blockers.

### 420. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 10-20 mg OD
- **Rationale:** Reduces CV risk and lipid levels.

### 421. Mebeverine (undefined)
- **Class:** Antispasmodic
- **Dosing:** 135 mg TID (20 min before meals)
- **Rationale:** Direct smooth muscle relaxant; reduces colonic spasms without anticholinergic side effects.

### 422. Psyllium Husk (Isabgol) (undefined)
- **Class:** Bulk Laxative
- **Dosing:** 1-2 spoons HS with water
- **Rationale:** Soluble fiber regulates stool consistency (helps both C and D subtypes).

### 423. Rifaximin (undefined)
- **Class:** Antibiotic (Non-absorbable)
- **Dosing:** 550 mg TID x 14 days
- **Rationale:** Treats Small Intestinal Bacterial Overgrowth (SIBO) which often co-exists.

### 424. Diclofenac (undefined)
- **Class:** NSAID
- **Dosing:** 75 mg IM Stat
- **Rationale:** Reduces ureteric spasm and glomerular filtration, providing superior pain relief to opioids.

### 425. Tamsulosin (undefined)
- **Class:** Alpha-1 Blocker
- **Dosing:** 0.4 mg OD
- **Rationale:** Relaxes distal ureter smooth muscle to facilitate passage of distal stones.

### 426. Potassium Citrate (undefined)
- **Class:** Urinary Alkalinizer
- **Dosing:** 1080 mg TID
- **Rationale:** Citrate inhibits crystal aggregation; alkalization dissolves uric acid stones.

### 427. Eculizumab (undefined)
- **Class:** Monoclonal Antibody (C5 Inhibitor)
- **Dosing:** 900 mg IV q2 weeks
- **Rationale:** Blocks terminal complement activation, halting intravascular hemolysis. Requires Meningococcal vaccine.

### 428. Ravulizumab (undefined)
- **Class:** Long-acting C5 Inhibitor
- **Dosing:** Weight based IV q8 weeks
- **Rationale:** Longer half-life improves adherence and quality of life.

### 429. Folic Acid (undefined)
- **Class:** Vitamin
- **Dosing:** 5 mg OD
- **Rationale:** Supports high erythropoietic drive.

### 430. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 6 mg OD x 10 days
- **Rationale:** Reduces systemic inflammation and mortality in severe disease (RECOVERY Trial).

### 431. Remdesivir (undefined)
- **Class:** Antiviral
- **Dosing:** 200mg Load -> 100mg OD x 5 days
- **Rationale:** Inhibits viral RNA polymerase. Modest benefit in shortening recovery time if given early.

### 432. Enoxaparin (undefined)
- **Class:** LMWH
- **Dosing:** Prophylactic/Therapeutic SC OD/BD
- **Rationale:** Prevents venous thromboembolism and microthrombi associated with COVID-19.

### 433. IVIG (undefined)
- **Class:** Immunoglobulin
- **Dosing:** 0.4 g/kg/day IV x 5 days
- **Rationale:** Neutralizes pathogenic autoantibodies. Equally effective as Plasma Exchange.

### 434. Plasmapheresis (PLEX) (undefined)
- **Class:** Procedure
- **Dosing:** 5 sessions Alternate days
- **Rationale:** Removes circulating antibodies and complement. Preferred in severe/rapidly progressive cases if available.

### 435. Gabapentin (undefined)
- **Class:** Gabapentinoid
- **Dosing:** 300 mg TID
- **Rationale:** Symptomatic relief for severe back/limb pain associated with nerve inflammation.

### 436. Cisplatin (undefined)
- **Class:** Platinum Agent
- **Dosing:** 20 mg/m2 Days 1-5
- **Rationale:** Curative backbone. Cross-links DNA. High emetogenic potential and nephrotoxicity.

### 437. Etoposide (undefined)
- **Class:** Topoisomerase II Inhibitor
- **Dosing:** 100 mg/m2 Days 1-5
- **Rationale:** Synergistic with Cisplatin. Risk of secondary leukemia.

### 438. Bleomycin (undefined)
- **Class:** Antitumor Antibiotic
- **Dosing:** 30 units Days 1, 8, 15
- **Rationale:** Pulmonary fibrosis risk; omitted in patients with lung issues (EP regimen).

### 439. Polyvalent Anti-Snake Venom (ASV) (undefined)
- **Class:** Antivenom
- **Dosing:** 10 Vials IV Infusion Stat
- **Rationale:** Neutralizes circulating venom. Repeat if coagulation doesn't correct in 6 hours or neuro signs worsen.

### 440. Neostigmine (undefined)
- **Class:** AChE Inhibitor
- **Dosing:** 0.04 mg/kg IV q30min
- **Rationale:** Increases ACh at NMJ to overcome post-synaptic blockade. Always give with Atropine.

### 441. Atropine (undefined)
- **Class:** Anticholinergic
- **Dosing:** 0.6 mg With Neostigmine
- **Rationale:** Prevents bradycardia and secretions caused by Neostigmine.

### 442. Tadalafil (undefined)
- **Class:** PDE5 Inhibitor
- **Dosing:** 5-10 mg OD / PRN
- **Rationale:** Long half-life (36h) reduces 'timing pressure', breaking the anxiety cycle.

### 443. Sildenafil (undefined)
- **Class:** PDE5 Inhibitor
- **Dosing:** 50 mg PRN
- **Rationale:** Ensures erection occurs despite mild anxiety, restoring confidence.

### 444. Buspirone (undefined)
- **Class:** Anxiolytic
- **Dosing:** 5-10 mg TID
- **Rationale:** Reduces anxiety without sexual side effects common to SSRIs.

### 445. Normal Saline (undefined)
- **Class:** Crystalloid
- **Dosing:** 1-2 L Bolus -> High Rate Continuous
- **Rationale:** Increases GFR to flush nephrotoxic myoglobin. Target UO 3ml/kg/hr.

### 446. Sodium Bicarbonate (undefined)
- **Class:** Alkalinizer
- **Dosing:** 50-100 mEq/L IV Infusion
- **Rationale:** Aim Urine pH > 6.5. Prevents dissociation of myoglobin into toxic ferrihemate and cast formation.

### 447. Mannitol (undefined)
- **Class:** Osmotic Diuretic
- **Dosing:** 0.5 g/kg IV
- **Rationale:** Scavenges free radicals and forces diuresis. Use only after volume repletion.

### 448. Tacrolimus (undefined)
- **Class:** Calcineurin Inhibitor
- **Dosing:** 0.1% Ointment BD
- **Rationale:** Immunomodulator without steroid side effects (atrophy). Safe for long-term use on face.

### 449. Clobetasol (undefined)
- **Class:** Potent Corticosteroid
- **Dosing:** 0.05% Cream OD (Cycles)
- **Rationale:** Suppresses T-cell activity. Use cyclically (2 weeks on/off) to prevent atrophy.

### 450. Methoxsalen (undefined)
- **Class:** Psoralen
- **Dosing:** Topical/Oral With UVA
- **Rationale:** Photosensitizer + UV light stimulates melanocyte migration from hair follicles.

### 451. CPAP Device (undefined)
- **Class:** Mechanical
- **Dosing:** Titrated Pressure Every night
- **Rationale:** Pneumatic splint keeps airway open. Not a drug, but the primary 'prescription'.

### 452. Modafinil (undefined)
- **Class:** Wakefulness Promoter
- **Dosing:** 100-200 mg Morning
- **Rationale:** Used only after CPAP is optimized to treat persisting somnolence.

### 453. Fluticasone (Nasal) (undefined)
- **Class:** Corticosteroid
- **Dosing:** 2 sprays OD
- **Rationale:** Reduces nasal resistance to improve CPAP tolerance.

### 454. Benzathine Penicillin G (undefined)
- **Class:** Antibiotic
- **Dosing:** 1.2 Million Units IM Stat (then q3-4 weeks)
- **Rationale:** Eliminates carrier state and prevents recurrent Strep infections.

### 455. Aspirin (undefined)
- **Class:** NSAID
- **Dosing:** 50-100 mg/kg/day Divided q4-6h
- **Rationale:** High dose required for anti-inflammatory effect. Dramatic relief of joint pain is typical.

### 456. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1-2 mg/kg OD
- **Rationale:** Suppresses inflammation in patients with heart failure or cardiomegaly.

### 457. Ibuprofen / Aspirin (undefined)
- **Class:** NSAID
- **Dosing:** 600-800 mg / 650-1000 mg TID
- **Rationale:** High doses required for anti-inflammatory effect. Taper slowly after CRP normalizes.

### 458. Colchicine (undefined)
- **Class:** Anti-inflammatory
- **Dosing:** 0.5 mg BD x 3 months
- **Rationale:** Inhibits microtubule assembly and neutrophil function.

### 459. Pantoprazole (undefined)
- **Class:** PPI
- **Dosing:** 40 mg OD
- **Rationale:** Mandatory with high-dose NSAID therapy.

### 460. Haloperidol (undefined)
- **Class:** Antipsychotic (Typical)
- **Dosing:** 0.5-1 mg PO/IM SOS
- **Rationale:** Dopamine antagonist. Use low dose only if patient is a danger to self/others. Watch QTc.

### 461. Quetiapine (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 12.5-25 mg HS
- **Rationale:** Lower EPS risk; useful for nocturnal agitation.

### 462. Thiamine (undefined)
- **Class:** Vitamin
- **Dosing:** 100 mg IV/IM Daily
- **Rationale:** Empiric coverage for Wernicke's in confusing cases.

### 463. Phenoxybenzamine (undefined)
- **Class:** Alpha-Blocker (Non-selective)
- **Dosing:** 10 mg BD titrated BD
- **Rationale:** Irreversible alpha blockade controls BP and expands blood volume (allow 10-14 days).

### 464. Propranolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** 10-20 mg TID
- **Rationale:** Started ONLY after adequate alpha blockade to control heart rate.

### 465. Sodium Nitroprusside (undefined)
- **Class:** Vasodilator
- **Dosing:** Infusion Continuous
- **Rationale:** Rapidly titratable for hypertensive surges during tumor handling.

### 466. Gluten-Free Diet (undefined)
- **Class:** Dietary
- **Dosing:** Lifelong Daily
- **Rationale:** Only effective treatment. Reverses mucosal damage and prevents malignancy.

### 467. Iron / Calcium / Vit D (undefined)
- **Class:** Supplements
- **Dosing:** Therapeutic Daily
- **Rationale:** Corrects malabsorption deficits. Bone density scan recommended.

### 468. Dapsone (undefined)
- **Class:** Sulfone
- **Dosing:** 50-100 mg OD
- **Rationale:** Treats the skin rash (does not treat the gut; diet still needed).

### 469. Artesunate (undefined)
- **Class:** Artemisinin Derivative
- **Dosing:** 2.4 mg/kg IV at 0, 12, 24h
- **Rationale:** Rapidly clears parasitemia. Follow with oral ACT when patient can swallow.

### 470. Clindamycin / Doxycycline (undefined)
- **Class:** Antibiotic
- **Dosing:** Standard BD
- **Rationale:** Synergistic antimalarial action; ensures radical cure.

### 471. Dextrose (undefined)
- **Class:** Carbohydrate
- **Dosing:** 25% or 50% IV Bolus
- **Rationale:** Critical supportive care; parasites consume glucose rapidly.

### 472. Human Tetanus Immunoglobulin (HTIG) (undefined)
- **Class:** Antitoxin
- **Dosing:** 3000-6000 IU IM Stat
- **Rationale:** Neutralizes circulating toxin ONLY. Bound toxin cannot be reversed (symptoms persist for weeks).

### 473. Metronidazole (undefined)
- **Class:** Antibiotic
- **Dosing:** 500 mg IV Q6H
- **Rationale:** Eradicates vegetative bacteria. Preferred over Penicillin (which acts as GABA antagonist).

### 474. Diazepam (undefined)
- **Class:** Benzodiazepine
- **Dosing:** 10-40 mg/hr IV Infusion
- **Rationale:** GABA agonist to control rigidity. Very high doses often required.

### 475. Levothyroxine (undefined)
- **Class:** Thyroid Hormone
- **Dosing:** Age based OD
- **Rationale:** Early treatment prevents further intellectual compromise.

### 476. Donepezil (undefined)
- **Class:** AChE Inhibitor
- **Dosing:** 5-10 mg OD
- **Rationale:** Symptomatic management of cognitive decline in adults.

### 477. Digoxin (undefined)
- **Class:** Cardiac Glycoside
- **Dosing:** Pediatric dosing BD
- **Rationale:** Management of congenital heart defects prior to surgery.

### 478. Somatropin (undefined)
- **Class:** Growth Hormone
- **Dosing:** 0.045-0.05 mg/kg/day SC Daily
- **Rationale:** Start early (age 4-5) to optimize final adult height.

### 479. Ethinylestradiol (undefined)
- **Class:** Estrogen
- **Dosing:** Low dose Daily
- **Rationale:** Induces secondary sexual characteristics. Start around age 12.

### 480. Progesterone (undefined)
- **Class:** Progestin
- **Dosing:** Cyclic Monthly
- **Rationale:** Added after 2 years of estrogen to prevent endometrial hyperplasia.

### 481. Testosterone Enanthate (undefined)
- **Class:** Androgen
- **Dosing:** 200 mg IM q2-3 weeks
- **Rationale:** Virilization, muscle mass, bone density, and libido improvement.

### 482. Anastrozole (undefined)
- **Class:** Aromatase Inhibitor
- **Dosing:** 1 mg OD
- **Rationale:** Reduces conversion of testosterone to estrogen (Adjunct, surgery preferred).

### 483. Calcium / Vit D (undefined)
- **Class:** Supplement
- **Dosing:** Standard Daily
- **Rationale:** Prevents osteoporosis associated with hypogonadism.

### 484. Imatinib (undefined)
- **Class:** Tyrosine Kinase Inhibitor (1st Gen)
- **Dosing:** 400 mg OD
- **Rationale:** Competitively inhibits ATP binding site of BCR-ABL kinase.

### 485. Dasatinib (undefined)
- **Class:** TKI (2nd Gen)
- **Dosing:** 100 mg OD
- **Rationale:** More potent; effective against many mutations. Risk of pleural effusion.

### 486. Hydroxyurea (undefined)
- **Class:** Cytoreductive
- **Dosing:** 1-2 g Daily
- **Rationale:** Lowers WBC count rapidly before confirming diagnosis/starting TKI.

### 487. Somatropin (undefined)
- **Class:** Growth Hormone
- **Dosing:** 0.035 mg/kg/day SC Daily
- **Rationale:** Improves height, increases lean muscle mass, and decreases fat mass. Contraindicated in severe obesity/apnea.

### 488. Topiramate (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 25-100 mg BD
- **Rationale:** Mood stabilization and mild appetite suppression.

### 489. Testosterone / Estrogen (undefined)
- **Class:** Hormone
- **Dosing:** Replacement Cyclic
- **Rationale:** Puberty induction and bone health.

### 490. Supportive Care (undefined)
- **Class:** N/A
- **Dosing:** N/A N/A
- **Rationale:** Focus on comfort, feeding (NG tube), and family counseling due to life-limiting nature.

### 491. Diuretics (Furosemide) (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 1 mg/kg BD
- **Rationale:** Symptomatic relief of pulmonary congestion if cardiac defects are present.

### 492. Phenobarbital (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 3-5 mg/kg OD
- **Rationale:** Seizures are common; monotherapy preferred to minimize sedation.

### 493. Comfort Measures (undefined)
- **Class:** Palliative
- **Dosing:** Titrated PRN
- **Rationale:** Opioids/Benzodiazepines for distress/seizures.

### 494. Anticonvulsants (undefined)
- **Class:** Various
- **Dosing:** Standard Maintenance
- **Rationale:** Management of structural epilepsy.

### 495. Physiotherapy (undefined)
- **Class:** Therapy
- **Dosing:** Daily Ongoing
- **Rationale:** Improves motor milestones.

### 496. Speech Therapy (undefined)
- **Class:** Therapy
- **Dosing:** Regular Ongoing
- **Rationale:** Sign language often needed due to severe speech delay.

### 497. Melatonin (undefined)
- **Class:** Supplement
- **Dosing:** 2-5 mg HS
- **Rationale:** Regulates circadian rhythm issues common in neurodevelopmental disorders.

### 498. Stimulants (Methylphenidate) (undefined)
- **Class:** CNS Stimulant
- **Dosing:** Titrated OD/BD
- **Rationale:** Improves focus and hyperactivity. Monitor for anxiety worsening.

### 499. Sertraline (undefined)
- **Class:** SSRI
- **Dosing:** 25-50 mg OD
- **Rationale:** Treats social anxiety and mood instability.

### 500. Risperidone (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 0.5-2 mg BD
- **Rationale:** FDA approved for irritability associated with Autism/Fragile X.

### 501. Sodium Valproate (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 20-30 mg/kg BD
- **Rationale:** Broad spectrum control. Seizures in Angelman are often refractory.

### 502. Clonazepam (undefined)
- **Class:** Benzodiazepine
- **Dosing:** 0.05 mg/kg HS
- **Rationale:** Treats myoclonic jerks and aids sleep initiation.

### 503. Melatonin (undefined)
- **Class:** Supplement
- **Dosing:** 3-6 mg HS
- **Rationale:** Addresses the severe sleep fragmentation common in AS.

### 504. Calcium Carbonate (undefined)
- **Class:** Supplement
- **Dosing:** Titrated QID
- **Rationale:** Maintains serum calcium.

### 505. Calcitriol (undefined)
- **Class:** Active Vitamin D
- **Dosing:** 0.25 mcg OD
- **Rationale:** Required due to lack of PTH-mediated Vit D activation.

### 506. Cotrimoxazole (undefined)
- **Class:** Antibiotic
- **Dosing:** Prophylactic MWF
- **Rationale:** PCP prophylaxis if CD4 counts are very low.

### 507. Amlodipine (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** Age based OD
- **Rationale:** Treats vascular stiffness. Beta-blockers used with caution in SVAS.

### 508. Low Calcium Diet (undefined)
- **Class:** Dietary
- **Dosing:** Restriction Daily
- **Rationale:** Reduces calcium load; steroids used in severe cases.

### 509. Sodium Valproate / Levetiracetam (undefined)
- **Class:** Anticonvulsant
- **Dosing:** Standard BD
- **Rationale:** Broad spectrum coverage; often requires polytherapy.

### 510. Gastrostomy (PEG) (undefined)
- **Class:** Surgical
- **Dosing:** N/A Continuous
- **Rationale:** Ensures adequate nutrition due to severe hypotonia/clefts.

### 511. Ascorbic Acid (undefined)
- **Class:** Vitamin C
- **Dosing:** 100-300 mg Daily x 1 month
- **Rationale:** Rapidly corrects deficiency. Spontaneous bleeding stops within 24h.

### 512. Nicotinamide (undefined)
- **Class:** Vitamin B3
- **Dosing:** 100-300 mg Divided Doses
- **Rationale:** Preferred over Nicotinic Acid (Niacin) to avoid flushing side effects.

### 513. B-Complex (undefined)
- **Class:** Multivitamin
- **Dosing:** 1 tab OD
- **Rationale:** Deficiencies rarely occur in isolation; B2 and B6 are needed for Niacin metabolism.

### 514. Thiamine (Vit B1) (undefined)
- **Class:** Vitamin
- **Dosing:** 100 mg (Wernicke's: 500mg) IV/IM -> PO
- **Rationale:** Parenteral route mandatory for cardiac/neuro symptoms due to poor gut absorption in deficiency.

### 515. Furosemide (undefined)
- **Class:** Diuretic
- **Dosing:** 20 mg IV
- **Rationale:** Cautious use for heart failure; Thiamine is the actual cure for the pump failure.

### 516. Vitamin A (Retinol) (undefined)
- **Class:** Vitamin
- **Dosing:** 100,000 - 200,000 IU Day 0, 1, and 14
- **Rationale:** WHO Schedule: Massive doses required to replenish liver stores rapidly.

### 517. Artificial Tears (undefined)
- **Class:** Lubricant
- **Dosing:** q2h PRN
- **Rationale:** Symptomatic relief for dry eyes.

### 518. Antibiotic Eye Ointment (undefined)
- **Class:** Antimicrobial
- **Dosing:** Topical BD
- **Rationale:** Prevents secondary bacterial infection in compromised cornea.

### 519. Phytomenadione (Vit K1) (undefined)
- **Class:** Vitamin
- **Dosing:** 1-10 mg PO/SC/IV
- **Rationale:** IV acts fastest (6-8h). Oral takes 24h. Anaphylaxis risk with rapid IV push.

### 520. Fresh Frozen Plasma (FFP) (undefined)
- **Class:** Blood Product
- **Dosing:** 15 ml/kg Stat
- **Rationale:** Immediate replacement of factors (Vit K takes time to work).

### 521. Alpha-Tocopherol (undefined)
- **Class:** Vitamin E
- **Dosing:** 800-1200 IU Daily
- **Rationale:** High doses required to penetrate CNS and arrest progression.

### 522. Water-soluble Vitamin E (undefined)
- **Class:** Formulation
- **Dosing:** Standard Daily
- **Rationale:** TPGS form enables absorption without bile salts.

### 523. Riboflavin (undefined)
- **Class:** Vitamin B2
- **Dosing:** 10-20 mg Daily
- **Rationale:** Rapidly resolves mucocutaneous lesions.

### 524. B-Complex (undefined)
- **Class:** Multivitamin
- **Dosing:** 1 tab OD
- **Rationale:** Always treat with other B vitamins.

### 525. Pyridoxine (undefined)
- **Class:** Vitamin B6
- **Dosing:** 50-100 mg OD
- **Rationale:** Corrects metabolic defects. High doses (gram quantities) needed for acute INH overdose seizures.

### 526. B-Complex (undefined)
- **Class:** Multivitamin
- **Dosing:** Standard OD
- **Rationale:** Maintains balance of other B vitamins.

### 527. Latanoprost (undefined)
- **Class:** Prostaglandin Analog
- **Dosing:** 1 drop OD (Night)
- **Rationale:** Increases uveoscleral outflow. Most potent IOP lowering effect with once-daily dosing.

### 528. Timolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** 0.5% Drop BD
- **Rationale:** Decreases aqueous humor production. Caution in asthma/bradycardia (systemic absorption).

### 529. Acetazolamide (undefined)
- **Class:** Carbonic Anhydrase Inhibitor
- **Dosing:** 250-500 mg Stat / QID
- **Rationale:** Systemic CAI rapidly reduces aqueous production in emergency. Follow with Laser Iridotomy.

### 530. Moxifloxacin (undefined)
- **Class:** Fluoroquinolone
- **Dosing:** 0.5% Drop TID x 5-7 days
- **Rationale:** Broad spectrum, preservative-free options available. DOC for contact lens wearers.

### 531. Olopatadine (undefined)
- **Class:** Mast Cell Stabilizer/Antihistamine
- **Dosing:** 0.1% Drop BD
- **Rationale:** Dual action provides rapid itch relief and long-term control.

### 532. Artificial Tears (undefined)
- **Class:** Lubricant
- **Dosing:** Q4H PRN
- **Rationale:** Symptomatic relief. No specific antiviral exists for Adenovirus.

### 533. Ranibizumab / Bevacizumab (undefined)
- **Class:** Anti-VEGF Monoclonal Ab
- **Dosing:** 0.5 mg / 1.25 mg Intravitreal Monthly
- **Rationale:** Inhibits angiogenesis and reduces vascular permeability, drying the macula.

### 534. Aflibercept (undefined)
- **Class:** VEGF Trap
- **Dosing:** 2 mg Intravitreal q8 weeks
- **Rationale:** Binds VEGF-A, VEGF-B, and PlGF; longer duration of action.

### 535. AREDS2 Formula (undefined)
- **Class:** Antioxidant Supplement
- **Dosing:** 1 cap BD
- **Rationale:** Reduces risk of progression to advanced AMD by 25%. Beta-carotene removed to safer for smokers.

### 536. Ranibizumab (undefined)
- **Class:** Anti-VEGF
- **Dosing:** 0.3 mg Intravitreal
- **Rationale:** First-line for center-involving edema with vision loss. Restores blood-retinal barrier.

### 537. Dexamethasone Implant (Ozurdex) (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.7 mg Intravitreal q4-6 months
- **Rationale:** Sustained release steroid for cases resistant to Anti-VEGF or post-vitrectomized eyes.

### 538. Pan-Retinal Photocoagulation (PRP) (undefined)
- **Class:** Laser Surgery
- **Dosing:** N/A Sessions
- **Rationale:** Sacrifices peripheral retina to reduce oxygen demand and VEGF drive, regressing new vessels.

### 539. Prednisolone Acetate (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1% Drop Hourly (Acute) -> Taper
- **Rationale:** Aggressive topical suppression of inflammation. Shake bottle well (suspension).

### 540. Atropine / Cyclopentolate (undefined)
- **Class:** Cycloplegic
- **Dosing:** 1% Drop BD/TID
- **Rationale:** Dilates pupil to prevent Synechiae and relaxes ciliary muscle to relieve pain/spasm.

### 541. Methotrexate / Azathioprine (undefined)
- **Class:** Immunosuppressant
- **Dosing:** Systemic Maintenance
- **Rationale:** Steroid-sparing agents required for vision-threatening posterior involvement.

### 542. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 800 mg TID x 5-10 days
- **Rationale:** Kills invasive trophozoites in liver and bowel wall. Avoid Alcohol (Disulfiram-like reaction).

### 543. Diloxanide Furoate (undefined)
- **Class:** Luminal Amoebicide
- **Dosing:** 500 mg TID x 10 days
- **Rationale:** Eradicates cysts in the gut lumen to prevent relapse and transmission.

### 544. Chloroquine (undefined)
- **Class:** Antimalarial
- **Dosing:** 600 mg OD x 2 days -> 300mg
- **Rationale:** Concentrates in the liver; used as adjunct if Metronidazole response is poor.

### 545. Liposomal Amphotericin B (undefined)
- **Class:** Antifungal/Antiprotozoal
- **Dosing:** 10 mg/kg Single Dose IV
- **Rationale:** Highest cure rate (>90%) with single dose. Nephrotoxicity is reduced in liposomal form.

### 546. Miltefosine (undefined)
- **Class:** Phospholipid Analogue
- **Dosing:** 50 mg BD x 28 days
- **Rationale:** First oral agent. Contraindicated in pregnancy (Teratogenic).

### 547. Sodium Stibogluconate (undefined)
- **Class:** Antimonial
- **Dosing:** 20 mg/kg IV/IM Daily
- **Rationale:** High resistance in Bihar/Nepal; rarely used now due to cardiotoxicity.

### 548. Tinidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 2 g Single Dose
- **Rationale:** Single dose cure rate >90%. Better tolerated than Metronidazole.

### 549. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 400 mg TID x 5-7 days
- **Rationale:** Standard therapy; avoid alcohol.

### 550. Nitazoxanide (undefined)
- **Class:** Antiprotozoal
- **Dosing:** 500 mg BD x 3 days
- **Rationale:** Broad spectrum (covers Cryptosporidium too).

### 551. Pyrimethamine (undefined)
- **Class:** Antifolate
- **Dosing:** 200mg Load -> 50-75mg OD
- **Rationale:** Inhibits dihydrofolate reductase. Must give with Folinic Acid.

### 552. Sulfadiazine (undefined)
- **Class:** Sulfonamide
- **Dosing:** 1-1.5 g QID
- **Rationale:** Synergistic with Pyrimethamine. Hydration needed to prevent crystalluria.

### 553. Leucovorin (Folinic Acid) (undefined)
- **Class:** Vitamin
- **Dosing:** 10-25 mg OD
- **Rationale:** Prevents bone marrow suppression caused by Pyrimethamine.

### 554. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 2 g Stat (Single Dose)
- **Rationale:** 95% cure rate. Single dose improves compliance. Avoid alcohol for 24h.

### 555. Tinidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 2 g Stat
- **Rationale:** Longer half-life, fewer GI side effects, but more expensive.

### 556. Metronidazole (7 day) (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg BD x 7 days
- **Rationale:** Multi-dose regimen preferred in HIV-positive women.

### 557. Albendazole (undefined)
- **Class:** Anthelmintic
- **Dosing:** 15 mg/kg (max 800mg) BD x 8-28 days
- **Rationale:** Penetrates CNS to kill cysts. Must give WITH steroids to prevent inflammatory flare.

### 558. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.1 mg/kg BD
- **Rationale:** Suppresses inflammation caused by dying parasite. Started 1 day BEFORE Albendazole.

### 559. Phenytoin / Levetiracetam (undefined)
- **Class:** Anticonvulsant
- **Dosing:** Standard Maintenance
- **Rationale:** Prevent seizures during acute inflammatory phase.

### 560. Albendazole (undefined)
- **Class:** Anthelmintic
- **Dosing:** 10-15 mg/kg BD
- **Rationale:** Shrinks cysts. Given for 1-6 months. Essential pre-op to prevent seeding.

### 561. Praziquantel (undefined)
- **Class:** Anthelmintic
- **Dosing:** 40 mg/kg Weekly
- **Rationale:** More effective against protoscoleces released during rupture.

### 562. Epinephrine (undefined)
- **Class:** Sympathomimetic
- **Dosing:** 0.5 mg IM Stat
- **Rationale:** Emergency management of cyst fluid reaction.

### 563. Albendazole (undefined)
- **Class:** Anthelmintic
- **Dosing:** 400 mg Stat
- **Rationale:** Inhibits microtubule synthesis, starving the worm. 100% cure rate.

### 564. Mebendazole (undefined)
- **Class:** Anthelmintic
- **Dosing:** 100 mg BD x 3 days
- **Rationale:** Effective and safe. Less systemic absorption.

### 565. Piperazine (undefined)
- **Class:** Paralytic
- **Dosing:** 75 mg/kg Stat
- **Rationale:** Flaccid paralysis of worms allows them to pass without stimulating localized aggregation (which Albendazole might worsen in obstruction).

### 566. Albendazole (undefined)
- **Class:** Anthelmintic
- **Dosing:** 400 mg Stat
- **Rationale:** Effective against adults. Single dose usually sufficient.

### 567. Ferrous Ascorbate (undefined)
- **Class:** Iron Supplement
- **Dosing:** 100 mg elemental BD
- **Rationale:** Replenishes iron stores. Continue for 3 months after Hb normalizes.

### 568. Albumin / Protein (undefined)
- **Class:** Supportive
- **Dosing:** Dietary/IV Daily
- **Rationale:** Corrects edema caused by protein-losing enteropathy.

### 569. Mebendazole (undefined)
- **Class:** Anthelmintic
- **Dosing:** 100 mg Stat, Repeat in 2 weeks
- **Rationale:** Kills adults but not eggs. Second dose kills newly hatched worms.

### 570. Albendazole (undefined)
- **Class:** Anthelmintic
- **Dosing:** 400 mg Stat, Repeat in 2 weeks
- **Rationale:** Equally effective. Treat whole family.

### 571. White Soft Paraffin (undefined)
- **Class:** Barrier
- **Dosing:** Apply anal region HS
- **Rationale:** Relieves itching and traps worms.

### 572. Riluzole (undefined)
- **Class:** Glutamate Antagonist
- **Dosing:** 50 mg BD
- **Rationale:** Inhibits glutamate release, reducing excitotoxicity. Monitor LFTs.

### 573. Edaravone (undefined)
- **Class:** Free Radical Scavenger
- **Dosing:** 60 mg IV Infusion (Cycles)
- **Rationale:** Slows functional decline in select patients. Requires port access.

### 574. Baclofen (undefined)
- **Class:** Muscle Relaxant
- **Dosing:** 10-20 mg TID
- **Rationale:** GABA-B agonist. Reduces painful cramps and stiffness.

### 575. Tetrabenazine (undefined)
- **Class:** VMAT2 Inhibitor
- **Dosing:** Titrated (max 100mg) TID
- **Rationale:** Depletes dopamine stores. Black box warning for Depression/Suicide.

### 576. Deutetrabenazine (undefined)
- **Class:** VMAT2 Inhibitor
- **Dosing:** 6-48 mg BD
- **Rationale:** Deuterated form with better pharmacokinetic profile and fewer neuropsychiatric side effects.

### 577. Haloperidol (undefined)
- **Class:** Antipsychotic
- **Dosing:** 1-5 mg BD
- **Rationale:** Dopamine blockade treats both movement and behavioral symptoms.

### 578. Penicillamine (undefined)
- **Class:** Copper Chelator
- **Dosing:** 250-500 mg QID (Empty stomach)
- **Rationale:** Promotes urinary copper excretion. Requires Pyridoxine (B6) supplementation.

### 579. Zinc Acetate (undefined)
- **Class:** Metallothionein Inducer
- **Dosing:** 50 mg elemental TID
- **Rationale:** Blocks intestinal absorption of copper. Safer than chelators.

### 580. Trientine (undefined)
- **Class:** Chelator
- **Dosing:** 500 mg BD
- **Rationale:** Alternative chelator with fewer side effects (Lupus-like reaction/nephrotoxicity).

### 581. Propranolol (undefined)
- **Class:** Beta Blocker (Non-selective)
- **Dosing:** 40-120 mg BD/LA
- **Rationale:** Blocks peripheral beta-2 receptors in muscle spindles. Efficacy 50-70%.

### 582. Primidone (undefined)
- **Class:** Barbiturate
- **Dosing:** 50-250 mg HS
- **Rationale:** Metabolized to Phenobarbital. Start low to avoid sedation.

### 583. Topiramate (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 25-100 mg BD
- **Rationale:** Effective but side effects (paresthesia/cognitive dulling) limit use.

### 584. Pramipexole / Ropinirole (undefined)
- **Class:** Dopamine Agonist
- **Dosing:** Low dose 2h before bed
- **Rationale:** Rapid relief but high risk of Augmentation long-term.

### 585. Gabapentin Enacarbil / Pregabalin (undefined)
- **Class:** Alpha-2-Delta Ligand
- **Dosing:** 300-600 mg / 75 mg Evening
- **Rationale:** Treats sensory symptoms without augmentation risk. Benefits sleep.

### 586. Ferrous Bisglycinate (undefined)
- **Class:** Iron Supplement
- **Dosing:** 325 mg OD with Vit C
- **Rationale:** Brain iron repletion is curative in many cases.

### 587. Carbamazepine (undefined)
- **Class:** Sodium Channel Blocker
- **Dosing:** 100-200 mg BD (Titrate up)
- **Rationale:** Stabilizes hyperexcitable nerve membranes. Only FDA-approved drug for TN. Monitor Na+ and WBC.

### 588. Oxcarbazepine (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 300 mg BD
- **Rationale:** Better tolerability and fewer drug interactions than Carbamazepine, though higher risk of Hyponatremia.

### 589. Gabapentin (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** 300 mg TID
- **Rationale:** Used if Carbamazepine is contraindicated or ineffective; fewer side effects.

### 590. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 60 mg OD x 5 days -> Taper
- **Rationale:** Reduces nerve edema in the canal. Significantly improves recovery rate.

### 591. Valacyclovir (undefined)
- **Class:** Antiviral
- **Dosing:** 1 g TID x 7 days
- **Rationale:** Added to steroids for severe palsy or suspected Zoster, though evidence is mixed for pure Bell's.

### 592. Artificial Tears / Ointment (undefined)
- **Class:** Lubricant
- **Dosing:** Frequent Day/Night
- **Rationale:** Crucial to prevent exposure keratitis due to lagophthalmos (inability to close eye).

### 593. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** 100% via Non-rebreather 12-15 L/min x 15 min
- **Rationale:** Vasoconstriction via serotonin pathways; effective in 70% within 15 mins.

### 594. Sumatriptan (undefined)
- **Class:** Triptan
- **Dosing:** 6 mg SC Stat
- **Rationale:** Subcutaneous route is essential for rapid onset (Oral is too slow for short attacks).

### 595. Verapamil (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** 240-480 mg Divided (High dose)
- **Rationale:** Drug of choice for prevention. Requires ECG monitoring for PR prolongation.

### 596. Acetazolamide (undefined)
- **Class:** Carbonic Anhydrase Inhibitor
- **Dosing:** 500-1000 mg BD
- **Rationale:** Reduces CSF production by choroid plexus. High doses often needed.

### 597. Topiramate (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 25-100 mg BD
- **Rationale:** Weak CAI activity + appetite suppression helps weight loss (synergistic).

### 598. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 40 mg BD
- **Rationale:** Added if Acetazolamide alone is insufficient or poorly tolerated.

### 599. Betahistine (undefined)
- **Class:** Histamine Analog
- **Dosing:** 16-24 mg TID
- **Rationale:** Improves microcirculation in stria vascularis, reducing endolymph pressure.

### 600. Hydrochlorothiazide / Acetazolamide (undefined)
- **Class:** Diuretic
- **Dosing:** Standard OD
- **Rationale:** Reduces fluid accumulation in the inner ear.

### 601. Meclizine / Promethazine (undefined)
- **Class:** Vestibular Suppressant
- **Dosing:** 25 mg SOS
- **Rationale:** Symptomatic relief for nausea and spinning sensation.

### 602. Methylprednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 g IV OD x 5 days
- **Rationale:** High dose pulse therapy to halt acute inflammation. Follow with Plasma Exchange if poor response.

### 603. Eculizumab (undefined)
- **Class:** Monoclonal Antibody (C5 Inhibitor)
- **Dosing:** 900-1200 mg IV q2 weeks
- **Rationale:** Prevents complement-mediated astrocyte destruction. Highly effective.

### 604. Rituximab (undefined)
- **Class:** Anti-CD20 mAb
- **Dosing:** 1 g IV q6 months
- **Rationale:** Depletes B-cells (source of antibodies); standard off-label preventive therapy.

### 605. Amifampridine (3,4-DAP) (undefined)
- **Class:** Potassium Channel Blocker
- **Dosing:** 15-30 mg TID
- **Rationale:** Prolongs depolarization, keeping calcium channels open longer to release ACh.

### 606. Pyridostigmine (undefined)
- **Class:** AChE Inhibitor
- **Dosing:** 60 mg QID
- **Rationale:** Less effective than in MG, but used in combination.

### 607. Chemotherapy (Etoposide/Platinum) (undefined)
- **Class:** Antineoplastic
- **Dosing:** Protocol Cycle
- **Rationale:** Treating the cancer often resolves the paraneoplastic syndrome.

### 608. Modafinil (undefined)
- **Class:** Wakefulness Promoter
- **Dosing:** 200 mg Morning
- **Rationale:** First-line; non-amphetamine stimulant with low abuse potential.

### 609. Sodium Oxybate (undefined)
- **Class:** CNS Depressant (GHB)
- **Dosing:** 2.25-4.5 g Twice nightly
- **Rationale:** Consolidates night sleep to improve day alertness. Highly regulated.

### 610. Venlafaxine (undefined)
- **Class:** SNRI
- **Dosing:** 75 mg OD
- **Rationale:** Suppress REM sleep (off-label) to control cataplexy/paralysis.

### 611. Methylprednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 g IV OD x 3-5 days
- **Rationale:** Standard first-line therapy to reduce edema and immune attack.

### 612. Plasma Exchange (PLEX) (undefined)
- **Class:** Procedure
- **Dosing:** 5 sessions Alternate days
- **Rationale:** Removes circulating antibodies; improves recovery in severe cases.

### 613. Baclofen (undefined)
- **Class:** Muscle Relaxant
- **Dosing:** 10 mg TID
- **Rationale:** Manages long-term stiffness post-recovery.

### 614. Clonidine (undefined)
- **Class:** Alpha-2 Agonist
- **Dosing:** 0.1 mg BD
- **Rationale:** Modulates norepinephrine; first-line due to benign side effect profile vs antipsychotics.

### 615. Aripiprazole (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 2-5 mg OD
- **Rationale:** Dopamine stabilizer; effective for tic suppression with lower metabolic risk than Risperidone.

### 616. Tetrabenazine (undefined)
- **Class:** VMAT2 Inhibitor
- **Dosing:** 12.5 mg BD
- **Rationale:** Dopamine depleter; avoids tardive dyskinesia risk of neuroleptics.

### 617. Nusinersen (undefined)
- **Class:** Antisense Oligonucleotide
- **Dosing:** 12 mg Intrathecal (Loading -> q4mo)
- **Rationale:** Modifies SMN2 splicing to include exon 7, increasing production of functional SMN protein.

### 618. Risdiplam (undefined)
- **Class:** Splicing Modifier
- **Dosing:** Weight based Oral Daily
- **Rationale:** Systemic small molecule that crosses BBB; easier administration than intrathecal injections.

### 619. Onasemnogene abeparvovec (undefined)
- **Class:** Gene Therapy
- **Dosing:** Single infusion Once lifetime
- **Rationale:** Viral vector (AAV9) delivers a functional copy of the SMN1 gene.

### 620. Baclofen (undefined)
- **Class:** Muscle Relaxant
- **Dosing:** Titrated TID / Intrathecal Pump
- **Rationale:** GABA-B agonist. Reduces tone to improve comfort and hygiene.

### 621. Botulinum Toxin A (undefined)
- **Class:** Neurotoxin
- **Dosing:** Muscle/Weight based IM q3-6 months
- **Rationale:** Blocks ACh release. Targets specific muscles (e.g., Gastrocnemius for toe walking) to delay surgery.

### 622. Diazepam (undefined)
- **Class:** Benzodiazepine
- **Dosing:** Low dose HS
- **Rationale:** Adjunct for severe stiffness affecting sleep.

### 623. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 2 g IV BD
- **Rationale:** Excellent CNS penetration; covers Strep and Gram-negatives.

### 624. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg IV Q8H
- **Rationale:** Covers Anaerobes (Bacteroides) common in dental/sinus sources.

### 625. Vancomycin (undefined)
- **Class:** Glycopeptide
- **Dosing:** 15-20 mg/kg IV BD
- **Rationale:** Added if post-neurosurgery or trauma.

### 626. Rabies Immunoglobulin (RIG) (undefined)
- **Class:** Passive Immunity
- **Dosing:** 20 IU/kg Stat (Day 0)
- **Rationale:** Infiltrate into/around the wound to neutralize virus before nerve entry. Lifesaving.

### 627. Rabies Vaccine (undefined)
- **Class:** Active Immunity
- **Dosing:** 0.5/1 ml (IM/ID) Day 0, 3, 7, 14, 28
- **Rationale:** Stimulates antibody production. Never give in same syringe/site as RIG.

### 628. Midazolam / Haloperidol (undefined)
- **Class:** Sedative
- **Dosing:** Titrated PRN
- **Rationale:** Palliation for agitation and spasms in established disease.

### 629. Acetazolamide (undefined)
- **Class:** Carbonic Anhydrase Inhibitor
- **Dosing:** 250-500 mg BD
- **Rationale:** Reduces CSF production. Limited efficacy compared to surgery.

### 630. Ventriculoperitoneal (VP) Shunt (undefined)
- **Class:** Surgical Device
- **Dosing:** N/A Continuous
- **Rationale:** Drains excess CSF to peritoneal cavity. Programmable valves prevent over-drainage.

### 631. Desmopressin (undefined)
- **Class:** ADH Analog
- **Dosing:** 0.1-0.2 mg Oral/Intranasal BD
- **Rationale:** Replaces missing ADH. Potent antidiuretic with minimal pressor activity.

### 632. Hydrochlorothiazide (undefined)
- **Class:** Thiazide Diuretic
- **Dosing:** 25 mg BD
- **Rationale:** Paradoxical effect: Induces mild hypovolemia -> increases proximal tubule water reabsorption.

### 633. Amiloride (undefined)
- **Class:** K-Sparing Diuretic
- **Dosing:** 5-10 mg BD
- **Rationale:** Blocks Lithium entry into collecting duct cells via ENaC channel.

### 634. Tolvaptan (undefined)
- **Class:** Vaptan (V2 Receptor Antagonist)
- **Dosing:** 15 mg OD
- **Rationale:** Promotes free water excretion (aquaresis) without losing electrolytes. Hepatotoxic risk > 30 days.

### 635. Hypertonic Saline (3%) (undefined)
- **Class:** Crystalloid
- **Dosing:** Bolus (100ml) Stat (Severe)
- **Rationale:** Rapidly raises Na to stop cerebral edema. Stop once symptoms resolve.

### 636. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** 20 mg BD
- **Rationale:** Increases free water excretion if urine osmolality is very high.

### 637. Spironolactone (undefined)
- **Class:** Mineralocorticoid Receptor Antagonist
- **Dosing:** 25-100 mg OD
- **Rationale:** Blocks aldosterone effects. Gynecomastia is a side effect.

### 638. Eplerenone (undefined)
- **Class:** MRA (Selective)
- **Dosing:** 25-50 mg BD
- **Rationale:** Fewer anti-androgenic side effects than Spironolactone.

### 639. Amlodipine (undefined)
- **Class:** CCB
- **Dosing:** 5-10 mg OD
- **Rationale:** Adjunct antihypertensive.

### 640. Cabergoline (undefined)
- **Class:** Dopamine Agonist
- **Dosing:** 0.25-0.5 mg Weekly / Twice Weekly
- **Rationale:** Shrinks tumor and normalizes prolactin in >90%. Better tolerated than Bromocriptine.

### 641. Bromocriptine (undefined)
- **Class:** Dopamine Agonist
- **Dosing:** 2.5-5 mg Daily
- **Rationale:** Preferred in pregnancy due to extensive safety data.

### 642. Oral Contraceptives (undefined)
- **Class:** Hormone
- **Dosing:** Standard Daily
- **Rationale:** Restores estrogen/periods if fertility not desired and dopamine agonist intolerant.

### 643. Levothyroxine (undefined)
- **Class:** Thyroid Hormone
- **Dosing:** Suppressive dose (>1.6 mcg/kg) OD
- **Rationale:** Suppresses TSH to <0.1 mIU/L to inhibit growth of residual cancer cells.

### 644. Radioactive Iodine (I-131) (undefined)
- **Class:** Radiopharmaceutical
- **Dosing:** 30-100 mCi Single dose
- **Rationale:** Destroys remnant thyroid tissue and micrometastases.

### 645. Lenvatinib (undefined)
- **Class:** Tyrosine Kinase Inhibitor
- **Dosing:** 24 mg OD
- **Rationale:** Anti-angiogenic for advanced metastatic disease.

### 646. Normal Saline (0.9%) (undefined)
- **Class:** Crystalloid
- **Dosing:** 1L bolus -> Maintenance Continuous IV
- **Rationale:** Restores intravascular volume. Switch to 0.45% Saline if Sodium is high/normal after initial bolus.

### 647. Regular Insulin (undefined)
- **Class:** Insulin
- **Dosing:** 0.1 U/kg/hr IV Infusion
- **Rationale:** Low dose infusion. Fluids alone drop glucose significantly; insulin is secondary to fluids in HHS.

### 648. Potassium Chloride (undefined)
- **Class:** Electrolyte
- **Dosing:** 20-40 mEq/L IV
- **Rationale:** Insulin drives K+ into cells; prophylactic replacement prevents fatal hypokalemia.

### 649. Hydrocortisone (undefined)
- **Class:** Glucocorticoid
- **Dosing:** 10-15 mg/m2/day Divided TID
- **Rationale:** Replaces cortisol AND suppresses ACTH to reduce androgen overproduction.

### 650. Fludrocortisone (undefined)
- **Class:** Mineralocorticoid
- **Dosing:** 0.05-0.2 mg OD
- **Rationale:** Replaces Aldosterone to maintain blood pressure and sodium balance.

### 651. Sodium Chloride (undefined)
- **Class:** Supplement
- **Dosing:** 1-2 g Divided
- **Rationale:** Breast milk is low sodium; supplements needed despite Fludrocortisone.

### 652. Ibuprofen (undefined)
- **Class:** NSAID
- **Dosing:** 400-800 mg TID
- **Rationale:** First-line for mild-moderate cases. Reduces gland inflammation and pain.

### 653. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 40 mg OD (Taper)
- **Rationale:** Dramatic relief of pain within 24-48h. Used if NSAIDs fail.

### 654. Propranolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** 10-40 mg TID
- **Rationale:** Symptomatic control of thyrotoxic symptoms.

### 655. Octreotide LAR (undefined)
- **Class:** Somatostatin Analog
- **Dosing:** 20-30 mg IM Monthly
- **Rationale:** Inhibits release of serotonin and vasoactive peptides. Controls flushing/diarrhea.

### 656. Telotristat Ethyl (undefined)
- **Class:** Tryptophan Hydroxylase Inhibitor
- **Dosing:** 250 mg TID
- **Rationale:** Inhibits serotonin synthesis peripherally.

### 657. Cyproheptadine (undefined)
- **Class:** Antihistamine/Antiserotonergic
- **Dosing:** 4 mg TID
- **Rationale:** Serotonin antagonist (5-HT2 receptor).

### 658. Omeprazole / Pantoprazole (undefined)
- **Class:** Proton Pump Inhibitor
- **Dosing:** 60-120 mg (High dose) Divided Doses
- **Rationale:** Massive doses required to control hypersecretion. Lifelong if tumor unresectable.

### 659. Octreotide (undefined)
- **Class:** Somatostatin Analog
- **Dosing:** Standard SC/IM
- **Rationale:** Inhibits gastrin secretion and tumor growth.

### 660. Calcium Carbonate / Vit D (undefined)
- **Class:** Supplement
- **Dosing:** Standard Daily
- **Rationale:** Chronic high dose PPI reduces calcium absorption.

### 661. Pirfenidone (undefined)
- **Class:** Antifibrotic
- **Dosing:** 801 mg TID
- **Rationale:** Inhibits TGF-beta and collagen synthesis. Slows FVC decline. Photosensitivity is a major side effect.

### 662. Nintedanib (undefined)
- **Class:** Tyrosine Kinase Inhibitor
- **Dosing:** 150 mg BD
- **Rationale:** Inhibits VEGF/FGF/PDGF receptors, blocking fibroblast proliferation. Diarrhea is common.

### 663. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** Titrated Continuous (LTOT)
- **Rationale:** Improves survival and prevents pulmonary hypertension.

### 664. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.5 mg/kg OD
- **Rationale:** Suppresses granulomatous inflammation. Not needed for asymptomatic Stage I/II.

### 665. Methotrexate (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 10-15 mg Weekly
- **Rationale:** Alternative for patients intolerant to steroids or with progressive disease.

### 666. Hydroxychloroquine (undefined)
- **Class:** Antimalarial
- **Dosing:** 200-400 mg OD
- **Rationale:** Effective for skin lesions and reduces 1-alpha-hydroxylase activity.

### 667. Sildenafil / Tadalafil (undefined)
- **Class:** PDE5 Inhibitor
- **Dosing:** 20 mg TID / 40 mg OD TID / OD
- **Rationale:** Increases cGMP to cause pulmonary vasodilation. Do not combine with Nitrates.

### 668. Bosentan / Ambrisentan (undefined)
- **Class:** Endothelin Receptor Antagonist
- **Dosing:** Standard BD / OD
- **Rationale:** Blocks vasoconstrictive effects of Endothelin-1. Teratogenic/Hepatotoxic (Bosentan).

### 669. Epoprostenol (undefined)
- **Class:** Prostacyclin Analog
- **Dosing:** Titrated Continuous IV
- **Rationale:** Most potent pulmonary vasodilator. Improves survival in advanced disease.

### 670. Azithromycin (undefined)
- **Class:** Macrolide
- **Dosing:** 250-500 mg 3x/week
- **Rationale:** Anti-inflammatory and immunomodulatory effect (not just antibacterial).

### 671. Hypertonic Saline (3-7%) (undefined)
- **Class:** Mucoactive Agent
- **Dosing:** Nebulized BD
- **Rationale:** Draws water into airway surface liquid to rehydrate mucus for easier clearance.

### 672. Ciprofloxacin / Tobramycin (undefined)
- **Class:** Antibiotic
- **Dosing:** Oral / Inhaled Cycle
- **Rationale:** Targeted therapy based on culture. Inhaled route minimizes systemic toxicity.

### 673. Fluticasone / Mometasone (undefined)
- **Class:** Intranasal Corticosteroid
- **Dosing:** 1-2 sprays OD
- **Rationale:** Most effective single therapy; treats all symptoms including congestion. Max effect takes 2 weeks.

### 674. Levocetirizine / Fexofenadine (undefined)
- **Class:** Antihistamine (Oral)
- **Dosing:** 5 mg / 120 mg OD
- **Rationale:** Blocks H1 receptors. Less effective for congestion than steroids.

### 675. Azelastine (undefined)
- **Class:** Antihistamine (Nasal)
- **Dosing:** 1-2 sprays BD
- **Rationale:** Onset in 15 mins (faster than oral). Bitter taste is a drawback.

### 676. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** High Flow Continuous
- **Rationale:** Accelerates resorption of pleural air by reducing nitrogen partial pressure in blood (Nitrogen Washout).

### 677. Needle Decompression (undefined)
- **Class:** Procedure
- **Dosing:** 14G Cannula Stat
- **Rationale:** Immediate life-saving maneuver to convert Tension to Simple pneumothorax.

### 678. Intercostal Drainage (ICD) (undefined)
- **Class:** Procedure
- **Dosing:** Chest Tube Continuous
- **Rationale:** Definitive management to re-expand lung.

### 679. Furosemide (undefined)
- **Class:** Diuretic
- **Dosing:** 40 mg BD
- **Rationale:** Reduces systemic fluid overload, resolving effusion.

### 680. Antibiotics (Co-amoxiclav) (undefined)
- **Class:** Antimicrobial
- **Dosing:** 1.2 g IV TID
- **Rationale:** Treats underlying pneumonia. Drain if complicated.

### 681. ATT (Anti-Tubercular) (undefined)
- **Class:** Regimen
- **Dosing:** Standard Daily
- **Rationale:** Primary treatment for TB effusion; drainage usually not needed unless massive.

### 682. Clindamycin (undefined)
- **Class:** Lincosamide
- **Dosing:** 600 mg IV Q8H -> Oral
- **Rationale:** Gold standard for lung abscess due to excellent tissue penetration and anaerobic efficacy.

### 683. Amoxicillin-Clavulanate (undefined)
- **Class:** Beta-lactam
- **Dosing:** 1.2 g / 625 mg IV TID / PO TID
- **Rationale:** Good coverage but Clindamycin is historically superior for lung abscess.

### 684. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg TID
- **Rationale:** Added if Penicillin is used, but NOT effective as monotherapy for lung infections.

### 685. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.15-0.6 mg/kg Stat (Oral/IM)
- **Rationale:** Long half-life; single dose reduces edema for 2-3 days. Cornerstone of therapy.

### 686. Nebulized Epinephrine (Racemic) (undefined)
- **Class:** Alpha/Beta Agonist
- **Dosing:** 0.5 ml (2.25%) Stat
- **Rationale:** Alpha-adrenergic vasoconstriction reduces mucosal edema rapidly. Observation for rebound required (2-4h).

### 687. Oxygen (undefined)
- **Class:** Medical Gas
- **Dosing:** Blow-by PRN
- **Rationale:** Non-threatening administration to avoid agitation.

### 688. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 50-100 mg/kg IV OD
- **Rationale:** Broad coverage for Hib and Strep.

### 689. Vancomycin (undefined)
- **Class:** Glycopeptide
- **Dosing:** 15 mg/kg IV Q6H
- **Rationale:** Added if MRSA is suspected (increasing prevalence).

### 690. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.15 mg/kg IV
- **Rationale:** Reduces airway swelling (Adjunct to airway security).

### 691. Labetalol (undefined)
- **Class:** Alpha/Beta Blocker
- **Dosing:** 20 mg IV bolus -> Infusion Titrated
- **Rationale:** Rapidly lowers HR (<60) and SBP (<120) simultaneously. Esmolol is an alternative.

### 692. Nitroprusside (undefined)
- **Class:** Vasodilator
- **Dosing:** 0.3-10 mcg/kg/min IV Infusion
- **Rationale:** Potent arterial vasodilator. Use ONLY after HR is controlled with beta-blockers.

### 693. Morphine (undefined)
- **Class:** Opioid
- **Dosing:** 2-4 mg IV
- **Rationale:** Reduces sympathetic surge caused by pain, lowering BP.

### 694. Cilostazol (undefined)
- **Class:** PDE3 Inhibitor
- **Dosing:** 100 mg BD
- **Rationale:** Vasodilator and antiplatelet; significantly increases walking distance. Contraindicated in Heart Failure.

### 695. Clopidogrel (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75 mg OD
- **Rationale:** Reduces risk of MI/Stroke. Preferred over Aspirin in some PAD trials (CAPRIE).

### 696. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 40-80 mg OD
- **Rationale:** Aggressive lipid lowering reduces major adverse limb events.

### 697. Nifedipine (undefined)
- **Class:** Calcium Channel Blocker (DHP)
- **Dosing:** 10-20 mg (Retard/XL) BD
- **Rationale:** Potent peripheral vasodilator. First-line therapy.

### 698. Sildenafil (undefined)
- **Class:** PDE5 Inhibitor
- **Dosing:** 20 mg TID
- **Rationale:** Promotes vasodilation via NO pathway; used for digital ulcers.

### 699. Bosentan (undefined)
- **Class:** Endothelin Receptor Antagonist
- **Dosing:** 62.5-125 mg BD
- **Rationale:** Prevents formation of new digital ulcers in systemic sclerosis.

### 700. Metoprolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** 25-50 mg BD
- **Rationale:** Reduces dP/dt (shear stress) on aortic wall (Theoretical benefit, widely used).

### 701. Telmisartan (undefined)
- **Class:** ARB
- **Dosing:** 40-80 mg OD
- **Rationale:** May inhibit TGF-beta signaling implicated in aneurysm formation (Marfan-link).

### 702. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 40 mg OD
- **Rationale:** Reduces perioperative cardiovascular events and MMP activity.

### 703. Iloprost (undefined)
- **Class:** Prostacyclin Analog
- **Dosing:** Infusion Daily x 1-4 weeks
- **Rationale:** Potent vasodilator and platelet inhibitor; aids ulcer healing and reduces amputation risk.

### 704. Cilostazol (undefined)
- **Class:** PDE3 Inhibitor
- **Dosing:** 100 mg BD
- **Rationale:** Vasodilator; symptomatic relief.

### 705. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75 mg OD
- **Rationale:** Prevents thrombotic progression (though less effective than in atherosclerosis).

### 706. Adenosine (undefined)
- **Class:** Nucleoside
- **Dosing:** 6 mg rapid IV push -> 12 mg Stat
- **Rationale:** Hyperpolarizes AV node cells, blocking conduction for <10 seconds. Must be flushed rapidly.

### 707. Verapamil / Diltiazem (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** IV Slow bolus Stat
- **Rationale:** Use if Adenosine fails or is contraindicated (Bronchospasm risk).

### 708. Metoprolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** 25-50 mg BD
- **Rationale:** Suppresses AV node conduction to prevent recurrence.

### 709. Metoprolol / Propranolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** Titrated to HR < 60 BD
- **Rationale:** Negative inotrope (reduces obstruction) and chronotrope (increases filling time).

### 710. Verapamil (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** 240 mg Divided
- **Rationale:** Improves diastolic relaxation. Avoid Nifedipine (vasodilation worsens gradient).

### 711. Disopyramide (undefined)
- **Class:** Antiarrhythmic (Class IA)
- **Dosing:** 100-200 mg TID
- **Rationale:** Potent negative inotrope reducing gradient. Used with beta-blocker.

### 712. Furosemide (undefined)
- **Class:** Diuretic
- **Dosing:** Low dose (20 mg) OD
- **Rationale:** Use with extreme caution; maintaining preload is vital for cardiac output.

### 713. Digoxin (undefined)
- **Class:** Inotrope
- **Dosing:** 0.125 mg OD
- **Rationale:** Used if LV function fails, but surgery is the only definitive treatment.

### 714. TAVR / SAVR (undefined)
- **Class:** Surgical / Interventional
- **Dosing:** Valve Replacement Once
- **Rationale:** Mechanical relief of obstruction. Medical therapy is palliative only.

### 715. Propranolol / Nadolol (undefined)
- **Class:** Beta Blocker
- **Dosing:** Titrated BD
- **Rationale:** Blunts sympathetic surge that triggers arrhythmia. Less effective in LQT3.

### 716. Mexiletine (undefined)
- **Class:** Sodium Channel Blocker
- **Dosing:** 150-200 mg TID
- **Rationale:** Shortens QT interval by blocking late sodium current.

### 717. Magnesium Sulfate (undefined)
- **Class:** Electrolyte
- **Dosing:** 2 g IV Bolus Stat
- **Rationale:** Stabilizes membrane potential to terminate polymorphic VT.

### 718. Normal Saline (undefined)
- **Class:** Crystalloid
- **Dosing:** 500 ml Bolus Stat
- **Rationale:** Temporizing measure to increase intracardiac pressure against pericardial pressure.

### 719. Dobutamine (undefined)
- **Class:** Inotrope
- **Dosing:** Infusion Continuous
- **Rationale:** Increases contractility/rate to maintain CO while awaiting drainage. Avoid vasodilators.

### 720. Pericardiocentesis (undefined)
- **Class:** Procedure
- **Dosing:** Needle Drainage Stat
- **Rationale:** Immediate removal of fluid is life-saving.

### 721. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg (40-60 mg) OD
- **Rationale:** Rapidly suppresses inflammation. Taper slowly over 12-18 months.

### 722. Methylprednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 g IV OD x 3 days
- **Rationale:** Pulse therapy to save remaining vision or contralateral eye.

### 723. Tocilizumab (undefined)
- **Class:** IL-6 Inhibitor
- **Dosing:** 162 mg SC Weekly
- **Rationale:** Steroid-sparing agent; highly effective in maintaining remission.

### 724. IVIG (undefined)
- **Class:** Immunoglobulin
- **Dosing:** 2 g/kg Single Infusion (10-12h)
- **Rationale:** Standard of Care. Neutralizes generalized inflammation and prevents coronary damage.

### 725. Aspirin (High Dose) (undefined)
- **Class:** Anti-inflammatory
- **Dosing:** 80-100 mg/kg/day Divided q6h
- **Rationale:** Reduces fever and inflammation until afebrile for 48h.

### 726. Aspirin (Low Dose) (undefined)
- **Class:** Antiplatelet
- **Dosing:** 3-5 mg/kg/day OD
- **Rationale:** Prevents thrombosis (especially with thrombocytosis). Continued for 6-8 weeks.

### 727. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Induction therapy to control acute inflammation.

### 728. Methotrexate (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 15-25 mg Weekly
- **Rationale:** Prevents relapse and allows steroid tapering.

### 729. Tocilizumab (undefined)
- **Class:** IL-6 Inhibitor
- **Dosing:** 162 mg SC Weekly
- **Rationale:** Highly effective for large vessel vasculitis resistant to conventional therapy.

### 730. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1 mg/kg OD
- **Rationale:** Mainstay for inducing remission.

### 731. Cyclophosphamide (undefined)
- **Class:** Alkylating Agent
- **Dosing:** Pulse or Oral Protocol
- **Rationale:** Used for mesenteric ischemia, renal failure, or severe neuropathy.

### 732. Entecavir + Plasma Exchange (undefined)
- **Class:** Antiviral + PLEX
- **Dosing:** Standard Daily
- **Rationale:** Treat the virus and remove immune complexes. Steroids used cautiously (can enhance viral replication).

### 733. Diosmin + Hesperidin (undefined)
- **Class:** Phlebotonic
- **Dosing:** 500-1000 mg BD
- **Rationale:** Increases venous tone and lymphatic drainage; reduces edema and heaviness.

### 734. Polidocanol (undefined)
- **Class:** Sclerosant
- **Dosing:** Injection Session
- **Rationale:** Causes endothelial damage and fibrosis to close small varicosities.

### 735. Pentoxifylline (undefined)
- **Class:** Hemorheologic Agent
- **Dosing:** 400 mg TID
- **Rationale:** Improves microcirculation and accelerates ulcer healing (adjunct to compression).

### 736. Cyclosporine (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 3-5 mg/kg Divided
- **Rationale:** Inhibits cytotoxic T-cell activity and halts progression better than steroids alone.

### 737. IVIG (undefined)
- **Class:** Immunoglobulin
- **Dosing:** 2-3 g/kg Total Over 3 days
- **Rationale:** Blocks Fas-mediated keratinocyte apoptosis (mechanism controversial but widely used).

### 738. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1-2 mg/kg OD
- **Rationale:** Controversial in TEN due to increased sepsis risk. Only use in very early phase.

### 739. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 1-1.5 mg/kg OD
- **Rationale:** Rapidly suppresses antibody production. Taper very slowly once new blisters stop.

### 740. Rituximab (undefined)
- **Class:** Anti-CD20 mAb
- **Dosing:** 1 g x 2 doses Day 0, 14
- **Rationale:** Depletes B-cells producing autoantibodies. Superior to Mycophenolate/Azathioprine.

### 741. Azathioprine (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 2.5 mg/kg OD
- **Rationale:** Steroid-sparing agent for long-term control.

### 742. Clobetasol (undefined)
- **Class:** Topical Corticosteroid
- **Dosing:** 0.05% Cream BD (Whole body)
- **Rationale:** Safer than systemic steroids in elderly; equally effective for extensive disease.

### 743. Doxycycline + Niacinamide (undefined)
- **Class:** Anti-inflammatory
- **Dosing:** 100mg + 500mg BD
- **Rationale:** Inhibits neutrophil chemotaxis and degranulation. Safer side effect profile.

### 744. Prednisolone (undefined)
- **Class:** Systemic Steroid
- **Dosing:** 0.5 mg/kg OD
- **Rationale:** Used if topical application is not feasible.

### 745. Clobetasol (undefined)
- **Class:** Topical Corticosteroid
- **Dosing:** 0.05% Ointment BD
- **Rationale:** Potent anti-inflammatory. First-line therapy.

### 746. Triamcinolone (undefined)
- **Class:** Intralesional Steroid
- **Dosing:** 5-10 mg/ml Monthly
- **Rationale:** Penetrates thick plaques better than topical creams.

### 747. Acitretin (undefined)
- **Class:** Oral Retinoid
- **Dosing:** 25 mg OD
- **Rationale:** Normalizes keratinization. Teratogenic (Avoid in pregnancy).

### 748. Clindamycin + Rifampicin (undefined)
- **Class:** Antibiotic Combo
- **Dosing:** 300mg + 600mg BD x 10 weeks
- **Rationale:** Synergistic anti-inflammatory and biofilm penetration. Standard induction therapy.

### 749. Adalimumab (undefined)
- **Class:** TNF Alpha Inhibitor
- **Dosing:** 40 mg Weekly SC
- **Rationale:** First FDA-approved biologic for HS. Targets the key inflammatory cytokine TNF-alpha.

### 750. Resorcinol (undefined)
- **Class:** Keratolytic
- **Dosing:** 15% Cream BD
- **Rationale:** Peels follicular hyperkeratosis to prevent occlusion.

### 751. Imiquimod (undefined)
- **Class:** Immune Response Modifier
- **Dosing:** 5% Cream 5x/week for 6 weeks
- **Rationale:** Induces local interferon production. Non-surgical option for low-risk lesions on trunk/limbs.

### 752. Vismodegib (undefined)
- **Class:** Hedgehog Pathway Inhibitor
- **Dosing:** 150 mg OD
- **Rationale:** Inhibits SMO protein in the Hedgehog pathway, which is overactive in BCC. Teratogenic.

### 753. 5-Fluorouracil (5-FU) (undefined)
- **Class:** Topical Chemo
- **Dosing:** 5% Cream BD x 4 weeks
- **Rationale:** Antimetabolite causing necrosis of rapidly dividing cells.

### 754. 5-Fluorouracil (5-FU) (undefined)
- **Class:** Topical Chemo
- **Dosing:** 5% Cream BD x 2-4 weeks
- **Rationale:** Causes inflammation and necrosis of dysplastic cells. Expect 'red face' reaction.

### 755. Cemiplimab (undefined)
- **Class:** PD-1 Inhibitor
- **Dosing:** 350 mg IV q3 weeks
- **Rationale:** Immunotherapy for tumors that cannot be cured by surgery/radiation.

### 756. Diclofenac Gel (undefined)
- **Class:** NSAID (Topical)
- **Dosing:** 3% Gel BD x 3 months
- **Rationale:** Less irritating than 5-FU; induces apoptosis via COX-2 inhibition.

### 757. Valacyclovir (undefined)
- **Class:** Antiviral
- **Dosing:** 1 g TID x 7 days
- **Rationale:** Higher bioavailability than Acyclovir. Stops viral replication.

### 758. Gabapentin (undefined)
- **Class:** Alpha-2-Delta Ligand
- **Dosing:** 300 mg HS -> Titrate TID
- **Rationale:** Treats acute neuritis and prevents central sensitization (Post-Herpetic Neuralgia).

### 759. Amitriptyline (undefined)
- **Class:** TCA
- **Dosing:** 10-25 mg HS
- **Rationale:** Adjunct for sleep and pain modulation in elderly.

### 760. Metronidazole (undefined)
- **Class:** Topical Antibiotic/Anti-inflammatory
- **Dosing:** 0.75% Gel BD
- **Rationale:** Reduces oxidative stress and inflammation. First-line topical.

### 761. Doxycycline (undefined)
- **Class:** Tetracycline
- **Dosing:** 40 mg (Sub-antimicrobial dose) OD
- **Rationale:** Anti-inflammatory effect at low dose without antibiotic resistance risk (Oracea).

### 762. Brimonidine (undefined)
- **Class:** Alpha-2 Agonist
- **Dosing:** 0.33% Gel OD
- **Rationale:** Vasoconstricts facial vessels to reduce redness temporarily (Cosmetic).

### 763. Triamcinolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 2.5-10 mg/ml Intralesional q4-6 weeks
- **Rationale:** Suppresses local T-cell attack. Most effective for <50% scalp involvement.

### 764. Baricitinib (undefined)
- **Class:** JAK Inhibitor
- **Dosing:** 2-4 mg OD
- **Rationale:** Blocks JAK-STAT pathway involved in cytokine signaling. FDA approved for severe AA.

### 765. Minoxidil (undefined)
- **Class:** Vasodilator
- **Dosing:** 5% Solution BD
- **Rationale:** Stimulates anagen phase growth; used with steroids to speed up regrowth.

### 766. Emollients (White Soft Paraffin) (undefined)
- **Class:** Moisturizer
- **Dosing:** Liberal Q4H
- **Rationale:** Restores skin barrier. Foundation of therapy; steroid sparing.

### 767. Mometasone / Fluticasone (undefined)
- **Class:** Topical Corticosteroid
- **Dosing:** Cream/Ointment OD (Acute flare)
- **Rationale:** Anti-inflammatory. Use potent steroids for short bursts to calm flare.

### 768. Tacrolimus (undefined)
- **Class:** Calcineurin Inhibitor
- **Dosing:** 0.03% or 0.1% BD
- **Rationale:** Non-steroidal option; avoids skin atrophy in thin-skinned areas.

### 769. Ketoconazole (undefined)
- **Class:** Antifungal
- **Dosing:** 2% Shampoo/Cream 2-3x/week
- **Rationale:** Reduces Malassezia population.

### 770. Zinc Pyrithione / Selenium Sulfide (undefined)
- **Class:** Cytostatic/Antifungal
- **Dosing:** Shampoo Alternate days
- **Rationale:** Reduces cell turnover and fungal load.

### 771. Hydrocortisone (undefined)
- **Class:** Mild Corticosteroid
- **Dosing:** 1% Cream BD x 1 week
- **Rationale:** Reduces itch and redness. Use mild potency on face.

### 772. Terbinafine (undefined)
- **Class:** Allylamine
- **Dosing:** 250 mg OD x 12 weeks
- **Rationale:** Fungicidal; accumulates in nail matrix. Highest cure rate (~76%). Monitor LFTs.

### 773. Itraconazole (undefined)
- **Class:** Azole
- **Dosing:** 200 mg BD x 1 week/month Pulse Therapy (3 pulses)
- **Rationale:** Broad spectrum. Pulse dosing improves compliance and reduces side effects.

### 774. Amorolfine (undefined)
- **Class:** Nail Lacquer
- **Dosing:** 5% Weekly x 6-12 months
- **Rationale:** Topical option if oral contraindicated or <50% nail involvement.

### 775. Fluconazole (undefined)
- **Class:** Azole
- **Dosing:** 300-400 mg Weekly x 2 doses
- **Rationale:** Delivered to skin via sweat. Exercise after taking improves efficacy.

### 776. Selenium Sulfide / Ketoconazole (undefined)
- **Class:** Shampoo/Lotion
- **Dosing:** 2.5% / 2% Apply 10 mins Daily x 1 week
- **Rationale:** Keratolytic and antifungal. Cost effective.

### 777. Clotrimazole (undefined)
- **Class:** Cream
- **Dosing:** 1% BD
- **Rationale:** Standard topical azole.

### 778. Permethrin (undefined)
- **Class:** Pyrethroid
- **Dosing:** 1% Lotion Apply 10 min -> Rinse
- **Rationale:** Neurotoxic to lice. Repeat in 7-10 days to kill newly hatched nymphs.

### 779. Ivermectin (undefined)
- **Class:** Anti-parasitic
- **Dosing:** 200-400 mcg/kg Stat (Repeat day 8)
- **Rationale:** Oral agent; paralyzes lice. Excellent for outbreaks or non-compliance with topicals.

### 780. Wet Combing (undefined)
- **Class:** Mechanical
- **Dosing:** Conditioner + Comb Every 3 days x 2 weeks
- **Rationale:** Physical removal of lice interrupting lifecycle without chemicals.

### 781. Vancomycin (undefined)
- **Class:** Glycopeptide
- **Dosing:** 15-20 mg/kg IV BD
- **Rationale:** Broad coverage for Gram-positives. Essential until culture results.

### 782. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 2 g IV OD
- **Rationale:** Added for Salmonella (Sickle cell) or Polymicrobial infections.

### 783. Rifampicin (undefined)
- **Class:** Biofilm Agent
- **Dosing:** 300-450 mg BD
- **Rationale:** Unique ability to penetrate Staphylococcal biofilms on hardware.

### 784. Vancomycin (undefined)
- **Class:** Glycopeptide
- **Dosing:** 15 mg/kg IV BD
- **Rationale:** Covers MRSA.

### 785. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 2 g IV OD
- **Rationale:** Excellent synovial penetration.

### 786. Analgesics (Opioids/NSAIDs) (undefined)
- **Class:** Pain control
- **Dosing:** Titrated PRN
- **Rationale:** Pain is severe; control allows for better examination and mobilization.

### 787. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 15-20 mg OD (Morning)
- **Rationale:** Low dose is sufficient for PMR (unlike GCA which needs high dose). Taper slowly over 1 year.

### 788. Methotrexate (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 10-15 mg Weekly
- **Rationale:** Used if relapses occur during taper or steroid side effects are severe.

### 789. Calcium / Vit D (undefined)
- **Class:** Supplement
- **Dosing:** Standard Daily
- **Rationale:** Mandatory with chronic steroid therapy.

### 790. Methotrexate (undefined)
- **Class:** DMARD
- **Dosing:** 15-25 mg Weekly
- **Rationale:** Treats both skin and joints. First-line oral agent.

### 791. Secukinumab (undefined)
- **Class:** IL-17 Inhibitor
- **Dosing:** 150-300 mg SC Monthly
- **Rationale:** Highly effective for both psoriatic skin and joint disease, including axial involvement.

### 792. Apremilast (undefined)
- **Class:** PDE4 Inhibitor
- **Dosing:** 30 mg BD
- **Rationale:** Oral small molecule; useful if biologics contraindicated.

### 793. Indomethacin (undefined)
- **Class:** NSAID
- **Dosing:** 50 mg TID
- **Rationale:** Usually responds well to NSAIDs alone. Acute phase treatment.

### 794. Sulfasalazine (undefined)
- **Class:** DMARD
- **Dosing:** 1 g BD
- **Rationale:** Used if symptoms persist > 3-6 months.

### 795. Doxycycline (undefined)
- **Class:** Antibiotic
- **Dosing:** 100 mg BD x 7d
- **Rationale:** Treats the trigger if GU infection is still active (does not cure the arthritis itself).

### 796. Zoledronic Acid (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 5 mg Single IV Infusion
- **Rationale:** Most potent osteoclast inhibitor. Single dose often provides remission for years.

### 797. Alendronate (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 40 mg OD x 6 months
- **Rationale:** Oral option if IV inaccessible. Requires strict upright posture instructions.

### 798. Calcitonin (undefined)
- **Class:** Hormone
- **Dosing:** 100 IU SC/IM Daily
- **Rationale:** Analgesic effect on bone pain but weaker antiresorptive efficacy.

### 799. Bortezomib (undefined)
- **Class:** Proteasome Inhibitor
- **Dosing:** 1.3 mg/m2 SC Days 1,4,8,11
- **Rationale:** Induces apoptosis in plasma cells by accumulating toxic proteins. Safe in renal failure.

### 800. Lenalidomide (undefined)
- **Class:** Immunomodulator
- **Dosing:** 25 mg OD (Days 1-21)
- **Rationale:** Direct cytotoxicity and anti-angiogenesis. Thrombosis risk requires aspirin/anticoagulation.

### 801. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 20-40 mg Weekly
- **Rationale:** Induces apoptosis in lymphoid cells; enhances efficacy of other agents.

### 802. Methotrexate (High Dose) (undefined)
- **Class:** Antifolate
- **Dosing:** 12 g/m2 IV Protocol
- **Rationale:** Primary agent for osteosarcoma. Requires Leucovorin rescue to prevent fatal toxicity.

### 803. Doxorubicin (undefined)
- **Class:** Anthracycline
- **Dosing:** 75 mg/m2 IV Protocol
- **Rationale:** Standard induction chemo to shrink tumor before limb-salvage surgery.

### 804. Cisplatin (undefined)
- **Class:** Platinum Agent
- **Dosing:** 100 mg/m2 IV Protocol
- **Rationale:** DNA cross-linker. Ototoxic/Nephrotoxic monitoring required.

### 805. Pamidronate (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 1 mg/kg/day IV x 3 days q4mo
- **Rationale:** Increases bone density and reduces fracture pain. Standard of care for pediatric OI.

### 806. Zoledronic Acid (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 0.05 mg/kg IV q6 months
- **Rationale:** More convenient dosing interval.

### 807. Calcium + Vitamin D (undefined)
- **Class:** Supplement
- **Dosing:** RDA based Daily
- **Rationale:** Ensure adequate substrate for bone mineralization.

### 808. Alendronate (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 70 mg Weekly
- **Rationale:** Retards bone resorption and may delay collapse (Controversial but commonly used).

### 809. Diclofenac / Tramadol (undefined)
- **Class:** Analgesic
- **Dosing:** Standard PRN
- **Rationale:** Symptomatic relief pending surgery.

### 810. Enoxaparin / Statins (undefined)
- **Class:** Anticoagulant/Lipid
- **Dosing:** Standard Daily
- **Rationale:** Used if thrombophilia or dyslipidemia is the underlying cause.

### 811. Hydroxychloroquine (undefined)
- **Class:** Antimalarial
- **Dosing:** 200-400 mg OD
- **Rationale:** Reduces flares, organ damage, and thrombosis. Requires annual eye screening.

### 812. Mycophenolate Mofetil (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 1 g BD
- **Rationale:** Standard induction/maintenance for renal involvement; teratogenic.

### 813. Belimumab (undefined)
- **Class:** Monoclonal Antibody
- **Dosing:** 10 mg/kg IV Monthly
- **Rationale:** Inhibits BLyS (B-cell survival factor). Reduces reliance on steroids.

### 814. Nifedipine (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** 10-20 mg TID
- **Rationale:** Vasodilator to prevent digital ulcers.

### 815. Mycophenolate Mofetil (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 1 g BD
- **Rationale:** Standard of care for SSc-ILD; stabilizes lung function.

### 816. Omeprazole (undefined)
- **Class:** PPI
- **Dosing:** 20-40 mg BD
- **Rationale:** Aggressive acid suppression needed due to lower esophageal sphincter incompetence.

### 817. Deflazacort (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.9 mg/kg OD
- **Rationale:** Preserves muscle strength. Preferred over Prednisone due to less weight gain.

### 818. Eteplirsen (undefined)
- **Class:** Exon Skipping Therapy
- **Dosing:** 30 mg/kg IV Weekly
- **Rationale:** Restores reading frame to produce truncated but functional dystrophin.

### 819. Enalapril / Carvedilol (undefined)
- **Class:** ACEi / Beta Blocker
- **Dosing:** Standard OD/BD
- **Rationale:** Started by age 10 to delay onset of heart failure.

### 820. Vincristine (undefined)
- **Class:** Vinca Alkaloid
- **Dosing:** 1.5 mg/m2 Protocol
- **Rationale:** Microtubule inhibitor. Neurotoxicity risk.

### 821. Doxorubicin (undefined)
- **Class:** Anthracycline
- **Dosing:** 37.5-75 mg/m2 Protocol
- **Rationale:** DNA Intercalator. Backbone of therapy.

### 822. Cyclophosphamide (undefined)
- **Class:** Alkylating Agent
- **Dosing:** 1.2 g/m2 Protocol
- **Rationale:** Standard induction chemotherapy agent.

### 823. Denosumab (undefined)
- **Class:** RANKL Inhibitor (Monoclonal Ab)
- **Dosing:** 120 mg SC Monthly
- **Rationale:** Inhibits osteoclast formation and function. Shrinks tumor and ossifies rim, facilitating surgery.

### 824. Zoledronic Acid (undefined)
- **Class:** Bisphosphonate
- **Dosing:** 4 mg IV Monthly
- **Rationale:** Reduces osteolysis and pain.

### 825. Calcium + Vit D (undefined)
- **Class:** Supplement
- **Dosing:** Standard Daily
- **Rationale:** Mandatory to prevent severe hypocalcemia caused by RANKL inhibition.

### 826. Ibrutinib (undefined)
- **Class:** BTK Inhibitor
- **Dosing:** 420 mg OD
- **Rationale:** Inhibits Bruton's Tyrosine Kinase, blocking B-cell survival signaling. Continuous therapy.

### 827. Venetoclax (undefined)
- **Class:** BCL-2 Inhibitor
- **Dosing:** Ramp up to 400 mg OD
- **Rationale:** Induces apoptosis in CLL cells dependent on BCL-2. Risk of Tumor Lysis Syndrome.

### 828. Rituximab (undefined)
- **Class:** Anti-CD20 mAb
- **Dosing:** 375-500 mg/m2 Monthly
- **Rationale:** Used with chemo (Fludarabine/Cyclophosphamide) in fit patients (younger).

### 829. Paracetamol (undefined)
- **Class:** Analgesic
- **Dosing:** 650 mg Q6H
- **Rationale:** Mainstay of supportive care.

### 830. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 40-60 mg OD (Short course)
- **Rationale:** Reduces massive tonsillar swelling ('Kissing tonsils'). Not for routine cases.

### 831. Acyclovir (undefined)
- **Class:** Antiviral
- **Dosing:** N/A N/A
- **Rationale:** EBV does not respond clinically to Acyclovir. Do NOT prescribe.

### 832. Isoniazid (H) (undefined)
- **Class:** Antitubercular
- **Dosing:** 5 mg/kg OD
- **Rationale:** Part of standard 6-month regimen (2HRZE + 4HRE).

### 833. Rifampicin (R) (undefined)
- **Class:** Antitubercular
- **Dosing:** 10 mg/kg OD
- **Rationale:** Potent bactericidal. Orange urine counseling needed.

### 834. Pyrazinamide (Z) (undefined)
- **Class:** Antitubercular
- **Dosing:** 25 mg/kg OD
- **Rationale:** Active in acidic environment of caseous necrosis.

### 835. Compression Bandaging (undefined)
- **Class:** Mechanical
- **Dosing:** Class II/III Daily
- **Rationale:** Reduces filtration and improves venous/lymphatic return. The only effective management.

### 836. Penicillin V (undefined)
- **Class:** Antibiotic
- **Dosing:** 250-500 mg BD (Prophylaxis)
- **Rationale:** Prevents Streptococcal infections which damage lymphatics further.

### 837. Benzopyrones (Coumarin) (undefined)
- **Class:** Phlebotonic
- **Dosing:** Research use OD
- **Rationale:** Reduces high protein edema (controversial efficacy/hepatotoxicity).

### 838. Cyclophosphamide (undefined)
- **Class:** Alkylating Agent
- **Dosing:** High Dose Protocol (CODOX-M)
- **Rationale:** Cell-cycle non-specific agent for rapidly dividing cells.

### 839. Rituximab (undefined)
- **Class:** Anti-CD20 mAb
- **Dosing:** 375 mg/m2 Protocol
- **Rationale:** Improves survival when added to chemo backbone.

### 840. Rasburicase (undefined)
- **Class:** Urate Oxidase
- **Dosing:** 0.2 mg/kg IV Daily
- **Rationale:** Converts uric acid to allantoin (soluble); prevents renal failure.

### 841. Nifedipine (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** 10-20 mg SL 15-30 min before meals
- **Rationale:** Relaxes smooth muscle of the LES. Used if surgery is contraindicated or delayed.

### 842. Isosorbide Dinitrate (undefined)
- **Class:** Nitrate
- **Dosing:** 5-10 mg SL Before meals
- **Rationale:** Reduces LES tone via NO pathway. High side effect profile (headache).

### 843. Botulinum Toxin (undefined)
- **Class:** Neurotoxin
- **Dosing:** 100 Units Endoscopic Injection
- **Rationale:** Inhibits ACh release causing LES paralysis. Effect lasts 6-12 months.

### 844. Metoclopramide (undefined)
- **Class:** Prokinetic / Antiemetic
- **Dosing:** 10 mg TID (30 min before meals)
- **Rationale:** D2 antagonist; increases gastric contraction. Black box warning for Tardive Dyskinesia (>12 weeks use).

### 845. Erythromycin (undefined)
- **Class:** Macrolide
- **Dosing:** 250 mg TID (Liquid form)
- **Rationale:** Motilin receptor agonist. Powerful but tachyphylaxis develops rapidly (4 weeks).

### 846. Domperidone (undefined)
- **Class:** Prokinetic
- **Dosing:** 10 mg TID
- **Rationale:** Peripheral D2 antagonist; does not cross BBB (less EPS risk) but QT prolongation concern.

### 847. Octreotide / Terlipressin (undefined)
- **Class:** Vasoactive Agent
- **Dosing:** Infusion Continuous x 3-5 days
- **Rationale:** Splanchnic vasoconstriction reduces portal inflow and variceal pressure.

### 848. Propranolol / Carvedilol (undefined)
- **Class:** Non-selective Beta Blocker
- **Dosing:** Titrated to HR 55-60 BD
- **Rationale:** Reduces cardiac output (Beta-1) and causes splanchnic vasoconstriction (Beta-2) to lower portal pressure.

### 849. Ceftriaxone (undefined)
- **Class:** Antibiotic
- **Dosing:** 1 g IV OD
- **Rationale:** Standard of care in acute variceal bleed; reduces rebleeding and mortality.

### 850. 5-Fluorouracil (5-FU) (undefined)
- **Class:** Antimetabolite
- **Dosing:** Protocol based IV Infusion
- **Rationale:** Backbone of gastric cancer regimens (FLOT/ECF).

### 851. Oxaliplatin / Cisplatin (undefined)
- **Class:** Platinum Agent
- **Dosing:** Protocol based IV
- **Rationale:** Synergistic DNA damage with 5-FU.

### 852. Trastuzumab (undefined)
- **Class:** HER2 Inhibitor
- **Dosing:** 6 mg/kg IV q3 weeks
- **Rationale:** Targeted therapy improving survival in HER2+ subset.

### 853. Pantoprazole (undefined)
- **Class:** Proton Pump Inhibitor
- **Dosing:** 80 mg IV bolus -> 8 mg/hr Continuous / BD
- **Rationale:** Neutral pH stabilizes clot formation and promotes mucosal healing.

### 854. Ondansetron (undefined)
- **Class:** Antiemetic
- **Dosing:** 4-8 mg IV TID
- **Rationale:** Prevents further retching which could propagate the tear.

### 855. Epinephrine (Local) (undefined)
- **Class:** Vasoconstrictor
- **Dosing:** 1:10,000 Endoscopic Injection
- **Rationale:** Hemostasis during endoscopy if spontaneous cessation fails.

### 856. Vancomycin (undefined)
- **Class:** Glycopeptide
- **Dosing:** 125 mg QID (Oral)
- **Rationale:** Oral formulation is not absorbed systemically; acts locally in the colon. IV Vancomycin is INEFFECTIVE for colitis.

### 857. Fidaxomicin (undefined)
- **Class:** Macrocyclic Antibiotic
- **Dosing:** 200 mg BD x 10 days
- **Rationale:** Narrow spectrum (spares healthy flora) leading to lower recurrence rates than Vancomycin.

### 858. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg TID
- **Rationale:** No longer first-line due to resistance and lower cure rates; use only if Vancomycin unavailable.

### 859. Ciprofloxacin (undefined)
- **Class:** Fluoroquinolone
- **Dosing:** 500 mg BD
- **Rationale:** Covers Gram-negative enteric rods (E. coli).

### 860. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg TID
- **Rationale:** Essential anaerobic coverage (Bacteroides). Used in combo with Cipro.

### 861. Amoxicillin-Clavulanate (undefined)
- **Class:** Beta-lactam
- **Dosing:** 875/125 mg BD
- **Rationale:** Single pill alternative covering both gram-negatives and anaerobes.

### 862. Calcium Dobesilate (undefined)
- **Class:** Venotonic
- **Dosing:** 500 mg BD
- **Rationale:** Reduces capillary permeability and improves lymphatic drainage.

### 863. Nitroglycerin / Diltiazem (undefined)
- **Class:** Vasodilator Ointment
- **Dosing:** 0.2% / 2% BD Topically
- **Rationale:** Relaxes internal anal sphincter spasm to restore blood flow and allow healing.

### 864. Lactulose / Psyllium (undefined)
- **Class:** Stool Softener
- **Dosing:** 15 ml / 1 spoon HS
- **Rationale:** Prevents straining and hard stools which perpetuate trauma.

### 865. Tetracycline / Doxycycline (undefined)
- **Class:** Antibiotic
- **Dosing:** 250 mg QID / 100 mg BD Long course (3-6 months)
- **Rationale:** Treats the presumed bacterial overgrowth/infection. Duration prevents relapse.

### 866. Folic Acid (undefined)
- **Class:** Vitamin
- **Dosing:** 5 mg OD
- **Rationale:** Corrects anemia and aids mucosal regeneration.

### 867. Vitamin B12 (undefined)
- **Class:** Vitamin
- **Dosing:** 1000 mcg IM Weekly
- **Rationale:** Repletes stores if ileum involved.

### 868. Lactase Enzyme (undefined)
- **Class:** Enzyme Supplement
- **Dosing:** Per meal With Dairy
- **Rationale:** Hydrolyzes lactose into glucose/galactose exogenously.

### 869. Calcium Carbonate (undefined)
- **Class:** Supplement
- **Dosing:** 500 mg BD
- **Rationale:** Replaces calcium lost by avoiding dairy.

### 870. Probiotics (undefined)
- **Class:** Supplement
- **Dosing:** Sachet OD
- **Rationale:** May improve colonic handling of lactose.

### 871. Vitamin E (undefined)
- **Class:** Antioxidant
- **Dosing:** 800 IU OD
- **Rationale:** Reduces oxidative stress and inflammation. Caution in history of prostate cancer.

### 872. Pioglitazone (undefined)
- **Class:** Thiazolidinedione
- **Dosing:** 30 mg OD
- **Rationale:** Improves insulin sensitivity and reduces liver fat content. Watch for weight gain/edema.

### 873. Semaglutide (undefined)
- **Class:** GLP-1 Agonist
- **Dosing:** 0.5-1 mg SC Weekly
- **Rationale:** Promotes significant weight loss and improves liver histology.

### 874. Therapeutic Phlebotomy (undefined)
- **Class:** Procedure
- **Dosing:** 500 ml (remove ~250mg Fe) Weekly until Ferritin < 50
- **Rationale:** Rapidly removes iron. Maintenance phlebotomy q3-4 months lifelong.

### 875. Deferasirox (undefined)
- **Class:** Iron Chelator
- **Dosing:** 10-20 mg/kg OD
- **Rationale:** Oral chelator for patients with anemia or poor venous access.

### 876. PPI (Pantoprazole) (undefined)
- **Class:** Acid Suppressant
- **Dosing:** 40 mg OD
- **Rationale:** Reduces non-heme iron absorption (requires acid).

### 877. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 30-60 mg OD
- **Rationale:** Rapidly suppresses inflammation. Taper once enzymes normalize.

### 878. Azathioprine (undefined)
- **Class:** Immunosuppressant
- **Dosing:** 1-2 mg/kg OD
- **Rationale:** Allows weaning of steroids to prevent long-term toxicity. Check TPMT enzyme first.

### 879. Budesonide (undefined)
- **Class:** Corticosteroid
- **Dosing:** 3 mg TID
- **Rationale:** High first-pass metabolism limits systemic side effects.

### 880. Ursodeoxycholic Acid (UDCA) (undefined)
- **Class:** Bile Acid
- **Dosing:** 13-15 mg/kg Divided Doses
- **Rationale:** Replaces toxic hydrophobic bile acids, protects cholangiocytes, and delays cirrhosis progression.

### 881. Obeticholic Acid (undefined)
- **Class:** FXR Agonist
- **Dosing:** 5-10 mg OD
- **Rationale:** Reduces bile acid synthesis. Worsens pruritus.

### 882. Cholestyramine (undefined)
- **Class:** Bile Acid Sequestrant
- **Dosing:** 4 g Before breakfast
- **Rationale:** Binds bile salts in gut. Separate from UDCA by 4 hours.

### 883. Lactulose (undefined)
- **Class:** Non-absorbable Disaccharide
- **Dosing:** 30 ml TID (Aim 2-3 soft stools)
- **Rationale:** Acidifies gut lumen (traps NH3 as NH4+) and acts as laxative to remove nitrogen load.

### 884. Rifaximin (undefined)
- **Class:** Antibiotic (Gut selective)
- **Dosing:** 550 mg BD
- **Rationale:** Reduces ammonia-producing gut bacteria with minimal systemic absorption. Added to Lactulose.

### 885. L-Ornithine L-Aspartate (LOLA) (undefined)
- **Class:** Amino Acid
- **Dosing:** Granules/IV TID
- **Rationale:** Stimulates urea cycle (Liver) and glutamine synthesis (Muscle) to lower ammonia.

### 886. Sunitinib / Pazopanib (undefined)
- **Class:** Tyrosine Kinase Inhibitor (TKI)
- **Dosing:** 50 mg / 800 mg OD
- **Rationale:** Inhibits VEGF/PDGF receptors to block angiogenesis. First-line targeted therapy.

### 887. Pembrolizumab + Axitinib (undefined)
- **Class:** Immunotherapy + TKI
- **Dosing:** Protocol Cycle
- **Rationale:** Combination therapy shows superior survival over Sunitinib alone.

### 888. Nivolumab (undefined)
- **Class:** PD-1 Inhibitor
- **Dosing:** 240 mg IV q2 weeks
- **Rationale:** Restores T-cell activity against tumor cells.

### 889. BCG (Bacillus Calmette-Guerin) (undefined)
- **Class:** Intravesical Immunotherapy
- **Dosing:** Instillation Weekly x 6
- **Rationale:** Induces local immune response to destroy tumor cells. Prevents recurrence and progression.

### 890. Mitomycin C (undefined)
- **Class:** Intravesical Chemo
- **Dosing:** 40 mg Post-TURBT Stat
- **Rationale:** Single dose within 24h of resection reduces recurrence by seeding.

### 891. Cisplatin + Gemcitabine (undefined)
- **Class:** Systemic Chemo
- **Dosing:** Protocol Cycle
- **Rationale:** Neoadjuvant therapy improves survival prior to Radical Cystectomy.

### 892. Tolvaptan (undefined)
- **Class:** V2 Receptor Antagonist
- **Dosing:** 45-90 mg BD (Split dose)
- **Rationale:** Slows cyst growth by inhibiting cAMP. Risk of hepatotoxicity (monitor LFTs) and massive polyuria.

### 893. Lisinopril / Telmisartan (undefined)
- **Class:** ACEi / ARB
- **Dosing:** Standard OD
- **Rationale:** Strict BP control (<130/80) slows renal function decline.

### 894. Ciprofloxacin / Trimethoprim (undefined)
- **Class:** Lipophilic Antibiotic
- **Dosing:** Standard BD
- **Rationale:** Must penetrate cyst fluid (Hydrophilic drugs like Ampicillin do not penetrate well).

### 895. Vincristine (undefined)
- **Class:** Vinca Alkaloid
- **Dosing:** Protocol Weekly
- **Rationale:** Microtubule inhibitor. Standard backbone of therapy.

### 896. Actinomycin-D (undefined)
- **Class:** Antibiotic
- **Dosing:** Protocol Pulse
- **Rationale:** Interferes with RNA synthesis. Highly effective.

### 897. Doxorubicin (undefined)
- **Class:** Anthracycline
- **Dosing:** Protocol Cycle
- **Rationale:** Added for advanced or high-risk histology.

### 898. Ramipril / Enalapril (undefined)
- **Class:** ACE Inhibitor
- **Dosing:** Max tolerated OD
- **Rationale:** Delays progression to ESRD by years if started at onset of proteinuria.

### 899. Losartan (undefined)
- **Class:** ARB
- **Dosing:** Standard OD
- **Rationale:** Alternative anti-proteinuric agent.

### 900. Cyclosporine (undefined)
- **Class:** Calcineurin Inhibitor
- **Dosing:** Trial BD
- **Rationale:** Controversial; sometimes used to reduce proteinuria but nephrotoxicity is a concern.

### 901. Solifenacin / Oxybutynin (undefined)
- **Class:** Anticholinergic
- **Dosing:** 5-10 mg / 5 mg OD / TID
- **Rationale:** Blocks M3 receptors on detrusor muscle to inhibit involuntary contractions.

### 902. Mirabegron (undefined)
- **Class:** Beta-3 Agonist
- **Dosing:** 25-50 mg OD
- **Rationale:** Relaxes detrusor during storage phase. No anticholinergic side effects (dry mouth/constipation).

### 903. Duloxetine (undefined)
- **Class:** SNRI
- **Dosing:** 40 mg BD
- **Rationale:** Increases pudendal nerve tone and urethral sphincter contraction strength.

### 904. Amlodipine (undefined)
- **Class:** Calcium Channel Blocker
- **Dosing:** 5-10 mg OD
- **Rationale:** Effective BP control without affecting renal hemodynamics significantly.

### 905. Telmisartan (undefined)
- **Class:** ARB
- **Dosing:** 40 mg OD
- **Rationale:** Blocks the high Angiotensin II levels. CONTRAINDICATED in Bilateral RAS.

### 906. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 40 mg OD
- **Rationale:** Plaque stabilization and lipid control.

### 907. Amitriptyline (undefined)
- **Class:** TCA
- **Dosing:** 10-25 mg HS
- **Rationale:** Modulates central pain processing and has anticholinergic effects to reduce frequency.

### 908. Pentosan Polysulfate (undefined)
- **Class:** Mucosal Protectant
- **Dosing:** 100 mg TID
- **Rationale:** Replenishes the defective GAG layer. Takes 3-6 months to show effect.

### 909. Hydroxyzine (undefined)
- **Class:** Antihistamine
- **Dosing:** 25 mg HS
- **Rationale:** Reduces mast cell degranulation in the bladder wall.

### 910. Terlipressin (undefined)
- **Class:** Vasopressin Analog
- **Dosing:** 1-2 mg IV q4-6h
- **Rationale:** Constricts splanchnic bed, shifting blood volume to systemic circulation to perfuse kidneys.

### 911. Albumin (undefined)
- **Class:** Colloid
- **Dosing:** 1 g/kg (max 100g) IV Daily
- **Rationale:** Increases oncotic pressure and binds vasodilators. Mandatory cofactor with Terlipressin.

### 912. Midodrine + Octreotide (undefined)
- **Class:** Vasopressor Combo
- **Dosing:** Oral / SC TID
- **Rationale:** Used if Terlipressin unavailable (less effective). Midodrine constricts systemic; Octreotide constricts splanchnic.

### 913. Supportive Care (undefined)
- **Class:** N/A
- **Dosing:** N/A N/A
- **Rationale:** Fluid management, dialysis if needed, and transfusions. Most children recover spontaneously.

### 914. Eculizumab (undefined)
- **Class:** C5 Inhibitor
- **Dosing:** Protocol IV
- **Rationale:** Blocks terminal complement pathway; prevents endothelial damage in non-Shiga toxin cases.

### 915. Furosemide (undefined)
- **Class:** Loop Diuretic
- **Dosing:** Titrated IV
- **Rationale:** Manages oliguria-associated volume expansion.

### 916. Cisplatin (undefined)
- **Class:** Platinum Agent
- **Dosing:** 40 mg/m2 Weekly
- **Rationale:** Radiosensitizer; enhances the effect of radiation therapy. Standard for locally advanced disease.

### 917. Paclitaxel + Carboplatin (undefined)
- **Class:** Chemotherapy Combo
- **Dosing:** Protocol Cycle
- **Rationale:** Palliative chemotherapy for stage IV disease.

### 918. Bevacizumab (undefined)
- **Class:** Anti-VEGF
- **Dosing:** 15 mg/kg q3 weeks
- **Rationale:** Improves survival in metastatic setting by inhibiting tumor angiogenesis.

### 919. Paclitaxel (undefined)
- **Class:** Taxane
- **Dosing:** 175 mg/m2 q3 weeks
- **Rationale:** Microtubule stabilizer. Standard adjuvant with Carboplatin.

### 920. Carboplatin (undefined)
- **Class:** Platinum Agent
- **Dosing:** AUC 5-6 q3 weeks
- **Rationale:** Less nephrotoxic/emetogenic than Cisplatin. Backbone of ovarian cancer therapy.

### 921. Olaparib (undefined)
- **Class:** PARP Inhibitor
- **Dosing:** 300 mg BD
- **Rationale:** Synthetic lethality: Blocks DNA repair in BRCA-deficient cells.

### 922. Megestrol Acetate (undefined)
- **Class:** Progestin
- **Dosing:** 160 mg OD
- **Rationale:** Opposes estrogen effect; used for hyperplasia or low-grade cancer in young women wanting pregnancy.

### 923. Carboplatin + Paclitaxel (undefined)
- **Class:** Chemotherapy
- **Dosing:** Protocol Cycle
- **Rationale:** Standard adjuvant therapy for high-risk or metastatic disease.

### 924. Pembrolizumab + Lenvatinib (undefined)
- **Class:** Immunotherapy + TKI
- **Dosing:** Protocol Cycle
- **Rationale:** New standard for advanced disease progression.

### 925. Methotrexate (undefined)
- **Class:** Antifolate
- **Dosing:** 1 mg/kg Days 1,3,5,7 (+ Folinic Acid)
- **Rationale:** Highly effective for persistent disease/choriocarcinoma. Cure rate ~100% in low risk.

### 926. Actinomycin-D (undefined)
- **Class:** Antibiotic
- **Dosing:** Pulse Cycle
- **Rationale:** Alternative single agent for low-risk GTN.

### 927. Oxytocin (undefined)
- **Class:** Uterotonic
- **Dosing:** Infusion During D&C
- **Rationale:** Controls bleeding during suction evacuation of the mole.

### 928. Combined Oral Contraceptive (COC) (undefined)
- **Class:** Hormone
- **Dosing:** Ethinylestradiol + Cyproterone OD (Cyclic)
- **Rationale:** Increases SHBG to bind free testosterone and suppresses LH-driven androgen production.

### 929. Metformin (undefined)
- **Class:** Biguanide
- **Dosing:** 500-1000 mg BD
- **Rationale:** Improves insulin sensitivity, lowers androgens, and facilitates spontaneous ovulation.

### 930. Letrozole (undefined)
- **Class:** Aromatase Inhibitor
- **Dosing:** 2.5 mg OD (Day 3-7)
- **Rationale:** First-line ovulation induction (superior to Clomiphene for live birth rates in PCOS).

### 931. Tranexamic Acid (undefined)
- **Class:** Antifibrinolytic
- **Dosing:** 1 g TID (during menses)
- **Rationale:** Reduces menstrual blood loss by 40-50% by stabilizing clots. Non-hormonal.

### 932. Leuprolide (undefined)
- **Class:** GnRH Agonist
- **Dosing:** 3.75 mg Depot Monthly
- **Rationale:** Induces temporary menopause to shrink fibroids and correct anemia before surgery.

### 933. Mifepristone / Ulipristal (undefined)
- **Class:** SPRM
- **Dosing:** 10-25 mg OD
- **Rationale:** Modulates progesterone receptors to reduce size and bleeding.

### 934. Ceftriaxone (undefined)
- **Class:** Cephalosporin (3rd Gen)
- **Dosing:** 1 g IV/IM OD
- **Rationale:** Effective against N. gonorrhoeae. Single dose for outpatient; daily for inpatient.

### 935. Doxycycline (undefined)
- **Class:** Tetracycline
- **Dosing:** 100 mg BD x 14 days
- **Rationale:** Essential to cover Chlamydia and prevent tubal damage. Mandatory 2-week course.

### 936. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg BD x 14 days
- **Rationale:** Treats Bacterial Vaginosis organisms involved in upper tract spread.

### 937. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg BD x 7 days
- **Rationale:** Gold standard. Avoid alcohol. Vaginal gel is an alternative.

### 938. Clindamycin (undefined)
- **Class:** Lincosamide
- **Dosing:** 300 mg BD x 7 days
- **Rationale:** Alternative oral or topical cream. Note: Cream weakens latex condoms.

### 939. Probiotics (Lactobacillus) (undefined)
- **Class:** Supplement
- **Dosing:** Vaginal/Oral Daily
- **Rationale:** Restores acidifying flora to prevent anaerobic overgrowth.

### 940. Estradiol (Transdermal) (undefined)
- **Class:** Estrogen
- **Dosing:** Patch/Gel Twice Weekly / Daily
- **Rationale:** Transdermal route avoids first-pass liver metabolism, lowering clot risk compared to oral.

### 941. Micronized Progesterone (undefined)
- **Class:** Progestogen
- **Dosing:** 100-200 mg HS
- **Rationale:** Prevents hyperplasia in women with a uterus. Also aids sleep.

### 942. Venlafaxine / Paroxetine (undefined)
- **Class:** SSRI/SNRI
- **Dosing:** Low dose OD
- **Rationale:** Effective for hot flashes if HRT is contraindicated (e.g., Breast Cancer history).

### 943. Labetalol (undefined)
- **Class:** Alpha/Beta Blocker
- **Dosing:** 20 mg IV -> Infusion Titrated
- **Rationale:** First-line antihypertensive in pregnancy. Avoids reflex tachycardia.

### 944. Magnesium Sulfate (undefined)
- **Class:** Anticonvulsant
- **Dosing:** 4 g Load -> 1-2 g/hr IV Infusion
- **Rationale:** Stabilizes neuronal membranes and causes vasodilation. Monitor reflexes/respiratory rate for toxicity.

### 945. Hydralazine (undefined)
- **Class:** Vasodilator
- **Dosing:** 5-10 mg IV q20min
- **Rationale:** Direct arterial vasodilator. Use if Labetalol fails or is contraindicated (Asthma/Bradycardia).

### 946. Methotrexate (undefined)
- **Class:** Antifolate
- **Dosing:** 50 mg/m2 IM Stat
- **Rationale:** Inhibits DNA synthesis in rapidly dividing trophoblasts. Criteria: HCG < 5000, Mass < 3.5cm, No cardiac activity.

### 947. Anti-D Immunoglobulin (undefined)
- **Class:** Immunoglobulin
- **Dosing:** 300 mcg IM Stat
- **Rationale:** Prevents Rh sensitization for future pregnancies.

### 948. Oxytocin (undefined)
- **Class:** Uterotonic
- **Dosing:** 10-40 Units IV Infusion
- **Rationale:** Stimulates rhythmic uterine contractions. Rapid onset.

### 949. Methylergometrine (undefined)
- **Class:** Ergot Alkaloid
- **Dosing:** 0.2 mg IM Stat
- **Rationale:** Potent tetanic contraction. Contraindicated in Hypertension/Preeclampsia.

### 950. Carboprost (PGF2a) (undefined)
- **Class:** Prostaglandin
- **Dosing:** 250 mcg IM q15min
- **Rationale:** Strong myometrial contraction. Contraindicated in Asthma.

### 951. Misoprostol (undefined)
- **Class:** PGE1 Analog
- **Dosing:** 800-1000 mcg Rectal/Sublingual
- **Rationale:** Effective, heat stable, easy to administer rectally during massive bleed.

### 952. Doxylamine + Pyridoxine (undefined)
- **Class:** Antihistamine / Vitamin B6
- **Dosing:** 10mg/10mg HS/BD
- **Rationale:** FDA approved for NVP. Safe and effective for mild-moderate cases.

### 953. Ondansetron (undefined)
- **Class:** 5-HT3 Antagonist
- **Dosing:** 4-8 mg TID
- **Rationale:** Potent antiemetic. Slight theoretical risk of cleft palate if used < 10 weeks (risk benefit analysis needed).

### 954. Thiamine (Vit B1) (undefined)
- **Class:** Vitamin
- **Dosing:** 100 mg IV Daily
- **Rationale:** Prevents Wernicke's Encephalopathy in prolonged vomiting.

### 955. Surgical Orchiopexy (undefined)
- **Class:** Procedure
- **Dosing:** Bilateral Stat
- **Rationale:** Untwisting and fixation of testis to scrotal wall to prevent recurrence.

### 956. Analgesics (Morphine) (undefined)
- **Class:** Opioid
- **Dosing:** Titrated IV
- **Rationale:** Pain control pending surgery.

### 957. Methylphenidate (undefined)
- **Class:** CNS Stimulant
- **Dosing:** 10-60 mg OD/BD
- **Rationale:** Blocks reuptake of Dopamine/NE. Immediate Release (Ritalin) or Extended Release (Concerta) available.

### 958. Atomoxetine (undefined)
- **Class:** SNRI (Non-stimulant)
- **Dosing:** 40-80 mg OD
- **Rationale:** Selective NE reuptake inhibitor. No abuse potential but slower onset (2-4 weeks).

### 959. Clonidine (undefined)
- **Class:** Alpha-2 Agonist
- **Dosing:** 0.1 mg HS
- **Rationale:** Adjunct for aggression or insomnia associated with stimulants.

### 960. Fluoxetine / Sertraline (undefined)
- **Class:** SSRIs
- **Dosing:** 60-80 mg / 200 mg OD
- **Rationale:** Potent serotonin reuptake inhibition desensitizes postsynaptic receptors.

### 961. Clomipramine (undefined)
- **Class:** TCA
- **Dosing:** 25-150 mg HS
- **Rationale:** Most potent serotonergic TCA but limited by anticholinergic/cardiac side effects.

### 962. Aripiprazole (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 5-10 mg OD
- **Rationale:** Dopamine modulation used when SSRIs alone provide partial response.

### 963. Sertraline / Paroxetine (undefined)
- **Class:** SSRIs
- **Dosing:** 50-100 mg OD
- **Rationale:** Treats core symptoms of anxiety, depression, and avoidance.

### 964. Prazosin (undefined)
- **Class:** Alpha-1 Blocker
- **Dosing:** 1-5 mg HS
- **Rationale:** Reduces sympathetic tone during sleep. Start low to avoid postural hypotension.

### 965. Venlafaxine (undefined)
- **Class:** SNRI
- **Dosing:** 75-150 mg OD
- **Rationale:** Effective for hyperarousal symptoms.

### 966. Diazepam / Chlordiazepoxide (undefined)
- **Class:** Benzodiazepine (Long acting)
- **Dosing:** 10-20 mg / 50 mg Stat / PRN (CIWA based)
- **Rationale:** Stimulates GABA receptors to dampen CNS excitation. Self-tapering effect.

### 967. Lorazepam (undefined)
- **Class:** Benzodiazepine (Short acting)
- **Dosing:** 2-4 mg IV/PO PRN
- **Rationale:** No active metabolites; safer in cirrhosis (LOT: Lorazepam, Oxazepam, Temazepam).

### 968. Thiamine (undefined)
- **Class:** Vitamin
- **Dosing:** 100-500 mg IV/IM Daily
- **Rationale:** Essential cofactor for glucose metabolism; deficiency causes encephalopathy.

### 969. Olanzapine (undefined)
- **Class:** Atypical Antipsychotic
- **Dosing:** 2.5-5 mg HS
- **Rationale:** Promotes weight gain and reduces obsessive rumination about food/body image.

### 970. Fluoxetine (undefined)
- **Class:** SSRI
- **Dosing:** 20-60 mg OD
- **Rationale:** Ineffective at low weight (starved brain); useful after weight restoration for relapse prevention.

### 971. Calcium + Vit D (undefined)
- **Class:** Supplement
- **Dosing:** Standard Daily
- **Rationale:** Supportive care for osteopenia.

### 972. Piperacillin-Tazobactam (undefined)
- **Class:** Antipseudomonal Penicillin
- **Dosing:** 4.5 g IV q6h
- **Rationale:** Broad coverage including Pseudomonas. First-line for high-risk patients.

### 973. Cefepime (undefined)
- **Class:** Cephalosporin (4th Gen)
- **Dosing:** 2 g IV q8h
- **Rationale:** Excellent Pseudomonas coverage; use if Penicillin allergic (mild).

### 974. Vancomycin (undefined)
- **Class:** Glycopeptide
- **Dosing:** 15 mg/kg IV BD
- **Rationale:** Added ONLY if: Hypotension, Mucositis, Catheter infection, or MRSA history.

### 975. Rasburicase (undefined)
- **Class:** Recombinant Urate Oxidase
- **Dosing:** 0.2 mg/kg IV Daily
- **Rationale:** Enzymatically degrades uric acid to soluble allantoin. Works rapidly (within 4h). Contraindicated in G6PD deficiency.

### 976. Allopurinol (undefined)
- **Class:** Xanthine Oxidase Inhibitor
- **Dosing:** 300-600 mg OD
- **Rationale:** Prevents formation of new uric acid. Does not reduce existing levels.

### 977. Normal Saline (undefined)
- **Class:** Crystalloid
- **Dosing:** 3 L/m2/day Continuous High Flow
- **Rationale:** Aggressive hydration to maintain high urine output and flush crystals.

### 978. Dexamethasone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 4 mg Q6H
- **Rationale:** Reduces tumor burden (Lymphoma) and peritumoral edema. Less effective for Lung Cancer.

### 979. Endovascular Stent (undefined)
- **Class:** Device
- **Dosing:** N/A Stat
- **Rationale:** Provides immediate relief of obstruction. Often preferred over radiation for rapid palliation.

### 980. Enoxaparin (undefined)
- **Class:** LMWH
- **Dosing:** 1 mg/kg BD
- **Rationale:** Treats associated catheter-related thrombosis.

### 981. Azacitidine / Decitabine (undefined)
- **Class:** Hypomethylating Agent (HMA)
- **Dosing:** 75 mg/m2 SC x 7 days/month
- **Rationale:** Restores tumor suppressor gene function. Improves survival and delays AML transformation.

### 982. Lenalidomide (undefined)
- **Class:** Immunomodulator
- **Dosing:** 10 mg OD
- **Rationale:** Promotes erythropoiesis and suppresses the malignant clone. Transfusion independence in >60%.

### 983. Erythropoietin (EPO) (undefined)
- **Class:** ESA
- **Dosing:** High dose Weekly
- **Rationale:** Stimulates red cell production if endogenous EPO is low (<500).

### 984. Hydroxyurea (undefined)
- **Class:** Cytoreductive
- **Dosing:** 500-1000 mg OD
- **Rationale:** Suppresses marrow production to keep platelets < 400k.

### 985. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75 mg OD
- **Rationale:** Prevents thrombotic events and treats erythromelalgia. Avoid if Platelets > 1.5M (Bleed risk).

### 986. Anagrelide (undefined)
- **Class:** Platelet Reducing Agent
- **Dosing:** 0.5 mg BD
- **Rationale:** Inhibits megakaryocyte maturation. Useful in younger patients (non-leukemogenic).

### 987. Amoxicillin (undefined)
- **Class:** Penicillin
- **Dosing:** 80-90 mg/kg/day BD
- **Rationale:** High dose required to overcome PBP resistance in Strep pneumoniae.

### 988. Amoxicillin-Clavulanate (undefined)
- **Class:** Beta-lactam/Inhibitor
- **Dosing:** 90 mg/kg/day BD
- **Rationale:** Adds coverage for beta-lactamase producing H. influenzae and M. catarrhalis.

### 989. Paracetamol / Ibuprofen (undefined)
- **Class:** Analgesic
- **Dosing:** 15mg/kg / 10mg/kg Q6H
- **Rationale:** Pain relief is the primary goal in the first 24 hours.

### 990. Amoxicillin-Clavulanate (undefined)
- **Class:** Beta-lactam
- **Dosing:** 625 mg TID x 5-7 days
- **Rationale:** Preferred over Amoxicillin alone due to high rates of beta-lactamase producing H. flu.

### 991. Doxycycline (undefined)
- **Class:** Tetracycline
- **Dosing:** 100 mg BD
- **Rationale:** Effective alternative with good tissue penetration.

### 992. Oxymetazoline (undefined)
- **Class:** Nasal Decongestant
- **Dosing:** 2 sprays BD (Max 3 days)
- **Rationale:** Vasoconstriction opens ostia. Limit use to prevent Rhinitis Medicamentosa (Rebound).

### 993. Penicillin V (undefined)
- **Class:** Penicillin
- **Dosing:** 500 mg TID x 10 days
- **Rationale:** GAS remains universally sensitive to Penicillin. Narrow spectrum.

### 994. Amoxicillin (undefined)
- **Class:** Penicillin
- **Dosing:** 500 mg BD x 10 days
- **Rationale:** Better tasting suspension for kids. equally effective.

### 995. Azithromycin (undefined)
- **Class:** Macrolide
- **Dosing:** 500 mg OD x 5 days
- **Rationale:** Used only if allergic; resistance is rising.

### 996. Ringer Lactate (undefined)
- **Class:** Crystalloid
- **Dosing:** 100 ml/kg in 3h Rapid IV
- **Rationale:** Best IV fluid; corrects acidosis and replaces electrolytes better than Normal Saline.

### 997. Doxycycline (undefined)
- **Class:** Antibiotic
- **Dosing:** 300 mg Single Dose
- **Rationale:** Reduces stool volume and duration of diarrhea. Single dose effective.

### 998. Zinc Sulfate (undefined)
- **Class:** Supplement
- **Dosing:** 20 mg OD x 14 days
- **Rationale:** Reduces severity and duration; WHO recommendation.

### 999. Doxycycline (undefined)
- **Class:** Tetracycline
- **Dosing:** 100 mg BD x 7 days
- **Rationale:** Effective oral therapy. Also used for prophylaxis (200mg weekly).

### 1000. Ceftriaxone / Penicillin G (undefined)
- **Class:** Antibiotic
- **Dosing:** 1 g / 1.5 MU IV OD / Q6H
- **Rationale:** IV therapy required for organ failure. Penicillin is the traditional drug of choice.

### 1001. Methylprednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** Pulse IV
- **Rationale:** Reduces vasculitis in lungs; life-saving in hemorrhagic pneumonitis.

### 1002. Orlistat (undefined)
- **Class:** Lipase Inhibitor
- **Dosing:** 120 mg TID with meals
- **Rationale:** Inhibits gastric/pancreatic lipases; preventing hydrolysis of triglycerides.

### 1003. Liraglutide (undefined)
- **Class:** GLP-1 Agonist
- **Dosing:** 3.0 mg (Saxenda) SC Daily
- **Rationale:** Delays gastric emptying and acts on hypothalamic satiety centers.

### 1004. Metformin (undefined)
- **Class:** Biguanide
- **Dosing:** 500 mg BD
- **Rationale:** Off-label use for weight loss in insulin-resistant phenotypes.

### 1005. Sapropterin (undefined)
- **Class:** BH4 Cofactor
- **Dosing:** 10-20 mg/kg OD
- **Rationale:** Enhances residual enzyme activity in responsive variants.

### 1006. Pegvaliase (undefined)
- **Class:** Enzyme Substitution
- **Dosing:** Titrated SC Daily
- **Rationale:** Recombinant enzyme that degrades phenylalanine.

### 1007. Nitisinone (undefined)
- **Class:** Enzyme Inhibitor
- **Dosing:** 2 mg OD
- **Rationale:** Inhibits enzyme upstream (4-HPPD) to prevent HGA formation.

### 1008. Ascorbic Acid (Vit C) (undefined)
- **Class:** Antioxidant
- **Dosing:** 1g BD
- **Rationale:** May prevent oxidation of HGA to pigment (controversial efficacy).

### 1009. NSAIDs (Naproxen) (undefined)
- **Class:** Analgesic
- **Dosing:** 500 mg BD
- **Rationale:** Symptomatic relief for arthritis.

### 1010. Cefazolin (undefined)
- **Class:** Cephalosporin (1st Gen)
- **Dosing:** 2 g IV Pre-op
- **Rationale:** Covers skin flora and some gram-negatives.

### 1011. Metronidazole (undefined)
- **Class:** Nitroimidazole
- **Dosing:** 500 mg IV Pre-op
- **Rationale:** Covers gut anaerobes (B. fragilis).

### 1012. Paracetamol (undefined)
- **Class:** Analgesic
- **Dosing:** 1 g IV Stat
- **Rationale:** Analgesia does not mask clinical signs.

### 1013. Propranolol (undefined)
- **Class:** Non-selective Beta Blocker
- **Dosing:** 20-40 mg BD
- **Rationale:** Reduces portal pressure via splanchnic vasoconstriction.

### 1014. Spironolactone (undefined)
- **Class:** Diuretic
- **Dosing:** 100 mg OD
- **Rationale:** Aldosterone antagonism helps fluid mobilization.

### 1015. Lactulose (undefined)
- **Class:** Osmotic Laxative
- **Dosing:** 30 ml TID
- **Rationale:** Traps ammonia in gut as ammonium (NH4+) for excretion.

### 1016. Polyethylene Glycol (PEG) (undefined)
- **Class:** Osmotic Laxative
- **Dosing:** 17 g OD
- **Rationale:** Retains water in stool via osmosis; non-habit forming.

### 1017. Bisacodyl (undefined)
- **Class:** Stimulant Laxative
- **Dosing:** 5-10 mg HS (Night)
- **Rationale:** Stimulates enteric nerves to increase motility.

### 1018. Psyllium (Isabgol) (undefined)
- **Class:** Bulk forming
- **Dosing:** 1 scoop HS with water
- **Rationale:** Adds bulk to stool to stimulate peristalsis.

### 1019. Voriconazole (undefined)
- **Class:** Antifungal (Azole)
- **Dosing:** 6 mg/kg (Load) -> 4 mg/kg BD
- **Rationale:** Superior to Amphotericin B for survival outcomes.

### 1020. Prednisolone (undefined)
- **Class:** Corticosteroid
- **Dosing:** 0.5 mg/kg OD
- **Rationale:** Suppresses hypersensitivity reaction.

### 1021. Itraconazole (undefined)
- **Class:** Antifungal
- **Dosing:** 200 mg BD
- **Rationale:** Reduces fungal burden as adjunct to steroids.

### 1022. Amphotericin B (Liposomal) (undefined)
- **Class:** Polyene Antifungal
- **Dosing:** 3-4 mg/kg IV OD
- **Rationale:** Rapidly fungicidal for CNS sterilization.

### 1023. Flucytosine (undefined)
- **Class:** Antimetabolite
- **Dosing:** 25 mg/kg QID
- **Rationale:** Prevents resistance and improves survival.

### 1024. Fluconazole (undefined)
- **Class:** Azole Antifungal
- **Dosing:** 400-800 mg OD
- **Rationale:** Excellent CSF penetration for long-term suppression.

### 1025. Praziquantel (undefined)
- **Class:** Anthelmintic
- **Dosing:** 10 mg/kg Single Dose
- **Rationale:** Increases membrane permeability causing worm paralysis.

### 1026. Niclosamide (undefined)
- **Class:** Anthelmintic
- **Dosing:** 2 g Single Dose
- **Rationale:** Inhibits oxidative phosphorylation (Not absorbed systemically).

### 1027. Senna/Laxative (undefined)
- **Class:** Purgative
- **Dosing:** Standard 2h post-treatment
- **Rationale:** Helps expel the paralyzed worm.

### 1028. Zolpidem (undefined)
- **Class:** Non-benzodiazepine Hypnotic
- **Dosing:** 5-10 mg HS (SOS)
- **Rationale:** Selective GABA-A agonist; induces sleep with less hangover.

### 1029. Melatonin (undefined)
- **Class:** Chronobiotic
- **Dosing:** 3-5 mg 2h before bed
- **Rationale:** Regulates sleep-wake cycle (useful in elderly/jet lag).

### 1030. Doxepin (undefined)
- **Class:** TCA (Low dose)
- **Dosing:** 3-6 mg HS
- **Rationale:** H1 antagonist effect promotes sleep continuity.

### 1031. Pregabalin (undefined)
- **Class:** Gabapentinoid
- **Dosing:** 75 mg BD (Titrate up)
- **Rationale:** Binds alpha-2-delta calcium channels to reduce neurotransmitter release.

### 1032. Duloxetine (undefined)
- **Class:** SNRI
- **Dosing:** 30-60 mg OD
- **Rationale:** Increases descending inhibitory pain pathways.

### 1033. Amitriptyline (undefined)
- **Class:** TCA
- **Dosing:** 10-25 mg HS
- **Rationale:** Sodium channel blockade + Norepinephrine reuptake inhibition.

### 1034. Amlodipine (undefined)
- **Class:** CCB
- **Dosing:** 5-10 mg OD
- **Rationale:** Vasodilation reduces arterial stiffness.

### 1035. Atorvastatin (undefined)
- **Class:** Statin
- **Dosing:** 20-40 mg HS
- **Rationale:** Pleiotropic effects improve endothelial function.

### 1036. Aspirin (undefined)
- **Class:** Antiplatelet
- **Dosing:** 75 mg OD
- **Rationale:** Prevents thrombotic events in diseased vessels.

